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ABSTRACT 
 
Heather E Doherty 
The role of Quantitative variations in Connective Tissue Growth Factor gene 
expression in Cardiac Hypertrophy and Fibrosis 
(Under the direction of Nobuyo Maeda) 
 
 
Connective tissue growth factor (CTGF) is a secreted, extracellular matrix 
(ECM) bound signaling molecule. While it stimulates maintenance and repair of the 
ECM, increased Ctgf gene expression is strongly associated with excess deposition 
of ECM in conditions of chronic organ injury and fibrotic diseases.  High expression 
of Ctgf is also associated with cardiac fibrosis following chronic hypertension, 
myocardial infarction, and other cardiovascular diseases.  Cardiac fibrosis is a major 
cause of heart dysfunction leading to heart failure, for which there is currently no 
effective treatments.  The prevailing opinion in the field is that high expression of 
Ctgf causes fibrotic disease, and it has been proposed that inhibiting Ctgf expression 
will reduce fibrosis.  This hypothesis, however, has not been directly tested. To test 
whether genetic variations in Ctgf expression modify hypertrophy or fibrosis, I have 
generated seven strains of mice that differ in their basal Ctgf expression levels 
across a 30-fold range, including utilizing a novel method of swapping the 3’UTR to 
achieve altered gene expression.  Mice were naturally aged or treated with 
angiotensin II infusion or with transverse aortic constriction, to evaluate how altered 
basal Ctgf gene expression modifies cardiac hypertrophy and cardiac fibrosis related 
phenotypes. Contrary to the expectations, cardiac fibrosis in mice with higher basal 
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Ctgf gene expression is increased only slightly or not at all, and mice with lower Ctgf 
gene expression had equal degrees of cardiac fibrosis compared to wild type mice.  
In contrast, both increased and reduced Ctgf gene expression mildly enhanced 
cardiac hypertrophy.  Furthermore, cardiac hypertrophy was not always increased in 
the presence of increased fibrosis, or visa versa, showing disconnects between 
these two phenotypes.  Thus my experiments suggest that CTGF is not likely to be 
the master regulator of cardiac fibrosis, and that drug interventions to reduce Ctgf 
gene expression may not prevent fibrosis and could exacerbate cardiac hypertrophy.  
The allelic series of varying Ctgf gene expression generated as part of my work will 
be a useful tool to clarify the role of CTGF in other fibrotic diseases and could be 
used to further understand what other roles CTGF may play in human disease. 
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
 
Coronary heart disease (CHD) is the leading killer in the United States, 
accounting for 1 in every 5 deaths in 2003 [1, 2].  Forty percent of CHD incidents 
result in death.  Even for those who survive cardiac ischemia caused by 
cardiovascular disease or high blood pressure, permanent scarring of the heart 
tissue is a largely unavoidable consequence.  For instance, following myocardial 
infraction (MI), scarring of the myocardium occurs at the site of ischemia as well as 
in regions of the heart where blood flow was not disrupted [3, 4].  Scarring of the 
heart can cause reduced tissue elasticity and can disrupt electrical conductivity, both 
of which are ultimately responsible for much of the long-term impairment in heart 
function that follows cardiac damage [3, 5].  Reduction of tissue scarring is a likely 
target for improving long-term outcomes in patients with an ischemic event.  Despite 
the therapeutic potential of anti-fibrotic treatment, it remains a largely neglected field. 
Myocardial scarring is characterized by necrosis of myocardial tissue followed 
by replacement with fibrillar collagen, primarily composed of collagen I and III [4].  
Collagen buildup and scar tissue contraction at the site of injury often results in 
ventricular diastolic dysfunction [3, 4].  In both humans and animal models, sites of 
MI scarring have enhanced expression of transforming growth factor beta (TGFβ) 
and angiotensin II (AngII).  Both peptides are upstream inducers of connective tissue 
growth factor (CTGF) expression, which is thought to be a primary profibrotic 
signaling molecule [6, 7].  CTGF is widely expressed during development in all major 
organs, the vasculature, and the skeletal system [8].  In the adult, expression 
continues to be nearly ubiquitous and functions in extracellular matrix (ECM) 
maintenance and repair.  Specifically, a marked induction of CTGF expression 
occurs in healthy wound healing and in pathological fibrosis [9].  Due to the 
profibrotic profile of upstream inducers of CTGF expression, its known function in 
fibrosis, and its localization to cardiac scars [3, 5, 10], many researchers in the field 
have suggested that CTGF has an essential role in cardiac fibrosis and other forms 
of tissue scarring [6, 9, 11-14]. 
 
A. CTGF protein and binding partners 
1. Protein 
CTGF was first identified in mouse fibroblasts as a serum-inducible, secreted 
protein encoded by an immediate-early gene [15].  The human ortholog, discovered 
around the same time, was identified in the conditioned media of human umbilical 
vein endothelial cells and thought to have mitogenic activity [16].  The CTGF protein 
{a.k.a. CCN2, hypertrophic chondrocyte specific gene 24, (Hcs24), or fibroblast-
inducible secreted protein (Fisp12)} is a member of the CCN (Cyr61, CTGF, and 
Nov) family [16, 17].  Each functional domain of a CCN family gene is self-contained 
within a single exon, and it has been suggested that the CCN family of genes was 
evolutionarily assembled via exon reshuffling [18].  Each exon contains a single 
functional domain, originally from another gene, that were combined to make the first 
ancestral CCN-like gene [19].  A series of gene duplications, followed by functional 
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divergence, has created a family of genes with a shared set of functional domains 
and a modular structure.  This family was originally characterized as growth factors 
[16, 17], but has been collectively reclassified as extracellular signaling molecules 
that principally modify the signaling of other molecules [20].  All six CCN proteins 
(Cyr61, Ctgf, Nov and CCN4-6, which were previously called WISP1-3) are well-
conserved across bony vertebrate species and are grouped due to their shared 
multimodular exon structure and similar cysteine-rich amino acid sequence [17, 19]. 
 
Exon: 1 2 3 4 5  
 
 
 
von Willenbrand 
repeat domain 
Thrombospondin  
binding domain 
Cysteine knot domain 
Heparin binding domain 
IGF protein 
binding domain 
Signal 
sequence 
 
1Amino Acid #: -21 22-96 96-179 179-249 250-348 
Figure 1.1. Schematic structure of CTGF protein with location of motifs. The boxes represent 
exons, with the related functional elements.  Below each box is the number of the amino acids 
occurring in each portion of the protein.  The signaling leader sequence in exon 1 is snipped off 
generating a mature protein including amino acids 22-348. 
 
The Ctgf gene contains five exons that code for a 38kDa protein that contains 
one leader sequence and four functional domains (Fig 1.1). It is a secreted protein 
with the N-terminal amino acid signal sequence required for Golgi-mediated 
secretion encoded in Exon 1 [21].  Exon 2 encodes a domain with an insulin-like 
growth factor (IGF) binding motif that mediates weak but significant IGF binding [22].  
Exon 3 encodes a domain containing a von Willenbrand factor type C repeat motif 
that mediates oligmerization to other proteins such as TGFβ [22].  Exon 4 encodes a 
thrombospondin type 1 domain that mediates cell attachment through integrin α6β1 
and possibly other integrins [7, 19, 22].  Finally, Exon 5 encodes a cysteine knot 
motif common in many growth factors.  The domain in Exon 5 also mediates binding 
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to heparin sulfate proteoglycans, low density lipoprotein receptor related protein 
(LRP1), and several different integrins [17, 19, 22-24] (also reviewed in [7, 9] and 
diagramed in Fig 1.1). 
CTGF undergoes post translational modification including glycosylation, but 
this is not required for secretion and no other function attributed to this modification 
to date [21].  Studies have also documented that CTGF is proteolytically cleaved into 
fragments ranging in size from 10-31 kDa which can be found in a number of 
biological fluids (see more details in section E).  The points of cleavage generally 
occur between functional domains creating pieces of CTGF that contain subsets of 
the functional domains [19].  Although the exact function of each of these fragments 
is not known, it has been shown that the C-terminal 10 kDa fragment, containing a 
very highly conserved region across mammalian species, is mitogenic (can stimulate 
fibroblast proliferation), binds heparin, and is sufficient to mediate cell adhesion 
through association with integrins [25, 26]. 
 
2. CTGF protein and cell adhesion 
CTGF has a large number of binding partners, and most of these interactions 
appear to be largely cell-type dependent and contextually determined.  This multi-
functionality could be attributed to CTGF’s unusual localization as it can be found 
anchored to ECM components as well as in cell culture medium and in bodily fluids 
in vivo [19].  I will briefly mention a few of the better-studied of these binding 
partners, but it is important to note that this is not an exhaustive list since reports of 
new binding partners and new functions for old binding partners is increasing. 
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The association of CTGF with integrins, whether a CTGF fragment or the full-
length protein, occurs in a variety of cell types and is thought to be at least partially 
cell-type specific.  For example, CTGF reportedly binds to integrins αvβ3 in 
endothelial cells [27], αIIbβ3 in platelets [28], α6β1 in human foreskin fibroblasts [29], 
αMβ2 in blood monocytes [7, 19, 30], and α5β1 in chondrocytes [31].  The binding of 
CTGF to various integrins mediates cell adhesion and in some cases activates cell 
signaling cascades.  In other cases, the functional consequences of interactions 
between CTGF and integrins are unknown.  Most likely more integrins will be added 
to this list in the future as other interactions are discovered. 
Immobilized CTGF alone is sufficient to mediate cell adhesion of fibroblasts to 
a untreated coverslips via a unique mechanism.  CTGF bind directly to the coverslip 
then binds both integrin α6β1 and heparin, which are bound to the cell surface, and 
thus acts as adhesive bridge between the coverslip and the cell [29].  This 
interaction is unusual in that it requires both integrin α6β1 and heparin for functional 
binding.  In addition, binding of CTGF to α6β1 integrin stimulates downstream 
signaling and has functional consequences, including long-term activation of 
mitogen activated protein kinases (MAPKs), Rho family GTPases {in this case one 
of the Ras-related C3 botulinum toxin substrate (Racs)}, and matrix 
metalloproteinases (MMP-1 and MMP-3).  In addition, there is transient activation of 
focal adhesion kinase (FAK) that results in actin cytoskeletal reorganization to 
promote paxillin-containing focal adhesion formation, cell spreading, and active 
formation of filopodia and lamellipodia [29].  Other studies have shown that CTGF is 
a strong chemokinetic and chemotactic agent.  Cells exposed to CTGF become 
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generally more mobile and migrate towards an area with concentrated CTGF protein 
[27].  Evidence of CTGF as a chemotactic, pro-cell adhesion, and an activator of 
FAK suggests that CTGF can stimulate migration to a region, function as a tether of 
cells to the ECM, and influence cell signaling behavior.  Altogether, the evidence 
suggests that CTGF may be an important adhesive signaling molecule. 
 
3. The CTGF receptor or lack thereof 
A specific receptor for CTGF binding to the cell surface has yet to be 
identified.  CTGF does independently bind LRP1, leading to CTGF internalization 
and endosomal degradation [21].  It is unclear, however, if any signal transduction 
results from CTGF binding to LRP or if binding to LRP simply represents a 
mechanism for CTGF degradation [9, 21]. 
CTGF may act primarily by altering the signaling of other molecules.  For 
example, as described above, CTGF binds to TGFβ at a binding site within the Von 
Willenbrand factor motif.  Abreu et al. have shown that CTGF increases TGFβ 
binding to the TGFβ type II receptor, consequently amplifying the effects of TGFβ 
signaling [32].  In addition, CTGF binds to cell surface proteins such as heparin and 
integrins.  These proteins act as required co-receptors for CTGF’s role in cell 
adhesion and angiogenesis and may, in fact, be the primary signaling receptors for 
CTGF [19, 29].  Aside from heparin and integrins, other signaling molecules, such as 
TGFβ, may act as co-factors and be another primary method by which CTGF binds 
the cell surface and influences molecular signaling [7, 20].   
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B. CTGF gene structure and regulation 
1. CTGF promoter and gene regulation 
The CTGF gene consists of five exons.  Exon one encodes the signaling 
sequence for shuttling of the protein from the endoplasmic reticulum (ER) to the 
Golgi and exons two through five code for each of the four functional domains as 
mentioned above [7, 9].  The promoter of the CTGF gene contains multiple response 
elements suggesting the existence of many upstream activators and repressors of 
CTGF and that CTGF is part of a complex regulatory network (Fig 1.2).  The known 
upstream signaling molecules that can increase or decrease Ctgf gene expression 
include, but are not limited to the following: peroxisome proliferators activated 
receptor gamma (PPARγ), TGFβ, AngII, vascular endothelial growth factor (VEGF), 
tumor necrosis factor alpha (TNFα), and nitric oxide (NO) [33-42].  In addition, Ctgf 
gene expression is modulated by a number of environmental cues such as skin or 
vascular wounding, high glucose, fluid flow sheer stress, and cell stretch [33-42].  
Binding sites or response elements to some of these molecules and phenotypes 
have been mapped to the CTGF 5’-UTR and upstream region for some regulators of 
CTGF expression and/or different CTGF protein functions (Fig 1.2) (reviewed in [9]).  
For example, CTGF expression is increased in response to cell stretch in mesangial 
cells, smooth muscle cells and chondrocytes, but it is unknown if this response also 
occurs in cardiomyocytes [42-44].  In smooth muscle cells increased CTGF 
expression is mediated through NFκB binding to the stretch response element in the 
CTGF promoter [43] (Fig 1.2), but the same mechanism may or may not be used in 
the other reported cell types.  Thus, the current literature consists of many disparate 
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models of regulation of CTGF expression in different cell types with little cohesive 
sense of whether each stimulus is cell-type specific or universal. 
 
53 415’ 2 3’ 
Sp1/Sp3 binding site Basal Control Element-1 
SMAD binding site VEGF binding site 
AP1 binding site Exon 
Stretch (NFкB) response element  
 
Figure 1.2. Schematic of the CTGF gene including upstream binding sites in the promoter.  
The five exons are numbered.  Not to scale. 
 
2. CTGF and Transforming Growth Factor-Beta 
TGFβ expression has long been linked to pathological fibrosis in diabetic 
nephropathy, scleroderma, cardiac fibrosis, as well as fibrosis in other organs.  The 
interaction between TGFβ and CTGF is thought to be one of the most important in 
the regulation of fibrosis [6, 45, 46].  In a mouse model of scleroderma, application of 
either CTGF or TGFβ alone to the skin can induce transient fibrosis but both TGFβ 
and CTGF is required to produce severe persistent fibrosis [11, 47].  This finding 
suggests that a synergy of the signaling of both molecules is required to sustain a 
fibrotic phenotype in cells.  CTGF expression is induced by TGFβ receptor signaling, 
but the relationship between the two molecules is complicated [6].  TGFβ-induced 
Ctgf gene expression occurs by way of the mitogen activated protein kinase/ 
extracellular signal-regulated kinase (MAPK/Erk) pathway with translocation of 
SMAD3 and SMAD4 {named for a combination of the C. elegans gene family sma 
(small) and the Drosophila gene family MAD (mothers against decapentaplegic)} into 
the nucleus required [48].  The exact molecular pathway has not been completely  
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Figure 1.3. CTGF, TGFβ, and PPARγ regulatory relationship.  A) Cyclical regulation of CTGF and 
TGFβ.  B) Regulation of TGFβ-induced CTGF expression by PPARγ.  Gene expression changes are 
in italics. 
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determined and may vary in different cell types with both the rat sarcoma protein 
(Ras) and phospholipase C (PKC) also having been implicated in TGFβ-dependent 
regulation of CTGF gene expression [9].  Downstream of TGFβ, and thought to be 
mediated by CTGF, is increased expression of procollagen I, III, and IV as well as 
fibronectin expression, and possibly other ECM proteins (Fig 1.3a). 
More recently, CTGF was shown to directly bind TGFβ in the extracellular 
space in a protein to protein interaction that amplifies TGFβ signaling by increasing 
the binding of TGFβ to the TGFβ receptor II at low ligand concentrations [32].  TGFβ  
and CTGF appear to work together synergistically in a complex network to generate, 
regulate, and maintain normal ECM as well as induce pathological profibrotic 
signaling.  As CTGF is at the top and bottom of the regulatory pathway with TGFβ, it 
may have partial autocrine regulation.  Without some brake on such a cyclic 
regulatory pathway CTGF expression could continue to increase endlessly. 
PPARγ is better known for its role in type II diabetes and adipogenesis [49], 
but recent findings by Fu et al., report that PPARγ is a regulator of TGFβ-induced 
CTGF gene expression [33].  Another study by Fu et al. showed that TGFβ, long 
thought to repress PPARγ expression, actually initially stimulates PPARγ expression 
at one hour after TGFβ treatment then it represses PPARγ expression by 4 hours 
[50].  While neither of these papers directly suggest the idea, the combination of the 
two findings could suggest that PPARγ acts in conjunction with TGFβ to form a 
cyclic regulatory feedback loop controlling CTGF gene expression.  The timing of 
TGFβ’s induction of first CTGF expression then PPARγ expression is such that Ctgf 
expression is initially upregulated by TGFβ signaling then quickly shut down by 
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PPARγ.  The loop is completed when PPARrγ expression is then repressed by 
TGFβ signaling through AP1 and SMAD3/4 [50].  Finally, repression of PPARγ 
allows initiation of a new signal to induce CTGF expression (Fig 1.3b).  In summary, 
the initial signal induces a primary result (increased CTGF gene expression) but also 
has a secondary signal (increased PPARγ gene expression) that ensures the 
primary response is shut off in a timely manner.  In chronic fibrotic disease, this 
regulatory loop and/or other regulators of Ctgf may be overwhelmed and Ctgf 
expression is not repressed in a timely manner, thus causing persistent and 
pathological profibrotic signaling [9]. 
 
3. Angiotensin II and CTGF 
AngII is the terminal signaling molecule in the Renin-Angiotensin System 
(RAS), which is a primary signaling pathway that controls systemic blood pressure.  
Increases in renin expression and renin levels result in increased circulating AngII  
[51].  Increased AngII is a pro-hypertensive signal that increases blood pressure by 
two mechanisms.  First it acts in the kidney to cause retention of salts, which in turn 
causes fluid retention and increased blood volume [52].  AngII also acts in the 
vascular smooth muscle cells (VSMCs) as a potent vasoconstrictor [51-53] (Fig 1.4).  
The general model is that chronic high blood pressure (a.k.a. hypertension) leads to 
cardiac hypertrophy, which in turn is thought to lead to cardiac fibrosis.  Buildup of 
inflexible, non-conductive collagens reduces cardiac elasticity as well as disrupts 
electrical signaling in the heart causing the majority of the heart dysfunction related 
to chronic hypertension [54].  Recently, however, studies have shown that cardiac 
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fibrosis can occur in the absence of hypertrophy shedding doubt on this canonical 
model of hypertrophy causing fibrosis [55]. 
 
Angiotensin II 
AT1 receptor
MAPK 
 
Figure 1.4. Angiotensin II signaling in blood pressure regulation and angiotensin II regulation 
of CTGF gene expression.  
 
AngII-mediated induction of CTGF gene expression has been well described 
in a number of tissues [35, 56-59].  In fibroblasts, AngII signals through the AT1 
receptor and requires p42/p44 MAPK and RhoA signaling to maximally induce 
CTGF expression [56].  In cardiomyocytes, AngII induction of CTGF expression 
requires activation of PKC [58].  In fibroblasts and VSMCs, induction of CTGF 
expression occurs in a TGFβ-independent manner [56, 60] (Fig 1.4). Induction of 
CTGF expression by AngII in the heart has been shown to occur in rat and mouse 
models of myocardial infarction scarring and hypertension [3, 5, 10, 56].  Cell types 
likely to produce CTGF in response to AngII include, but are not limited to, vascular 
smooth muscle cells, cardiomyocytes, cardiac fibroblasts, and in pathological 
Kidney Vascular SMCsFibroblasts 
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conditions myofibroblasts [5, 10, 61].  In addition, treatment with the AT1 receptor 
inhibitor, losartan, attenuated CTGF expression in infarcted hearts showing a strong 
connection between AngII and CTGF [10]. 
In addition to direct AngII-induced CTGF gene expression through the MAPK 
pathway, AngII is likely to indirectly increase CTGF expression.  In VSMCs and 
vascular endothelial cells (VECs) hypertension related changes in fluid flow 
dynamics in the blood, such as increased sheer stress and turbulent blood flow, 
induce expression of CTGF [42, 62-64].  Multiple reports also show CTGF 
expression is induced in response to mechanical stresses such as tension, cell 
stretch, and static pressure [42, 62-64] such that CTGF is likely being expressed in 
one or more cell types in response to the mechanical stresses brought on by 
hypertension.  Therefore, AngII is inducing CTGF expression directly through the 
AT1 receptor and indirectly due to hypertension-related phenotypes which in 
combination may further induce CTGF expression locally in the cardiac tissue and 
vasculature.  Increased CTGF expression in hypertension is thought to be a key 
cause of hypertension-induced fibrosis in the heart and other tissues; however, no in 
vivo model has clearly tested this hypothesis. 
 
4. The CTGF 3’-UTR and CTGF micro RNAs 
In addition to regulation by response elements in the 5’UTR and regulation by 
other proteins in signaling cascades, CTGF is also know to be regulated by 3’UTR 
elements and micro RNAs (miRNAs).  Some of these elements are implicated by 
sequence homology, while others have defined functions.  The CTGF 3’UTR 
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includes multiple AU-rich elements that likely play a role in RNA stability.  In addition, 
several regions of the CTGF 3’-UTR are highly conserved between humans and 
mice, implying a possible regulatory role [65].  These sequences in the 3’UTR of the 
CTGF gene are not known to have a defined regulatory function, but do require 
further scrutiny. 
In chondrocyte differentiation, miRNA 18a has been shown to target the 
CTGF 3’UTR and repress CTGF expression, thereby preventing chondrocyte 
maturation [66].  In addition, two cardiac miRNAs that decrease in abundance during 
left ventricle pathological hypertrophy, miR-133 and miR-30, bind to the CTGF 
3’UTR and downregulate CTGF protein production [67].  The known decrease in 
these two miRNAs in cardiac hypertrophy, and their regulatory role in CTGF 
abundance, hint that there may be a role for CTGF in cardiac hypertrophy. 
Another RNA element targeting the CTGF 3’UTR has been demonstrated by 
Kubota et al. is called cis-acting element of structure-anchored repression 
(CAESAR).  The transcript for CAESAR is within the 3’-UTR of CTGF gene and 
overlaps the coding sequence of exon five by 16 bp [68, 69].  The minimal CAESAR 
element able to reduce CTGF protein levels is about 200 bp in length [69] (Fig 1.5).  
Whether this element is transcribed only in conjunction with the CTGF gene 
transcript, or can be separately transcribed, is unknown.  In addition, there are 
conflicting reports about how CAESAR reduces CTGF protein abundance.  One 
report suggests that CAESAR acts to reduce translation efficiency by slowing the 
association of CTGF mRNA with the ribosome [70].  Other reports suggested that 
CAESAR may affect CTGF abundance by altering CTGF mRNA stability [71, 72].  
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Using a reporter assay, CAESAR has been shown to act as a repressor of CTGF 
protein production in response to hypoxia [69, 71, 72], but the regulatory role of 
CAESAR in other functions of CTGF is unclear. 
 
0-16
CAESAR element
+174
CTGF  Exon 5 
 
Figure 1.5. Schematic of the CTGF CAESAR element.  The CAESAR element overlaps the last 
exon of the CTGF gene.  The remaining portion of the element is within the CTGF 3’UTR. 
 
The examples above are a subset of a larger number of molecules 
responsible for inducing, repressing, and generally regulating CTGF.  For a molecule 
like CTGF, where acute expression is likely crucial to wound healing while chronic 
expression could be pathological, proper regulation of gene expression, whether at 
the RNA or protein level, maintains a balance between tissue repair and tissue 
damage.  In addition, a large number of biological inputs (hypoxia, cell stretch, NO 
and glucose concentration, etc.) and outputs (cell adhesion, angiogenesis, ECM 
breakdown and deposition, etc.) that CTGF coordinates indicate that CTGF is at the 
hub of a regulatory nexus where it acts to coordinate response to a complex set of 
signals.  As a consequence, dysregulation of one or more of these pathways may be 
responsible for chronic pathological expression of CTGF. 
Taken together, all the evidence from cell culture supports a model of tight 
and complex regulation of Ctgf.  The list of Ctgf regulators contains over 100 
different proteins, drugs, and environmental cues including stimuli as diverse as 
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hormones such as testosterone [73], growth factors such as TGFβ [6], and 
mechanical stimuli such as cell stretch and fluid shear stress [43, 74].  Unfortunately, 
most of these regulators of Ctgf have been discovered in different cell types and 
under different culture conditions leaving no unified sense of the in vivo function of 
CTGF. 
 
C. Models of CTGF in development and disease 
1. Animal models of altered Ctgf gene expression 
Experiments in both animals and cells have shown that CTGF is important in 
development.  In a transgenic mouse model of Ctgf over-expression in bone (using 
the collagen XI promoter), animals were born, but were dwarfed, and X-rays showed 
that the femur and hind limb bones were less dense than wild type littermates [75].  
Another group reported similar findings in a bone/cartilage specific over-expression 
of Ctgf using the osteocalcin promoter [76].  On the other end of the spectrum, Ctgf 
null embryos are born but die shortly after birth.  Ivkovic et al. suggested that 
improper ossification and general malformation of the skeleton, including the ribs, 
ultimately caused the neonates to die due to respiratory failure [77].  In vitro models 
showed that over-expression of CTGF induces premature osteoblastogenesis [78].  
Other reports suggest that CTGF is important in the proliferation and differentiation 
of chondrocytes [79, 80].  Both in vivo and in vitro models, such as these, establish a 
role for Ctgf in bone development and growth. 
CTGF has also been implicated in the differentiation of other cell types 
including adipocytes.  In preadipotcytes CTGF is abundantly expressed, but as 
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preadipocytes differentiate into mature adipocytes, CTGF expression is considerably 
reduced.  In addition, over-expression of CTGF prior to or during differentiation of 
preadipocytes was shown to reduce the ability of cells to become mature adipocytes 
[81].  Osteocytes, chondrocytes and adipocytes are all derived from the 
mesenchymal lineage [82].  Proper Ctgf expression and functional regulation in 
general may be an important factor in cell type determination or transdifferentiation 
within the mesenchymal lineage [83]. 
 
2. Myocardial Infarction model of cardiac fibrosis and scarring 
As discussed above, amongst the upstream regulators of CTGF expression, 
TGFβ and AngII are of particular importance to fibrosis [6, 10].  As a method of 
examining wound healing in cardiac tissue, a number of research groups have 
induced MI in rats by left coronary artery ligation or similar methods [3-5, 10, 84, 85] 
and found that following MI, TGFβ, AngII and CTGF are all highly expressed in both 
infarcted and uninfarcted cardiac tissue [3, 5, 10].  In the area of scar formation 
CTGF is expressed by fibroblast-like cells [3], while in the granulation tissue CTGF is 
primarily expressed by endothelial cells [3, 85].  In the uninfarcted perivascular 
region, both vascular endothelial cells and interstitial fibroblast-like cells are the 
major expressers of CTGF [10].  The combination of TGFβ and CTGF is thought to 
be required for fibroblast proliferation and myofibroblast differentiation [86], which 
are both part of the fibrotic process.  CTGF is expressed in a variety of cells in 
response to injury and CTGF, in conjunction with TGFβ, is thought to have an 
important profibrotic role in the post MI healing process [3, 5, 10, 85]. 
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AngII also has a clear influence on myofibroblasts.  Sun Y et al. showed that 
in infarcted rat myocardium, myofibroblasts are the primary cell type expressing the 
AT1 receptor [4].  Myofibroblasts are a nearly ubiquitous marker of healing and 
scarring tissue (reviewed in [87]).  In MI scar tissue, myofibroblasts persist long after 
wound healing is complete, as opposed to apoptosing, which they do in normal 
wound healing in the skin [5].  Elevated TGFβ and CTGF levels in MI scars has also 
been observed [3], implicating the two proteins as a cause of myofibroblast 
persistence.  Myofibroblasts not only promote tissue contraction, but also synthesize 
elevated levels of ECM components, such as collagen I and III, as well as matrix 
degrading proteases such as matrix metalloproteinase (MMP-2) [5, 88-90]. The 
persistence of myofibroblasts within a healing tissue eventually leads to excessive 
scarring and functional impairment of the tissue.  Thus, persistence of 
myofibroblasts in the healing tissue changes the properties of the resulting healed 
wound [89]. 
Rat models of MI clearly show that CTGF, in conjunction with TGFβ and 
AngII, acts throughout the process of wound healing and scar formation in cardiac 
tissue.  In MI, CTGF is expressed early and is thought to act as a profibrotic factor 
that signals increased ECM production as well as myofibroblasts differentiation to 
create a profibrotic environment that ultimately leads to cardiac scarring and 
dysfunction [3-5, 10, 84, 85].  A role for CTGF in cardiac fibrosis is implied by its 
induction by AngII, but it seems that the function of CTGF almost always overlaps 
with that of TGFβ making an individual role for CTGF in cardiac fibrosis unclear. 
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D. Genetic variants of CTGF in human disease 
Like all human diseases, some people appear more prone to cardiac fibrosis 
than others.  The central position that CTGF occupies within fibrosis-related 
signaling pathways suggests that natural allelic variation in the CTGF gene and 
resulting variations in the levels of CTGF expression may be a factor in determining 
fibrosis susceptibility.  A recent study revealed a single nucleotide polymorphism 
(SNP) in the 5’ upstream region of the CTGF gene that associated with risk and 
severity of systemic scleroderma (systemic sclerosis) [12].  The C to G transversion 
located 945 bp upstream of the transcription start site is associated with increased 
scleroderma risk.  In particular, those subjects who are homozygous for the G allele 
seem especially prone to having two of the more severe phenotypes associated with 
systemic sclerosis, fibrosing aveolitis and the presence of anti-topoisomerase I 
antibodies.  The authors suggested that the SNP at -945 modulates the level of 
CTGF expression.  In vitro, the G allele caused both higher basal and induced levels 
of CTGF gene expression.  In addition, differential binding of the stronger 
transcription factor, Sp1, preferentially to the G risk allele increased expression and 
preferential binding of the weaker transcription factor, Sp3, to the C allele, produced 
lower CTGF expression levels [12].  This study establishes CTGF as a candidate 
gene for risk and severity of systemic sclerosis further strengthening the association 
between CTGF and fibrotic disease. 
Another report of a connection between CTGF variants and fibrotic disease 
focuses on hepatic fibrosis following Schistosomiasis infection.  In 1999, Dessein et 
al. examined 65 family pedigrees in a village in Sudan looking for genetic factors that 
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modulate the severity of liver damage following Schistosoma mansoni infection.  
They mapped a locus in human chromosome 6q22-23 which was associated with a 
more severe hepatic fibrosis following infection [91].  The CTGF gene was within the 
candidate interval.  The same group then followed up using a candidate gene 
approach and genotyped SNPs within and nearby the CTGF gene.  They found four 
SNPs upstream or downstream of the CTGF gene that associated with severity of 
Schistosomiasis liver damage in a diverse sampling of populations (Chinese, 
Sudanese, and Brazilians).  Two of these SNPs showed independent association in 
each of the populations [92].  Further study of these SNPs could reveal any role they 
may have in CTGF expression levels or function. 
In addition to the 5’-upstream SNP mentioned above, recent extensive SNP 
discovery efforts in the human genome have uncovered 35 SNPs in the human 
CTGF gene including two 5’-UTR or upstream SNPs, fifteen 3’-UTR SNPs, eleven 
intronic SNPs (including one in a splice site), three synonymous and four non-
synonymous protein coding SNPs [65].  This number of SNPs is a large for such a 
small gene and is a particularly large number of non-synonymous amino acids 
changes.  All of these amino acid substitutions are likely to be non-conservative and, 
therefore, functionally relevant (Table 1.1).  The diversity of natural variation in the 
CTGF gene suggests that functional variation exists within the human population, 
and these changes may alter the likelihood of development or severity of cardiac 
fibrosis.  Unfortunately, little or no meaningful allele frequency data is available for 
the four non-synonymous coding SNPs, and the importance of any phenotypic 
variation resulting from these SNPs has not been studied.  Aside from SNPs that 
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change the amino acid sequence, a large number of intronic and UTR variations are 
present in the human CTGF gene, which suggests variations in expression level, 
protein and mRNA stability, as well as binding site strength and specificity may exist 
within human populations. 
 
Amino Acid 
number (Exon) 
Protein Domain Amino Acid 
Change 
Functional Change 
42 (2) IGF binding 
domain 
Cys → Arg 
 
neutral sulfur-containing to basic + 
charged 
83 (2) IGF binding 
domain 
Asp → His 
 
acidic + charged to slightly basic - 
charged 
118 (3) von Willebrand 
repeat domain 
Asn → Ser 
 
highly hydrophilic to less hydrophilic 
 
296 (5) Cysteine knot 
domain 
Tyr → His 
 
weak aromatic acid to basic 
aromatic 
 
Table 1.1. Location and description of the four non-synonymous coding SNPs in the human 
CTGF gene. IGF = Insulin-like growth factor 
 
Another peculiarity of CTGF worth mentioning is the highly conserved C-
terminal amino acid sequence.  In the last 150 amino acids of CTGF, there are less 
than 10 amino acid differences in any pair-wise comparison between the human, 
mouse, rat, bovine, pig, and rabbit sequences (my own observation).  For instance, 
there are only two differences between the human and bovine sequence in the last 
150 amino acids.  The reason for this very high level of amino acid sequence 
conservation is unknown, but it suggests that there has been strong purifying 
selection and thus it is likely that an essential conserved function resides in this 
region.  Strong conservation of the CTGF gene between species is an encouraging 
observation and suggests that the phenotypes and molecular relationships observed 
in mouse models are likely to be conserved in humans. 
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E. CTGF protein levels as a noninvasive measurement of fibrotic disease in 
humans 
 
CTGF has been identified at measurable levels in a wide variety of human 
biological fluids including urine, serum/plasma, amniotic, follicular, peritoneal and 
cerebrospinal fluids [93, 94].  In humans and mouse models of fibrotic disease both 
plasma and urine levels of CTGF have become of particular interest.  CTGF levels in 
plasma and urine have been tested as a non-invasive biomarker for many fibrotic 
diseases including scleroderma, kidney allograft fibrosis, liver fibrosis (viral and non-
viral), diabetic retinopathy, end-stage renal disease, and heart failure [93, 95-99].  In 
all of these tests, CTGF levels in plasma or urine were positively correlated with 
severity or disease progression [100]. 
Reports of basal CTGF concentrations in plasma have varied widely with 
levels ranging from 3 ng/mL to 400 ng/mL [95-99].  Three studies, however, have 
reported very similar values for control subjects, suggesting the plasma level of 
CTGF for normal human adults is likely between 9 -15 ng/mL [95, 98, 99].  Under 
disease conditions those levels can increase three to five-fold [95, 97, 98].  Similarly, 
in mice the basal CTGF plasma level is about 20 ng/mL and can increase to 40-90 
ng/mL during kidney allograft fibrosis [95].  The similarity in the basal levels and 
responsiveness between humans and mice suggests that mouse models will be a 
reliable surrogate for studying changes in plasma CTGF levels during fibrotic 
disease.  In addition, the correlation of plasma CTGF levels to severity of fibrotic 
disease in humans suggests that even if CTGF in not causal of disease, it is likely an 
important biomarker of fibrotic disease.
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Summary 
Through a number of tissue culture models of fibrotic processes, many of the 
molecular pathways that control Ctgf expression have been elucidated.  This in vitro 
work has put CTGF at the center of a complicated set of inputs surrounding ECM 
maintenance and repair and implicated that it may have a function in fibrotic disease.  
It, however, remains to be shown whether Ctgf over-expression or modulation is 
truly a cause of fibrotic disease.  There have been a few models of altered Ctgf 
expression in vivo, but a model of global over-expression of Ctgf has yet to be 
reported.  My project will focus on generating mouse models with varying levels of 
Ctgf expression and challenging those animals with treatments that induce cardiac 
fibrosis and hypertrophy to elucidate the role of varying Ctgf expression in 
cardiovascular disease. 
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CHAPTER 2 
 
GENERATION OF MICE WITH ALTERED CTGF GENE COPY NUMBER 
 
A. Introduction 
 Ctgf has been implicated as an aggravating gene in fibrotic disease in a large 
number of organs and disease states.  Mounting evidence has shown that Ctgf is 
highly expressed in fibrotic disease in the retina, kidney, liver, lung and heart as well 
as in the fibrotic disorder systemic sclerosis [1-10].  However, there is a lack of clear 
evidence that Ctgf gene expression or presence of CTGF protein is causal in fibrotic 
disease.  Previously there have been several animal models of altered Ctgf gene 
expression.  The complete knockout of Ctgf in mice is lethal within hours of birth due 
to skeletal deformities of the rib cage that prevent normal breathing [11].  Increasing 
Ctgf expression by transgenic methods in bone and cartilage causes reduced bone 
density and bone size as well as dwarfing [12, 13].  Nevertheless, neither of these 
models address how genetically determined differences in basal Ctgf gene 
expression affects phenotypes related to fibrotic disease.  In order to understand if 
changes in Ctgf gene expression are causal in the pathology of fibrotic diseases 
there must be appropriate animal models to test the affects of altered Ctgf gene 
expression on a fibrosis phenotype.  In this chapter I describe two animal models 
with 50% and 150% of wild type Ctgf expression. 
 
B. Experimental procedures and Results 
1. Global, conventional KO of the Ctgf gene 
 The CTGF knockout mouse that will be utilized in all the following 
experiments was created by standard gene targeting methods.  In order to inactivate 
the Ctgf gene, we have made a targeting construct to delete exons 3 through 5 of 
the Ctgf gene in the genome in ES cells as illustrated in the second line of Figure 
2.1A.  The 5’ and 3’ arms of homology are a 4.7kb BamH1/Nhe1 fragment and a 
1.4kb Nsi1/Bg2 fragment, respectively, and a neomycin resistant gene (neo) was 
used as a selection marker.  Gene targeting in mouse ES cells (TC1) derived from a 
mouse of 129S6/SvEvTac (129/SvEv) background was carried out using the 
procedures described previously [14].  Cells with planned mutations were identified 
with PCR, followed by confirmation with Southern blot analyses, and used for 
generating mice carrying the mutations.  Briefly, for Southern blot analysis genomic 
DNA was purified from tissue then digested with the restriction enzyme BamH1 and 
separated on a 0.8% agarose grease gel at 50 mV overnight.  Southern blots were 
hybridized with a 600bp DNA fragment corresponding to sequence in exon 5 of the 
Ctgf gene.  Primer sequences for making the probe are 5’-
TCTCCAAGAAGACTCAGCCA-3’ (forward) and 5’-CCAGTGCACACTCCAATCTT-3’ 
(reverse).  The probe is radio-labeled with P32-dCTP using Klenow.  The WT band 
size is 12kb and the KO band size is 5kb (Fig 2.1B).   The Ctgf KO mice were 
established and maintained on a 129/SvEv background. 
Subsequently, Ctgf KO animals were PCR genotyped as appropriate using 
DNA from either toe or tail snips and standard protocols.  The PCR with the primers 
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for genotyping are: 5’-TCG AGT TCA GAA CCA GAG CT-3’ (common), 5’-TCC GAT 
TCC TAC CAG GAA GT-3’  (endogenous), and 5’-TTA TGG CGC GCC ATC GAT 
CT-3’ (neo) with the conditions (92°C for 30 sec., 58°C for 30 sec, 60°C for 7 min) 
for 35 cycles.  Because amplification is passing through the highly repetitive 3’UTR 
region the amplification step is done at a lower temperature to improve the 
processivity of the Taq enzyme.  The endogenous band is 550 bp and the KO band 
is 320 bp. 
 
 
Figure 2.1.  Ctgf knockout schematic and Southern blots confirming the presence of the 
knockout allele in animals.   A) Line 1 is the endogenous allele.  Line 2 is the construct for 
generating the knockout allele.  Line 3 is the knockout allele in the endogenous genome following 
homologous recombination.  B) Blot confirming the presence of the KO allele in animals showing a 
homozygous WT animal, a heterozygous KO animal and a control WT (SvEv) allele.  Abberviations: 
SvEv is 129(SvEv), Bg is Blg2, Bam is BamH1 and Swa is Swa1. 
 
 
2. Ctgf knockout mice 
Mice heterozygous for an inactivated Ctgf KO (Ctgf 1/0 or 1 copy) allele 
appear normal, are viable and fertile.  The heart, kidney, lung, liver, brain, and tail of 
these animals express Ctgf at approximately 50% of wild type (WT) levels (Fig 
2.3A).  Homozygotes are born but die within 12 hours after birth.  This result is 
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consistent with another Ctgf knockout mouse reported previously by Ivkovic et al. 
where exon 1, the TATA box, and the transcription start site were replaced with a 
Neo gene.  They reported that homozygous Ctgf knockout mice had malformed 
sterna and ribs which caused breathing difficulties in neonates just after birth [11] 
and heterozygous animals were viable, fertile, and lacking any overt phenotype. 
 
3. Duplication of the Ctgf gene 
In order to study the role that excess CTGF may play in fibrosis, the mouse 
Ctgf gene was duplicated in its endogenous chromosomal locus.  A targeting 
construct was made using a 6 kb DNA fragments containing 3.5 kb of the upstream 
region including the whole 5’-UTR and the complete Ctgf gene as a 5’ homology, a 
1.5 kb of the downstream region including the full 3’-UTR as 3’ homology, and a  
pACN-Neo in the arrangement shown in Figure 2.2A (second line).  The pACN-Neo 
cassette contains a testis-specific angiotensin converting enzyme gene promoter 
driving Cre recombinase and a neomycin gene all flanked by loxP sites [15].  The 
construct was electroporated into ES cells.  During the homologous recombination 
between the linearized construct and the endogenous genome, the gap between 
Swa1 and Nsi1 missing in the construct DNA was filled by way of double strand gap 
repair.  The result is a complete duplication of 9kb in total size where each copy of 
the Ctgf gene and regulatory sequence came partially from the endogenous genome 
and partially from the construct.  When the modified allele was passed through the 
germ line of the male chimeric mouse, Cre expression in testes from the pACN 
cassette was driven by the testes-specific angiotensin converting enzyme promoter,   
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Figure 2.2. Ctgf duplication schematic and Southern blots confirming the presence of the 
duplication allele in animals.  A) Line 1 is the endogenous allele.  Line 2 is the construct for 
generating the duplication allele.  Line 3 is the duplication allele in the endogenous genome following 
double strand break repair mediated recombination.  B) Blot showing homozygous duplication allele, 
a homozygous WT animal, and a WT (SvEv) allele.  Abberviations: SvEv is 129(SvEv), Bg is Blg2, 
Bam is BamH1 and Swa is Swa1. 
 
 
leading to recombination between the two loxP sites, and excision of the Neo 
cassette, which generates the final allele. The resulting duplication allele contains 
two 9 kb uninterrupted tandem copies of the Ctgf gene with the regulatory 
sequences intact (Fig 2.2A third line).  Presence of the correct allele was confirmed 
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by Southern blot using a 1.5 kb Nsi-Xho DNA fragment corresponding to the 3’ 
downstream of the Ctgf gene as a probe.   Genomic DNA was digested with the 
restriction enzyme with Bgl2 (Bg on Fig 2.2A), which cuts twice producing a 14kb 
WT band and a 25kb duplication band (Fig 2.2B). 
Animals heterozygous for the Ctgf duplication allele were genotyped by PCR 
with the primers: 5’-GATGTCCGGCCACAATCATA -3’ (forward) and 5’-
CGCCATCGTATCGATTGTAC -3’ (reverse) with the conditions: 92°C for 30 sec., 
58°C for 30 sec, 65°C for 7 min for 35 cycles.  A positive genotype is the presence of 
a 288 bp band and absence of a WT band.  This protocol only differentiates a 
homozygous WT mouse from a mouse carrying a duplication allele (heterozygous or 
homozygous for the duplication).  The Southern hybridization, which was used for 
confirming presence of the allele (described above), was used to differentiate 
between heterozygous and homozygous duplication animals. 
 
4. Animals with the Ctgf Duplication allele 
Heterozygotes for the Ctgf duplication allele have 3 functional copies (a.k.a. 3 
copy or 2/1) of the Ctgf gene and express Ctgf in the heart, kidney, lung, liver, and 
brain approximately 1.5 times more Ctgf than WT mice (Fig 2.3B).  Expression, 
however, in mice homozygous for the duplication (4 copy or 2/2) was about the 
same as wild type (Fig 2.3B).  In addition, both the 3 copy and 4 copy duplication 
mice show strong tendency for individual variations between animals creating wide 
distributions in Ctgf expression levels.  These wide distributions of expression levels 
are also seen in the WT animals suggesting a regulatory mechanism that is very 
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sensitive to environmental input.  Both Ctgf 3 copy and 4 copy mice are viable, 
fertile, and phenotypically normal upon external examination. 
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Figure 2.3. Ctgf gene expression levels in Ctgf mutant mice. a) Ctgf gene expression levels 
assayed by RT-PCR for Ctgf KO and WT littermates day 10 tail snips. KO: 43±9.9%, n=11 and WT: 
100±9.2%, n=21, p<0.001.  b) Combined Ctgf gene expression levels for multiple tissues assayed by 
RT-PCR for Ctgf duplication and WT animals.  Not all animals are littermates.  Tissues assayed were: 
heart, kidney, lung, liver, brain and tail. Total tissue samples WT: 100±6.4%, n=35; 3 copy: 
138±12.4%, n=21, p<0.005; and 4 copy: 97±10.0%, n=36, p = 0.38.  n equals between 2 and 12 
samples for each tissue for each genotype.  In both figures samples were normalized to β-actin and 
Ctgf expression level for WT was set to 100%. * indicates statistical significance verses WT from 
Student T-test. 
 
 
5. Isolation of mutant mouse embryonic fibroblasts 
 Mouse embryonic fibroblasts (MEFs) were isolated from embryos of the Ctgf 
KO and Ctgf duplication mice.  For heterozygous Ctgf KO cells, Ctgf KO/+ mice were 
crossed to WT mice and checked daily for mucosal plug.  For Ctgf 3 copy cells, WT 
mice were crossed to Ctgf 4 copy mice; for WT cells, WT mice were crossed; and for 
Ctgf 4 copy cells, Ctgf 4 copy mice were crossed.  Once a plug was observed, 
females were separated and watched for pregnancy.  Embryos were harvested 
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between E14 and E16, red tissues (liver, heart, and eyes) were removed, and 
embryos were homogenated using scissors or razor blades.  Homogenates were 
incubated in trypsin for 1-2 hours, then the supernatant was isolated and spun down 
for cells.  The remaining tissue was trypsinized for an additional 30 minutes and 
once again the supernatant was isolated and spun down for cells.  All cells were 
combined, rinsed with PBS and put through a 30 μm filter to remove any chunks of 
tissue.  The remaining cells were plated in standard tissue culture media containing 
10% FBS and designated passage zero (P0).  Cells were frozen in culture medium 
containing 20% FBS and 5% DMSO at -80°C in 1 mL aliquots until ready to use.  
 
6. Treatment of MEFs with TGFβ 
Prior to treatment with TGFβ, MEFs between passages p2 to p4 were 
counted and plated on P30 tissue culture plates with 1x105 cells per plate.  All cells 
in any given experiment were of the same passage.  When plates were 70-80% 
confluent, cells were first serum starved overnight then treated with TGFβ at 10 
ng/mL.  Cells were harvested prior to treatment (0 hours) and at 1, 2, 4, 6, and 12 
hours.  Cells were assayed for mRNA gene expression by RT-PCR using the 
following primer/probe sets for Ctgf mRNA expression: 5’-AGT CGC CTC TGC ATG 
GTC A-3’ (forward), 5’-GCG ATT TTA GGT GTC CGG AT-3’ (reverse), and 5’-FCC 
TGC GAA GCT GAC CTG GAG GAA AQ-3’ (probe) and for PPARγ gene expression 
5’-CTG ACG GGT TCT CGG TTG A-3’ (forward), 5’-ATC AGT GGT TCA CCG CTT 
CT-3’ (reverse), and 5’-F CTG AGA AGT CAC GTT CTG ACA GGA CQ-3’ (probe).  
All samples were normalized to β-actin using primer set: 5’-AAG AGC TAT AGA 
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CTG CCT GA-3’ (forward), 5’-ACG GAT GTC AAC GTC ACA CT-3’ (reverse), and 
5’-FCA CTA TTG GCA ACG AGC GGT TCC GQ-3’ (probe).  For all probes, F is 5’ 
fluorescein (FAM) and Q is the 3’ quencher (TAMRA).  All gene expression assays 
were performed as previously described [14].   
 
7. Regulation of Ctgf in Mouse Embryonic Fibroblasts 
In order to examine how Ctgf gene expression is regulated in the mutant 
mice, Ctgf mutant mouse embryonic fibroblast lines (MEFs) were established for 
each genotype and then treated with TGFβ to stimulate Ctgf gene expression.  Cells 
were harvested at set time points after treatment and then mRNA was isolated and 
gene expression levels determined.  Ctgf gene expression at time zero, prior to 
TGFβ treatment, in WT cells was set to 100% and all measurements were relative to 
that (Fig 2.4A).  At time zero Ctgf mutant cells express Ctgf at similar levels to what 
is observed in the Ctgf mutant animals (1 copy = 56±7%, 2 copy (WT) = 100±5%, 3 
copy = 213±17%, and 4 copy = 113±8%).  Previous reports have suggested that 
following TGFβ treatment Ctgf gene expression levels peak at two to four hours after 
treatment [16].  Consistent with this observation, I found that in 2 copy (WT) cells 
Ctgf mRNA expression levels peaked at about four hours after TGFβ treatment (2 
copy (WT) = 938±75%).  Ctgf expression also increased in mutant MEFs but Ctgf 
levels peaked at different time points in conjunction with altered Ctgf copy number.  
Ctgf expression levels in the 1 copy cells peaked later at 6 hours while the higher 
copy number mutants (3 and 4 copy) peaked earlier at 2 to 4 hours and 4 hours, 
respectively.  The 3 and 4 copy cells also showed the highest peak induction of Ctgf 
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expression and expression remained high the longest in the 3 copy cells (Fig 2.4A).  
Taken together this experiment suggested that altering Ctgf gene copy number not 
only changes baseline Ctgf expression levels but also how fast Ctgf mRNA 
accumulates, and how long Ctgf gene expression is maintained at a high level 
following stimulation. 
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Figure 2.4. TGFβ-induced expression of Ctgf and its putative regulator PPARγ. A) expression of 
Ctgf following stimulation of MEFs of given genotype with TGFβ. B) Expression of PPARγ following 
stimulation of MEFs of given genotype with TGFβ.  For each genotype n=3 for each timepoint.  Error 
bars are standard error of the mean.  Triplicate plates were harvested for each time point and for 
each genotype.   
 
We next examined whether altering Ctgf gene copy number changed the 
pattern of expression of PPARγ, a regulator of Ctgf mRNA expression levels.  Fu et 
al. identified PPARγ as a regulator of TGFβ-induced Ctgf expression in vascular 
smooth muscle cells (VSMCs) [16].  In their model, PPARγ responds to TGFβ 
stimulation with an initial increase in PPARγ gene expression, followed by a sharp 
decrease in PPARγ expression to below baseline expression levels [17].  To 
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investigate the response of PPARγ to TGFβ-induced Ctgf expression in fibroblasts, 
mRNA levels for PPARγ were determined in the same experiment.  Similar to what 
was observed with Ctgf mRNA levels, PPARγ gene expression had a temporally 
altered expression pattern in the Ctgf mutant MEFs (Fig 2.4B).  The PPARγ 
expression levels in 3 copy MEFs were highest at baseline, about twice that of other 
cell lines, and stayed high for the first hour following treatment.  The expression then 
sharply declined to approximately 10% of the starting levels by four hours of 
treatment.  In the WT and 4 copy MEFs, a small upward trend in expression was 
observed at one hour after TGFβ treatement and then at two hours, PPARγ 
expression began to decline.  Whereas, the 1 copy PPARγ expression levels started 
lower than WT and increased between one and two hours before declining by four 
hours.  In all cell lines, PPARγ expression levels were repressed by four hours 
following TGFβ treatment, which is consistent with previous observations [17].  Of 
particular interest, when Ctgf gene copy number was altered, there were changes in 
both the amplitude and the temporal dynamics of Ctgf and PPARγ gene expression. 
 
C. Discussion 
 The goal of generating a series of mouse strains with varying Ctgf gene 
expression is to produce lines of mice where the function of Ctgf in fibrotic disease 
can be elucidated.  In order to do this successfully, the strains have to show 
differences in Ctgf expression and be viable into adulthood where most fibrosis 
related diseases occur in humans.  Consistent with a previous report by Ikovic et al., 
the homozygous Ctgf knockout mice we generated are perinatal lethal and are, 
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therefore, not a useful model for studying fibrotic disease.  However, the Ctgf 
heterozygous knockout mice express about 50% of wild type levels of Ctgf and are 
viable and fertile animals. 
Both the Ctgf 3 copy and 4 copy mice are also viable and fertile.  The Ctgf 3 
copy mice express Ctgf at around 150% of wild type mice, although expression 
levels varied considerably between animals.  Unexpectedly, the Ctgf 4 copy mice on 
average express only slightly more Ctgf than wild type mice, but less than the 3 copy 
mice.  I also noted that the 4 copy mice had an even wider variation in gene 
expression between animals.  While both the 3 copy and 4 copy strains tend to have 
the widest distribution of Ctgf expression levels, even WT mice and cells within any 
given experiment can show considerable variation in Ctgf expression levels.  This 
tendency towards individual variation, in light of the large number of inputs to which 
Ctgf responds, suggests that Ctgf expression is highly responsive to environmental 
cues. 
 In tissue culture experiments with MEFs, basal Ctgf gene expression levels 
were very similar to what was observed in tissues isolated from animals.  Upon 
treatment with TGFβ to induce Ctgf gene expression, there were differences 
between Ctgf genotypes in both the amount of Ctgf gene expression and in the 
timing of when Ctgf expression peaked.  In addition, there were similar changes in 
levels and timing of expression for putative a regulator of Ctgf, PPARγ.  Changes in 
peak levels of Ctgf expression between genotypes are expected and likely to be 
important.  The temporal changes in Ctgf expression patterns, however, could be a 
tantalizing clue that it is not just the amount of Ctgf expression that matters but also 
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the kinetics of Ctgf expression.  Following a wound event, Ctgf expression is strongly 
induced as an important step in initiating the process of wound healing.  When a 
wound is healed Ctgf production must be inhibited or fibrosis will result.  Thus, 
disruption of the normal cycles of Ctgf expression and repression could be a cause 
of pathological fibrosis [18].  In MEFs, altering the Ctgf copy number affects the 
kinetics of Ctgf gene induction and repression and may suggest that the level of Ctgf 
expression is not the only important factor in understanding Ctgf abundance and 
function in a system.  Changing the length or amplitude of these cycles, as seen in 
Ctgf 1 copy and 3 copy MEFs, may have implications for phenotypic changes in 
these mice. 
Altering Ctgf copy number has also changed the gene expression pattern of 
PPARγ, a known regulator of Ctgf gene expression.  PPARγ is better known for its 
function in regulating fat storage, type II diabetes, and energy metabolism [19, 20], 
but Fu et al. showed that in VSMCs PPARγ is a regulator of TGFβ-induced Ctgf 
expression [16, 17].  Overall our data indicates that in MEFs treated with TGFβ, Ctgf 
mRNA levels peak at two hours after treatment, the expression level of PPARγ 
begins to decrease, which is similar to the observations of Fu et al. in VSMCs [16, 
17].  The similar response of MEFs and VSMCs to TGFβ treatment suggests PPARγ 
may be a regulator of TGFβ-induced Ctgf gene expression in a variety of cell types.  
In addition, our experiments and those of Fu et al. support the idea that PPARγ may 
have a functional role outside of metabolism. 
Interestingly, MEFs with altered Ctgf copy number show changes in both 
amount of PPARγ expression and the temporal dynamics of PPARγ expression, 
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which is most apparent in our experiment from zero to four hours.  Fu et al. showed 
that in response to TGFβ-induced Ctgf gene expression PPARγ initially increased in 
expression and then gene expression is repressed to below baseline levels.  While 
my experiment was not ideally set up to catch this pattern of increased then 
decreased PPARγ expression, I observed a baseline increase in 3 copy cells and 
increases in 4 copy and WT cells first and then a later peak in 1 copy cells.  
Although the changes were small and not statistically significant, they mirror the 
pattern of peaks seen in Ctgf gene expression with 3 copy cells starting high in 
expression with peaks in expression following in 4 copy, WT, and then 1 copy cells.  
The temporal changes in gene expression patterns suggests that in order to 
understand changes in Ctgf expression, information about expression levels and 
temporal dynamics of gene expression may be needed.  In addition, alteration of the 
pattern of PPARγ gene expression in Ctgf mutant cells implies that Ctgf mutant mice 
could potentially have altered phenotypes in related to PPARγ functions such as in 
fat storage or energy metabolism. 
Generally, when gene expression is changed through the addition or deletion 
of gene copies, the expectation is that the expression of a target gene will increase 
or decrease in proportion to the altered number of gene copies [21].  The Ctgf 
mutant mice we have generated do not simply follow this pattern.  Based on the 
basal gene expression in mice and response to TGFβ stimulation in tissue culture 
MEFs, preliminary findings indicate that the best strains for studying the effects of 
varied Ctgf gene expression are the heterozygous knockout (Ctgf 1 copy) mice and 
the heterozygous duplication (Ctgf 3 copy) mice in comparison to WT controls.  With 
46 
expression levels at about 50% and 150%, respectively, these two strains represent 
a three-fold range in Ctgf gene expression.  With the large number of known 
sequence variations [22] in the human Ctgf gene, variations in Ctgf gene expression 
levels of this magnitude could reasonably be expected to be found in the human 
population.  I have, therefore, chosen in the following chapters to focus on using 
these two lines of Ctgf mutant mice to determine if increased Ctgf expression is a 
causal factor in fibrotic disease and if reduced Ctgf gene expression can ameliorate 
fibrotic disease. 
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CHAPTER 3 
 
CTGF IN CARDIAC HYPERTROPHY AND CARDIAC FIBROSIS IN RESPONSE 
TO CARDIAC STRESS 
 
 
A. Introduction 
A large number of studies have implicated a role for CTGF in tissue scarring 
in the heart and other tissues [1-7], but a role for CTGF in cardiac hypertrophy is 
less clear.  Cardiac hypertrophy is a disease of complex pathology and genetics.  
Overall, cardiac hypertrophy is defined by an increased cardiomyocyte size and 
protein synthesis, as well as a basic change in the cell’s expression profile including 
induction of immediate early genes (c-fos and c-myc) and induction of fetal cardiac 
genes such as β-MHC (reviewed in [8, 9]).  The pathology of hypertrophy begins 
with the propagation of signals indicating cardiac wall stress and cell stretch from the 
cell membrane into the cardiomyocytes, a process about which a limited amount is 
known.  However, downstream early signal cascades include: release of intracellular 
calcium, transduction of mechanical signals as well as amplified angiotensin II 
(AngII) and endothelin signaling.  Calcium release activates calcineurin which 
dephosphorylates nuclear factor of activated T-cells 3 (NF-AT3) allowing 
translocation of NF-AT3 to the nucleus which initiates pro-hypertrophic gene 
expression in the cardiomyocyte [10].  Well characterized targets of these signaling 
cascades are β-myosin heavy chain (β-MHC), α-skeletal actin, phospholamban, and 
atrial natriuretic peptide (ANP) (reviewed in [8, 9]).  Other molecular pathways that 
 
 are activated include calcium-calmodulin–dependent protein kinases (CaM kinase) 
and mitogen-activated-protein kinases/ extracellular signal-regulated kinase 
(MAPK/ERK), the latter through the c-jun N-terminal kinase (JNK) [10].  Many of the 
molecular targets of these pathways during cardiomyocyte hypertrophy remain 
unknown, but the number of downstream effectors is though to be large. 
Hypertension was once thought the primary cause for cardiac hypertrophy.  
However, only 12-30% of people with mild to moderate hypertension go on to 
develop left ventricular hypertrophy (LVH) [11, 12].  In addition, some people with 
severe hypertension develop little LVH, and cases exist where only moderate 
hypertension results in severe LVH [13].  Clearly, factors other than hypertension 
contribute to determining the rate of development and severity of LVH.  Research 
estimates that up to 60% of the variation in LV mass is due to genetic factors 
independent of blood pressure [14].  In humans, numerous genes have been 
implicated in LVH mostly within the renin-angiotensin system (RAS), although new 
pathways are emerging.  Ctgf gene expression is induced by angiotensin II (AngII) 
and transforming growth factor beta (TGFβ) and thus CTGF could be acting as both 
a pro-hypertrophic and a profibrotic factor. 
In both rat and human cultured cardiomyocytes, CTGF treatment caused cell 
hypertrophy and increased expression of genetic markers of hypertrophy including 
alpha-skeletal actin and ANP [7].  In H9c2 cardiomyocytes, CTGF treatment induced 
expression of Col I and III as well as inflammatory cytokines such as tumor necrosis 
factor alpha (TNF-α) and interleukin 6 (IL-6) [15].  Collectively, these two studies 
suggest that CTGF may be mediating hypertrophic, fibrotic, and inflammatory 
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 signals in cardiac cells.  While evidence in cell culture points strongly to a role for 
CTGF in cardiac hypertrophy and fibrosis, there remains a lack of in vivo evidence 
for how CTGF functions in these processes.  To examine the role of CTGF in 
cardiac hypertrophy and fibrosis in vivo I have used three methods: 1) Inducing 
hypertension by infusion of angiotensin II [16, 17]; 2) Inducing hypertension by 
increasing renin expression with a renin transgene [18, 19]; and 3) Inducing cardiac 
pressure overload by trans-aortic constriction (TAC) [20].  Using the mouse strains 
described in the previous chapter, I can employ these methods to examine how 
altered Ctgf gene expression changes cardiac hypertrophy and fibrosis phenotypes. 
 
B. Materials and Methods 
1. Angiotensin II treatment 
AngII was infused using osmostic minipumps surgically inserted in 3–4 month 
old mice with 1, 2, or 3 copies of the Ctgf gene.  A dose of 2 mg AngII/ kg body 
weight/ day was delivered by the pump at 0.5 μl/hour for 14 days. Prior to AngII 
infusion and after 14 days of AngII treatment, mice were weighed and baseline 
echocardiograms were taken on un-anaesthetized mice using a Visualsonics Vevo 
small animal ultrasound machine (Vevo 660, 770, and 2100 models were used.).  In 
addition, for a subset of animals, the week prior to AngII infusion and for the last five 
days during AngII infusion systolic and diastolic blood pressure was measured by tail 
cuff, as previously described [21].  The animals were sacrificed on day 15 and heart, 
kidney, and lung were harvested for measurement of gross weight.  Organ to body 
weight ratios were calculated as (fresh heart weight in grams divided by body weight 
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 in grams) times 100 to get a percentage.  Small heart samples from the apex of each 
heart were taken for mRNA expression analysis by quantitative RT-PCR.  Additional 
heart tissue from untreated animals was also harvested at a later time to compare 
gene expression profile between treated and untreated mice. Tissue was also taken 
for thin sections stained either with Hematoxylin & Eosin (H&E) for examination of 
gross morphology or Masson’s trichrome stain for examination of collagen deposition 
by standard methods.  Heart sections from the animals were scored for fibrosis using 
the Masson’s Trichrome stained sections that were graded from 0 to 4 in 0.5 
intervals based on the total amount of fibrosis, extent and number of affected blood 
vessels, and level of destruction of normal tissue. 
 
2. Cross to Renin transgenic mice 
The Ctgf 3 copy mice were crossed to RenTgMK.129/SvEv heterozygous 
mice (RenTgMK+) to produce mice that were heterozygous for the RenTgMK 
transgene and had either 2 or 3 copies of the Ctgf gene (2 copy Ren+ and 3 copy 
Ren+, respectively).  Mice that were Ctgf 2 copy (WT) and Ctgf 3 copy from the 
same cross served as controls.  At an average 7 months of age, echocardiogram 
parameters were measured and then mice were sacrificed.  Following sacrifice Ren 
mice were treated the same as mice infused with AngII (see methods above). 
 
3. Trans-aortic Constriction (TAC) treatment 
Trans-aortic constriction or banding (TAC) is a surgical method of narrowing 
the aorta in order to restrict blood flow into the heart and produce a cardiac pressure 
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 overload.  Prior to surgery, baseline echocardiogram measurements were taken and 
then the aorta of each mouse was banded by minimally invasive surgical method, as 
previously described [20].  After two and four weeks of TAC, mice additional 
echocardiogram measurements were taken.  One week after the final echo (after 5 
weeks total of banding) mice were sacrificed and organs and tissues were harvested 
and analyzed the same as mice undergoing minipump insertion (see methods 
above). 
 
4. Statistical Modeling of Hypertrophy and Fibrosis 
 The effect of Ctgf gene copy number on cardiac hypertrophy, dilation, and 
cardiac fibrosis were modeled by combining many of the factors measured during or 
after AngII and TAC treatment (Table 3.1).  The models were based on what is 
currently known about the nature of each phenotype and a measurement was only 
included if there was general agreement in the literature that a change in this 
variable is generally correlated with a change in severity of the given phenotype.  
Each measurement taken during an experiment was designated an “outcome 
variable”.  Any factors that could not be controlled and may have had an impact on 
the results were treated as “covariates” including, experiment repetition, body weight 
at sacrifice and age at sacrifice.  Once the models were constructed I tested for 
correlations to two dependent variables of interest: Ctgf copy number and Ctgf gene 
expression levels in the heart at the time of sacrifice.  Using the statistical software 
package SAS (Cary, NC), statistical programs were written to determine if there was 
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 any correlation between each of the two dependent variables (tested separately) and 
the phenotypic models. 
 
 Models 
Outcome 
Variable 
Increased 
Fibrosis 
Increased 
Hypertrophy 
Increased 
Dilation 
LV FS   Decreased 
LV EF  Increased Decreased 
Stroke Volume   Decreased 
Heart Rate  Increased  
Cardiac Output   Decreased 
PW Thickening   Decreased 
RWT, systole  Increased Decreased 
RWT, diastole  Increased Decreased 
LV Vol, systole  Decreased Increased 
LV Vol, diastole  Decreased Increased 
LV Mass  Increased  
LV Mass/ BW  Increased  
Ctgf Increased   
Tgfβ Increased   
Fibronectin Increased   
Collagen I Increased   
Collagen III Increased   
Collagen IV Increased   
β-MHC  Increased  
ANP  Increased  
HW  Increased Decreased 
HW/ BW  Increased Decreased 
Histology Score Increased   
 
Table 3.1. Description of models for cardiac phenotypes.  The top eleven measurements were 
taken using conscious echocardiogram.  The next eight measurements in italics were made using 
RT-PCR to measure mRNA expression in cardiac tissue of the genes denoted.  HW and HW/BW  
measured at sacrifice and the Histology Score is a measure of cardiac fibrosis on thin histology 
sections.  All measurements were taken at the endpoint of treatment.  Abbreviations: LV = left 
ventricle, FS = fractional shortening, EF = ejection fraction, PW = posterior wall, RWT = relative wall 
thickness, Vol = Volume, BW = body weight, HW = heart weight. 
  
The first program consisted of the following four steps: 1) For each outcome 
variable in the model the values were ranked from 1 to n (n being the number of 
animals in the data set) using the command “proc rank”.  2) A mean of the rank 
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 values for all the outcome variables was calculated for each animal in the data set.  
A larger rank value indicates a more severe phenotype.  3) The mean ranks for each 
animal were then used to test if any of the three covariates (experimental repetition 
the animal came from, the age of the animal at sacrifice, and the body weight of the 
animal at sacrifice) were significantly altering the distribution of mean ranks using 
the command “proc GLM”.  If a significant p-value (p<0.05) resulted for any of the 
covariates, the mean ranks were adjusted for that covariate using “proc GLM”.  If no 
covariates significantly altered the mean rank distribution, then the mean ranks were 
used unadjusted in the next step.  4) The adjusted/unadjusted mean rank values for 
each animal were then tested for a linear association with Ctgf copy number to test if 
incremental changes in copy number produce an incremental phenotypic change 
using the command “proc freq” and the “cmh2” command.  The cmh2 command 
designates a Kruskal-Wallis test, which is a non-parametric form of an analysis of 
variances (ANOVA) [22].  The result of the test was reported as a p-value, and 
p<0.05 was considered statistically significant. 
The second statistical program tests for a correlation between Ctgf gene 
expression levels and the modeled phenotypes.  The first three steps are the same.  
In step 4) the adjusted/unadjusted mean rank value for each animal was tested for a 
correlation with endpoint Ctgf gene expression levels using the “proc CORR” 
command.  The default test for the proc CORR command is the Pearson’s 
correlation, which tests for a correlation between the rank values and the Ctgf gene 
expression as well as determines the degree of correlation (commonly known as 
Rho or r-value) [23].  An r-value ranges from -1 to 1 with a greater distance from a 
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 zero value indicating a greater correlation between the factors tested [23].   For 
example, if Ctgf gene expression increases as the rank value increases then a 
positive r-value results and if Ctgf gene expression decreases as the rank value 
increases then a negative r-value results.  The Pearson’s correlation also yields a p-
value indicating the likelihood that the correlation between the two factors tested 
occurred by chance, p<0.05 was considered statistically significant. 
 
5. Correction of p-values for multiple testing 
The Bonferroni correction was used to adjust for multiple testing because it is 
one of the most common and most stringent forms of correction for multiple testing 
[24].  The use of this method can become complicated when the number of tests 
actually performed is unclear, which is a common problem as there are no explicit 
rules for determining the number of tests that were performed [24]. 
For the purposes of this dissertation the p-value for significance was set to 
p<0.05, and p-values resulting from statistical tests were adjusted using the 
Bonferroni correction when largely or completely overlapping data sets were tested 
multiple times in the same statistical test.  For example, when the same or a largely 
overlapping set of wild type animal data for a given measurement was tested against 
a set of 1 copy data and a set of 3 copy data this reuse of the same data constitutes 
two tests, and the resulting p-values would be adjusted appropriately by multiplying 
by two.  However, when different measurements were compared or when data sets 
with less than 50% overlap were tested multiple times this partial overlap did not 
constitute multiple testing and no correction was made. 
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 B. Model 1. Angiotensin II Treatment 
Introduction 
Incidence of chronic hypertension in the United States is on the rise, one in 
three adults has high blood pressure (HBP) and another 37% of adults are pre-
hypertensive.  HBP represents a major risk factor for a cardiovascular event.  About 
seventy percent of people have HBP (>140/90 mm Hg) when they are diagnosed 
with their first heart attack, stroke, or congestive heart failure.  Blood pressure has 
been estimated to be ~50% heritable, establishing a clear genetic component [25].  
The Renin-Angiotensin system (RAS) is recognized as a major genetic component 
and master regulator of blood pressure in humans and animals. 
Angiotensin II (AngII) is the terminal signaling molecule in the RAS.  Increases 
in renin expression and renin levels result in increased circulating AngII [26].  
Increased AngII provides a pro-hypertensive signal that increases blood pressure by 
two mechanisms.  First, AngII acts in the kidney to cause retention of salts, which in 
turn causes fluid retention and increased blood volume [27].  Second, AngII also acts 
in the vascular smooth muscle cells (VSMCs) as a potent vasoconstrictor [26-28].  
Chronic HBP in humans leads to cardiac hypertrophy and cardiac fibrosis.  In 
addition, AngII acts directly on cardiomyocytes to alter their contractile properties as 
well as to induce cell hypertrophy and/or apoptosis depending on the balance of 
other molecular signals present [29, 30].  Cardiomyocyte apoptosis resulting from 
chronic exposure to high levels of AngII is repaired by replacement of dead cells with 
extracellular matrix (ECM) proteins, such as fibrillar collagen, resulting in a fibrotic 
scar [31].  Fibrotic scarring of the heart, and resulting loss of cardiac elasticity, 
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 causes the majority of the heart dysfunction related to chronic hypertension.  Over 
time hypertension and the resulting cardiac damage is a major risk factor for further 
complications of cardiovascular disease [12]. 
Administration of exogenous AngII or renin through an osmotic minipump or 
by injection has been shown to be an effective method of generating HBP in an 
animal model [16, 17].  In addition to effecting blood pressure, AngII acts as a pro-
fibrotic signaling molecule through the AT1 receptor.  One of the downstream targets 
of this signaling cascade is connective tissue growth factor (CTGF) [32]. CTGF is a 
known pro-fibrotic signaling molecule and has recently been described as a master 
regulator of fibrosis [4].  Induction of CTGF by AngII has been shown to occur in the 
case of fibrotic myocardial infarction scarring [33-36] and likely occurs in 
hypertensive phenotypes as well. 
Following cardiac injury there is an inflammatory response including 
expression of TGFβ.  In turn, TGFβ stimulates a wave of increased Ctgf expression.  
At the wound sight CTGF stimulates expression of collagen and fibronectin to rebuild 
damaged matrix, as well as acting in some cases to signal increased cells migration, 
apoptosis, and inflammation [35-37].  In healthy wound healing, CTGF expression 
will wane as the wound resolves, however, scarring and related fibrotic phenotypes 
result when Ctgf is not properly downregulated [34, 37].  Here we examine how 
altering Ctgf copy number in a mouse model alters the pathology of AngII-induced 
chronic hypertension. 
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 Results 
1. Blood pressure 
A common method of inducing hypertension in mouse models utilizes an 
osmotic minipump to deliver AngII.  These small implantable devices are more 
effective than periodic injection because they deliver drug in a known amount at a 
constant flow over a given period of time [38].  To induce hypertension, osmostic 
minipumps were surgically inserted into 3–4 month old mice with 1, 2, or 3 copies of 
the Ctgf gene.  AngII infusion of 2 mg/kg body weight/day has been shown to be 
sufficient to cause increased blood pressure, which results in damage to the heart 
and cardiac blood vessels [16, 17].  Before and at the end of AngII treatment animals 
were measured by tail cuff for blood pressure and echocardiogram for dynamic 
cardiac function.  After two weeks of treatment animals were sacrificed and tissues 
were weighed and harvested for measurement of mRNA expression of gene related 
to both cardiac fibrosis and cardiac hypertrophy. 
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Figure 3.1. Blood pressure measurements by tail cuff before and after AngII infusion.  Error 
values are standard error of the mean.  Sample size for 1 copy n=3, WT n=6, and 3 copy n=3.  
Abbreviations: S = systolic, D = diastolic 
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 Before treatment with AngII, blood pressure was measured in each mouse for 
five consecutive days and for the last five days during two weeks of AngII treatment 
the mice were measured again.  The average increase in blood pressure was not 
different between genotypes and averaged about 60 mm Hg (Fig 3.1).  An overall 
trend in diastolic and systolic BP exists before and after treatment where the 1 copy 
have the highest blood pressure and the 3 copy have the lowest blood pressure, but 
none of the differences reached statistical significance. 
 
2. Echocardiogram 
Prior to AngII treatment and after two weeks of treatment dynamic cardiac 
function was measured by echocardiogram.  Prior to treatment, the Ctgf 1 copy and 
the 3 copy mutants were nearly indistinguishable from WT mice (Table 3.2).  The 
only difference seen prior to treatment was that Ctgf 1 copy mice have slightly 
reduced left ventricle (LV) mass compared to wild type.   After 14 days of AngII 
treatment, all three genotypes showed a strong hypertrophic response to AngII 
infusion including increased LV ejection fraction (LV-EF), LV fractional shortening 
(FS) and relative wall thickness (RWT) as well as reduced LV volume (LV Vol) in 
diastole and systole (Table 3.2). 
After treatment, 1 copy mice have a statistically significantly smaller LV Vol in 
diastole and a larger RWT in diastole and systole (systole p-value was just 
suggestive) than WT mice (Table 3.2).  In addition, when initial values for LV Vol in 
diastole were subtracted from values at day 14, 1 copy animals had a greater 
reduction in LV Vol in diastole than WT animals (change in LV Vol, diastole: 1 copy = 
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 -26.2±3.2, n=13 and WT = -7.38±4.9, n=17, p = 0.01).  According to the 
echocardiogram measurements, the untreated Ctgf 1 copy mice had a larger  
 
Measurement Day Ctgf 1 copy 
WT 
(2 copy) 
p-value 
1 copy vs. WT 
0 47.6±2.6 47.8±1.7 0.483 Fractional 
Shortening (%) 14 74.4±3.4 72.8±2.4 0.305 
0 79.3±2.7 79.4±1.6 0.484 Ejection 
Fraction (%) 14 95.5±1.5 95.0±1.22 0.365 
0 29.0±2.4 26.4±1.2 0.172 Stroke volume 
(μL/beat) 14 11.7±1.4 16.4±1.4 0.029 
0 517±21 500±16 0.138 Heart Rate 
(beats/min) 14 672±13 688±12 0.237 
0 14705±1047 14223±646 0.360 Cardiac Output 
(uL/min) 14 7802±910 11317±1013 0.025 
0 44.7±5.0 37.1±2.7 0.324 Posterior Wall 
Thickening 14 38.0±5.4 43.3±3.9 0.358 
0 0.98±0.13 1.03±0.09 0.387 Relative wall 
thickness; sys 14 7.4±1.6 4.6±0.54 0.057 
0 0.33±0.03 0.37±0.02 0.182 Relative wall 
thickness; dias 14 0.96±0.09 0.66±0.03 0.004 
0 8.7±1.8 8.4±0.93 0.444 Left Ventricle 
Volume; syst 14 0.80±0.33 1.05±0.30 0.315 
0 37.7±4.0 37.1±2.3 0.449 Left Ventricle 
Volume; dias 14 11.5±1.6 18.6±1.4 0.010 
0 117±13 147±10 0.064 Left Ventricle 
Mass 14 128±13 132±6.9 0.090 
0 NA NA NA Left Ventricle 
Mass/ BW 14 0.484±0.05 0.523±0.03 0.254 
 
Table 3.2. Echocardiogram parameters for 1 copy mice prior to and after AngII treatment.  
Ejection fraction and fractional shortening was measured in percent, cardiac output was in μL/beat, 
LV volume was in μL and LV mass was in μg.  All other measurements are in units given or in 
arbitrary units.  Sample size for 1 copy n=13 and WT n=17. Error values are standard error of the 
mean and p-values are from Student T-test.  Any p-value < 0.05 is highlighted in bold and considered 
statistically significant.  Abbreviations: syst = systole, dias = diastole, and NA = not available. 
 
hypertrophic response to hypertension than WT indicating that Ctgf hemizygosity 
does not protect animals from the hypertrophic response to AngII infusion.  
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 The Ctgf 3 copy mice show no significant differences compared to WT in 
echocardiogram measurements prior to AngII treatment (Table 3.3).  As a result of 
AngII treatment, 3 copy mice show a strong hypertrophic response to hypertension.   
 
Measurement Day WT (2 copy) 
Ctgf 
3 copy 
p-value 
3 copy vs. WT 
0 50.9±1.6 51.5±1.6 0.405 Fractional 
Shortening (%) 14 64.1±1.9 76.2±1.9 0.0001 
0 82.7±1.5 83.3±1.4 0.390 Ejection 
Fraction (%) 14 92.1±1.1 97.2±0.5 0.0003 
0 28.0±1.5 30.9±1.8 0.137 Stroke volume 
(μL/beat) 14 13.3±1.1 13.2±0.9 0.477 
0 540±20 512±20 0.198 Heart Rate 
(beats/min) 14 637±11 660±11 0.106 
0 14649±612 15605±894 0.229 Cardiac Output 
(uL/min) 14 8486±716 8741±606 0.405 
0 39.2±3.9 38.9±3.3 0.475 Posterior Wall 
Thickening 14 29.8±3.3 33.2±3.1 0.251 
0 1.10±0.08 1.12±0.10 0.433 Relative wall 
thickness; sys 14 3.25±0.26 5.67±0.79 0.005 
0 0.38±0.02 0.38±0.02 0.463 Relative wall 
thickness; dias 14 0.85±0.06 0.82±0.04 0.374 
0 6.8±1.0 6.8±0.88 0.494 Left Ventricle 
Volume; syst 14 1.28±0.26 0.40±0.08 0.004 
0 34.8±2.4 37.8±2.5 0.233 Left Ventricle 
Volume; dias 14 14.6±1.2 13.6±0.9 0.287 
0 129±4.3 137±4.7 0.138 Left Ventricle 
Mass 14 146±9.9 138±6.5 0.271 
0 NA NA NA Left Ventricle 
Mass/ BW 14 0.542±0.03 0.542±0.03 0.289 
 
Table 3.3. Echocardiogram parameters for 3 copy mice prior to and after AngII treatment.  Left 
ventricle volume is measured in μL and LV mass is in μg.  All other measurements are in units given 
or in arbitrary units.  Sample size for WT n=31, and 3 copy n=23.  Error is standard error of the mean 
and p-values are from Student T-test with any p-value < 0.05 considered significant and highlighted in 
bold.  Abbreviations: syst = systole, dias = diastole, and NA = not available. 
 
The 3 copy mice have highly statistically significant differences in echocardiogram 
parameters compared to WT including: increased FS, LV-EF, RWT in systole, and 
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 decreased LV Vol in systole (Table 3.3).  Similar to 1 copy animals, 3 copy animals 
also had a greater reduction in LV Vol, diastole between zero to 14 days (change in 
LV Vol, diastole: WT = -9.74±4.9 and 3 copy = -23.8±2.3, p<0.01, WT n=20 and 3 
copy n=23).  While these differences were not all large (from 4% to 300% difference 
between WT and 3 copy), they were statistically significant and they suggest that 
Ctgf 3 copy animals do have a stronger hypertrophic response to AngII treatment.  
Clinically speaking, it is particularly interesting that both Ctgf 1 copy and 3 copy 
hearts had a greater reduction in left ventricle volume during the diastolic or relaxed 
portion of the cardiac cycle, a phenotype which is generally considered a poor 
prognostic indicator as it usually results from a loss of tissue elasticity that can be 
caused by fibrotic tissue. 
 
3. Necropsy 
 After 2 weeks treatment with AngII, mice were sacrificed and heart, kidney, 
and lung were weighed.  The heart to body weight (He/BW) and kidney to body 
weight ratio (Ki/BW) (organ weight in grams/ body weight in grams * 100) for the Ctgf 
1 copy mice was greater than the WT mice, although only the Ki/BW ratio reached 
statistical significance of p>0.05 (He/BW: 1 copy = 0.673±0.016 and WT = 
0.648±0.014, p=0.12 and Ki/BW: 1 copy = 0.724±0.011 and WT = 0.694±0.012, 
p<0.05, Table 3.4 column 1 and 2).  Increased organ to body weight ratio is one sign 
that an organ is fibrotic, and in the case of the heart, as heart weight increases 
generally the severity of hypertrophy increases.  There was no difference in lung/BW 
ratio between 1 copy and WT mice. 
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 Genotype Ratio 1 copy 2 copy set 1 2 copy set 2 3 copy 
He/ BW 0.673±0.016 0.648±0.014 0.669±0.026 0.650±0.013 
Ki/ BW 0.742±.011 0.694±0.012 0.683±0.009 0.685±0.010 
Lu/BW 0.429±.012 0.473±0.019 0.448±0.034 0.427±.0.014 
 
Table 3.4. Organ to body weight ratios for AngII treated mice. All measurements were of fresh 
tissue.  Heart/ Body Weight (He/BW) measurement is a percentage calculated by: (organ weight in 
grams/ total body weight in gram) x 100.  There were no statistically significant differences in total 
body weight between genotypes.  1 copy: n=13 for heart and kidney and n=5 for lung. 2 copy set 1: 
n=17 for heart and kidney and n=6 for lung.  2 copy set 2: n=17 for heart and kidney and n=4 for lung.  
3 copy: n=17 for heart and kidney and n=9 for lung. 
 
 
Also no significant difference existed in organ to body weight ratios for heart, kidney 
or lung between Ctgf 3 copy and WT mice (He/BW: WT = 0.669±0.026 and 3 copy = 
0.650±0.013, p=0.277 and Ki/BW: WT = 0.683±0.009 and 3 copy = 0.685±0.010, 
p=.464, and Lu/BW: WT = 0.979±0.035 and 3 copy = 0.952±0.019, p=0.264, Table 
3.4).  While little or no differences in gross organ weights occurred this result does 
not exclude the possibility of differences in cardiac fibrosis and hypertrophy, but 
could suggest the effect was small. 
 
4. Gene Expression Profiling 
To better understand the extent of the hypertrophic and fibrotic response of 
cardiac tissue, a portion of the apex of each heart was removed at sacrifice for 
examining mRNA expression using RT-PCR.  The genes αMHC, βMHC, and ANP 
were assayed as markers of hypertrophy and Ctgf, TGFβ1, fibronectin, and three 
collagens were assayed as markers of fibrosis.  Increases in all of these genes, 
except αMHC, are considered signs of increased hypertrophy and fibrosis, 
respectively. 
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 Gene: 1 copy (% of WT) Wild Type T-test p-value 
αMHC 101±11 100±5.0 0.482 
βMHC 461±131 100±18 0.002 
TGF-β1 family 122±15 100±6.2 0.090 
CTGF 60±7.6 100±5.1 0.0003 
ANP 208±13 100±9.1 0.004 
Fibronectin 135±19 100±15 0.128 
Collagen I 146±19 100±13 0.048 
Collagen III 155±22 100±13 0.054 
Collagen iV 120±9.2 100±8.5 0.112 
 
Table 3.5. mRNA expression of markers of cardiac hypertrophy and fibrosis in AngII treated 1 
copy and WT hearts.  1 copy: n=13 and WT: n=17.  Wild type AngII treated controls were set at 
100%.  Results were normalized to β-actin and separately for each experiment.  The p-values are 
from Student T-test and p-value<0.05 is considered statistically significant and highlighted in bold.  
 
βMHC mRNA was 4.6-fold higher in 1 copy mice than in WT mice and ANP is 
also about 2-fold higher than WT (Table 3.5).  Ctgf expression is close to the 
expected 50% and TGFβ1, fibronectin, and collagens III and IV were not induced 
above WT treated levels.  Collagen I was the only marker of fibrosis that was 
induced above WT levels and the difference was small.  Altogether this suggested 
that while Ctgf 1 copy mice had a greater hypertrophic response to AngII than WT, 1 
copy mice did not had a similar fibrotic response to AngII treatment as WT. 
All of the AngII treated WT and Ctgf 3 copy mice were also assayed for gene 
expression levels in comparison to each other.  The 3 copy expression levels of 
αMHC were significantly greater than WT, and the levels of βMHC were suggestively 
greater than WT.  In addition, collagen IV levels were significantly greater than WT 
and TGF-β, and collagen I and III levels were suggestively greater than WT (Table 
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 3.6).  Compared to WT, the 3 copy hearts appeared more hypertrophic and more 
fibrotic than WT. 
 
Gene: Wild Type 3 copy (% of WT) T-test p-value 
αMHC 100±4.5 141±14 0.007 
βMHC 100±12 273±97 0.054 
TGF-β1 family 100±5.7 136±19 0.054 
CTGF 100±6.6 157±40 0.099 
ANP 100±7.4 104±13 0.412 
Fibronectin 100±12 135±29 0.154 
Collagen I 100±13 176±42 0.063 
Collagen III 100±11 172±42 0.063 
Collagen IV 100±8.5 133±13 0.038 
 
Table 3.6. mRNA expression of markers of cardiac hypertrophy and fibrosis in AngII treated 
WT and 3 copy hearts. WT: n=20 and 3 copy: n=23.  Wild type AngII treated controls were set at 
100%.  Results were normalized to β-actin and separately for each experiment.  The p-values are 
from Student T-test and a p-value<0.05 is considered statistically significant and highlighted in bold.  
 
In order to understand the affect of AngII treatment separate from genotype, a 
subset of the WT and 3 copy AngII treated mice were assayed for gene expression 
levels in comparison to untreated age-matched controls. Untreated animals for each 
genotype were set to 100%, and gene expression levels for treated animals were 
measured relative to this.  Following treatment, βMHC levels increased moderately 
in WT hearts and over 12-fold in 3 copy hearts and αMHC levels were significantly  
decreased in both genotypes.  ANP levels were not appreciably altered for either 
genotype.  A change in MHC gene expression in this manner usually indicates the 
return to a pre-natal gene expression profile, often seen with cardiac hypertrophy, 
and it appeared to be stronger in 3 copy mice. 
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Wild Type 
T-test p-
value 
3 copy  (% WT 
untreated) 
T-test p-
value Gene: 
Untreated Treated  Untreated Treated  
αMHC 100±10 71.4±8.7 0.045 100±6.8 42.2±10 0.024 
βMHC 100±6.1 389±115 0.081 100±14 1253±423 0.004 
TGFβ-1  100±17 26.7±3.5 1.2x10-6 100±5.3 36.5±4.4 0.028 
CTGF 100±18 35.9±5.7 8.3x10-5 100±18 14.6±4.7 0.028 
ANP 100±13 102±15 0.470 100±34 74.8±17 0.416 
Fibronectin 100±9 48.6±11 0.008 100±11 58.4±15 0.267 
Table 3.7. mRNA expression of markers of cardiac hypertrophy and fibrosis in WT and 3 copy 
hearts verses untreated controls of the same genotype. Results are normalized to β-actin.  AngII 
untreated n = 6 for both genotypes and for AngII treated WT: n = 23 and 3 copy: n = 8 or 14.  
Untreated controls were set at 100% individually for each genotype.  Results were normalized 
separately for each experimental repetition and then combined.  The p-values are from Student T-test 
and a p<0.05 is considered significant and denoted in bold.   
  
In addition to comparing the gene expression profile of treated mice, the WT 
and 3 copy mice were also compared to untreated mice of their respective 
genotypes.  This comparison helps to understand how each genotype responded to 
treatment by normalizing expression to untreated control of the same genotype.  The 
only noticeable difference was that expression of βMHC in 3 copy mice was more 
markedly induced (Table 3.7).  In both WT and 3 copy mice following treatment, I 
observed markedly and statistically significantly suppressed expression of Ctgf, 
TGFβ, and fibronectin (Table 3.7).  This finding is in contrast to previous reports, 
which demonstrated significant increases in Ctgf, TGFβ and ECM gene expression 
[39, 40].  If active fibrosis was occurring in these hearts, this profile for fibrosis-
related genes is both surprising and perplexing, but may represent a novel finding. 
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5. Histology 
In order to determine the amount of cardiac fibrosis, thin sections of heart 
tissue were stained with Masson’s Trichrome to reveal collagen deposition then 
sections were scored for the degree of fibrosis.  The histology shows that some 
cardiac fibrosis was visible in all genotypes (Fig 3.2).  In general the fibrosis in the 
hearts of the 1 copy animals was more interstitial and diffuse in distribution with the 
majority of fibrotic tissue occurring on the interior of the left ventricle and in the 
papillary muscles (Fig 3.2A).  In wild type animals some hearts had practically no 
fibrosis like the one shown (Fig 3.2B), while other wild type hearts had some fibrosis 
and looked very similar in pattern and distribution to the 1 copy animals. 
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Figure 3.2. Masson’s Trichrome stained AngII treated hearts.  Heart tissue was fixed in 4% para-
formaldehyde and paraffin embedded.  5μm sections were stained using Masson’s trichrome 
protocol. Healthy tissue stains red and collagen and elastin stain blue. Panels A, B, and C are Ctgf 1, 
2, and 3 copy mouse hearts at 40x magnification and were typical left ventricle section for each 
genotype.  Panel D is a detail from panel C showing interstitial and invasive fibrosis in a Ctgf 3 copy 
heart at 200x magnification. 
 The 3 copy heart sections had a more focal pattern of fibrosis than the WT 
hearts with extensive areas where cardiac tissue was replaced with collagen and 
other ECM proteins (Fig 3.2C and magnified in Fig 3.2D).  The majority of the 
damage was localized to the left ventricle walls, the papillary muscles, and areas 
surrounding cardiac blood vessels.  While several 3 copy hearts had little fibrosis, 
the extent of fibrosis and overall damage to cardiac tissue was on average greater in 
3 copy animals than in WT animals. 
On average 1 copy animals had a slightly higher histology score than WT 
animals but the difference was not significant (1 copy = 1.6±0.17, n=13 and WT = 
1.4±0.23, n=17, p = 0.227).  When the unadjusted heart weight and the heart to body 
weight (He/BW) ratio was examined, 1 copy mice were no different from WT mice (1 
copy = 0.146 g ±0.004, n=13 and WT = 0.148 g ±0.004, n=17, p=0.383 and 1 copy = 
0.673±0.016, n=13 and WT = 0.648±0.014, n=17, p = 0.123).  In addition there was 
no difference in the average total body weight between the 1 copy and WT mice (1 
copy = 21.9±0.72, n=13 and WT = 22.9±0.40, n=17, p = 0.135).  Overall the 
histology and necropsy data suggest that there was no difference in the size of the 
heart or level of cardiac fibrosis between the 1 copy and WT mice. 
In contrast, the 3 copy animals had a significantly higher histology score and 
likely had overall increased fibrosis following AngII treatment (WT = 1.1±0.19, n=20 
and 3 copy = 1.5±0.17, n=23, p < 0.05).  The difference in the histology scores, 
however, was small and there was no significant difference between the genotypes 
in He/BW ratio (WT = 0.669±0.026, n=17 and 3 copy = 0.650±0.013, n=23, p = 
0.277).  In addition, there was no difference in unadjusted heart weight or total body 
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 weight between WT and 3 copy mice (WT = 0.160 g ±0.006, n=18 and 3 copy = 
0.152 g ±0.002, n=17, p=0.181 and WT = 23.9±0.50, n=18 and 3 copy = 23.6±0.58, 
n=17, p = 0.375). The differences in hypertrophy and fibrosis detected in the 
echocardiograms and histology slides, respectively, may have been too small to be 
observable in a gross measurement such as (He/BW) ratio. 
 
6. Statistical Modeling of Cardiac Hypertrophy and Fibrosis 
 Complicated phenotypes, such as hypertrophy and fibrosis, are not defined by 
a single measurement, but are instead defined by a large number of measurements.  
To better ascertain any differences in severity of cardiac hypertrophy or fibrosis 
phenotype between the genotypes tested, models of each phenotype were 
constructed using multiple measurements from the echocardiography, histology, 
necropsy, and RNA expression assay.  Each phenotype was tested for a relationship 
to Ctgf copy number or for a relationship to post-treatment Ctgf expression levels. 
Variations between sets of animals treated with AngII, experimental repetition, age of 
animal at sacrifice, and body weight of animal at sacrifice were adjusted for only 
when they had a significant effect on the distribution of the data set.   
 The primary phenotype of interest for the Ctgf mutant mice is cardiac fibrosis 
so the model of cardiac fibrosis was first tested for a Ctgf gene copy number effect 
and then a Ctgf gene expression level effect.  Ctgf gene copy number changes did 
not have an effect on severity of cardiac fibrosis when all Ctgf mutants were tested 
(1 copy: n=13, 2 copy n=31, and 3 copy n=23, p=0.52) or when just 2 and 3 copy 
mice from the same experiments were tested (2 copy n=20 and 3 copy n=23, 
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 p=0.83).  However, Ctgf gene expression levels were highly correlated to severity of 
fibrosis for both groups tested (1 copy: n=13, 2 copy n=31, and 3 copy n=23, 
p=0.0002, r=0.44 and 2 copy n=20 and 3 copy n=23, p=0.0002, r= 0.53).  When the 
r-values were squared to determine effect size, the Ctgf gene expression level 
explains roughly 20-30% of the differences in cardiac fibrosis as measured by our 
model.  The r-values were positive indicating that as the Ctgf gene expression levels 
increased the severity of fibrosis increased. 
 When a correlation between Ctgf gene copy number and the model of 
hypertrophy was tested for mice with 1, 2, or 3 copies of Ctgf, hypertrophy was 
significantly correlated to copy number (1 copy: n=13, 2 copy n=31, and 3 copy 
n=23, p=0.02).  If just 2 copy and 3 copy mice were tested in the same model there 
was also a significant correlation (2 copy n=20 and 3 copy n=23, p=0.02).  Similarly 
when a correlation between Ctgf gene expression levels and the model of 
hypertrophy was tested there was a significant correlation for all copy number tested 
together (1 copy: n=13, 2 copy n=31, and 3 copy n=23, p=0.01, r=0.31) and for just 2 
copy and 3 copy (2 copy n=20 and 3 copy n=23, p=0.004, r=0.43).  When the r-
values were squared to determine effect size, the Ctgf gene expression level 
explains roughly 10-20% of the differences in hypertrophic phenotype as measured 
by our model.  In addition, the r-values were positive indicating that as the Ctgf gene 
expression levels increased the severity of hypertrophy increased. 
Taken together the evidence from echocardiogram, gene expression profiling, 
histology, necropsy, and statistical modeling indicates that Ctgf 1 copy hearts were 
similar to WT or had a slightly increased hypertrophic and fibrotic cardiac response 
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 to AngII-induced hypertension.  This result is in contradiction to prevailing opinions 
that reducing Ctgf gene expression levels will have a protective affect.  The 3 copy 
hearts had a larger hypertrophic response to AngII-induced hypertension than the 
WT mice, but despite higher histology scores, did not have a clear increase in 
cardiac fibrosis.  Overall, Ctgf expression level, not Ctgf gene copy number, was the 
most closely correlated with severity of cardiac fibrosis and hypertrophy. 
 
C. Model 2. Renin Mice 
Introduction 
In the previous experiment the use of a minipump had several disadvantages 
including that they require surgical implantation and, therefore, a recovery period, 
and that there was considerable variation between animals of the same genotype, 
which made it more difficult to observe differences between genotypes.  In order to 
bypass the problems of minipump use, I therefore decided to use genetic 
modification to generate a more consistent mouse model of hypertension [18]. 
Renin is an upstream molecule in the RAS system, and when renin increases 
AngII also increases, creating conditions similar to treatment with an AngII minipump 
[19].  A mouse strain with genetically clamped renin over-expression was generated 
by Oliver Smithies et al. and named RenTgMK (Renin transgenic Marilyn Kozak).  
The strain carries a single copy of the renin gene incorporated into the liver-specific 
ApoA1/ApoC3 locus [18, 41].  The transgene is driven by the albumin promoter, has 
a 5’-UTR modified with addition of a Kozak ribosome entry sequence and the 3’-UTR 
from the β-globin gene resulting in renin being secreted at constitutively high levels 
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 from the liver.  Renin expressed from this allele is not sensitive to RAS feedback that 
would normally downregulate renin expressed in the kidney in order to maintain 
blood pressure homeostasis [18, 19, 41]. 
At birth, RenTgMK mice have increased left ventricle to body weight (LV/BW) 
ratio as measured by echocardiogram.  They have plasma renin at about 8 times 
wild type, which is comparable to what is seen in hypertensive human patients [19].  
In these mice, the increased renin results in elevated blood pressure of 146 mmHg, 
about 25 mmHg more than wild type animals.  As they mature RenTgMK mice 
develop significant cardiac fibrosis by 6 months of age, and half of the animals do 
not survive to one year of age [19].  Unlike mice receiving AngII by minipump, the 
RenTgMK animals have increased renin and, therefore, increased AngII throughout 
their lifetime.  Essentially, the RenTgMK mouse model produces a mouse with a 
lifelong minipump [19].  Using renin transgenic mice will facilitate the phenotyping of 
larger numbers of mice more easily without experiment to experiment variation or 
surgery and the associated recovery time.  
 
Results 
1. Echocardiogram 
Similar to the AngII experiments, prior to sacrifice functional cardiac 
parameters were measured by echocardiogram.  Mice of the genotypes, WT, Ctgf 3 
copy, Ctgf WT Ren heterozygous (WT-Ren+) and Ctgf 3 copy Ren heterozygous (3 
copy-Ren+) were measured at an average of 7 months old.  When WT mice were 
compared to WT-Ren+ mice and when 3 copy mice were compared to 3 copy-Ren+ 
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 mice, the mice carrying a Ren allele had a generally more hypertrophic profile with 
increased LV-EF and LV mass (Table 3.7).  Surprisingly, the level of hypertrophy at 
7 months old was less than previously described [19].  However, the Ren allele did 
increase the FS, LV-EF, RWT in systole and diastole, and the LV mass (Table 3.8, 
2-way ANOVA p-value for Renin status) indicating a hypertrophic phenotype.  In 
general, a larger difference existed between 3 copy mice with and without the Ren 
allele than the WT mice with and without the Ren allele.  Nevertheless, Ctgf copy 
number had no observable affect on hypertrophy as examined by echocardiogram  
 
Wild Type 3 copy  (% WT untreated) 
2-way ANOVA  
p-value 
Measurement without 
Ren Ren+ 
without 
Ren Ren+ 
Ctgf 
copy 
number 
Renin 
status 
Fractional 
Shortening, % 48.7±3.3 59.4±2.8 54.7±2.5 62.1±3.6 0.290 0.021 
Ejection 
Fraction, % 80.8±3.4 88.8±1.8 85.5±1.9 89.3±2.3 0.431 0.035 
Posterior Wall 
Thickening 36.4±6.0 38.7±4.9 42.8±5.0 40.7±4.0 0.503 0.902 
Relative wall 
thickness; s 1.20±0.18 2.18±0.48 1.4±0.14 2.81±0.64 0.400 0.025 
Relative wall 
thickness; d 0.45±0.07 0.60±0.11 0.43±0.03 0.59±0.06 0.826 0.040 
Left Ventricle 
Volume; s 6.24±1.4 3.89±0.98 5.39±0.84 4.23±1.18 0.960 0.197 
Left Ventricle 
Volume; d 32.2±2.56 29.1±3.9 36.2±3.0 31.5±3.4 0.443 0.272 
Left Ventricle 
Mass 134±17 182±12 156±10 195±10 0.178 0.001 
 
Table 3.8. Echocardiogram parameters of Ren and non-Ren mice.  WT: n=3, WT-Ren+: n=10, 3 
copy: n=11 and 3 copy-Ren+: n=14.  Ejection fraction and fractional shortening are measured in 
percent, LV volume is in μL and LV mass is in μg.  All other measurements are in units given or in 
arbitrary units.  Error values are standard error of the mean and p-values are from Student T-test.  
Any p-value < 0.05 is highlighted in bold.  Abbreviations: sys = systole and dias = diastole. 
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(Table 3.8, 2-way ANOVA p-value for Ctgf copy number), suggesting any genotype 
effect in the Ren background was not visible by echocardiogram. 
Unlike the 3 month old untreated controls in the AngII experiments, there were 
significant differences in a few parameters between the WT and Ctgf 3 copy non-
Ren mice.  In particular, Ctgf 3 copy mice had statistically significantly increased in 
LV-EF and FS (LV-EF and FS: WT vs. 3 copy p=0.04 for both), and nearly significant 
increases in posterior wall thickening (PWTh) and LV mass (PWTh: WT vs. 3 copy 
p=0.09 and LV mass: WT vs. 3 copy p=0.08).  The differences between WT and 3 
copy without the Ren gene was around 10%.  Even though the 3 copy mice had 
increased values for several echocardiogram parameters, they were still generally on 
the high end of the normal range.  This result suggests that the 3 copy animals may 
not be outright hypertrophic but may be headed in that direction. 
 
2. Histology and Necropsy 
   Following echocardiograms mice were sacrificed and organ weight and body 
weight were measured.  In addition, tissues were fixed and histology slides were 
made to examine levels of cardiac fibrosis.  The biggest differences in the Ren mice 
were in heart weight and heart to body weight ratio (Table 3.8).  Heart and He/BW 
ratios showed a strong Renin effect but no Ctgf copy number effect.  However, no 
significant differences existed in level of cardiac fibrosis on the scored Masson’s 
trichrome slides (WT = 0.8±0.60, n=3, WT-Ren+ = 1.4±0.28, n=9, 3 copy = 1.7±0.35, 
n=10, and 3 copy-Ren+ = 1.0±0.2, n=12.  Two-way ANOVA for Ctgf copy # effect  
p=0.995 and Renin genotype effect p=.438). 
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Wild Type 3 copy  (% WT untreated) 
2-way ANOVA p-
value Parameter without 
Ren Ren+ 
without 
Ren Ren+ 
Ctgf 
copy # 
Renin 
status 
Total Body 
Weight 29.8±2.1 27.2±0.96 31.0±0.91 29.8±1.1 0.474 0.138 
Heart 
Weight 0.142±0.01 0.200±0.02 0.161±0.01 0.194±0.01 0.303 0.002 
Heart 
Weight/ 
Total 
0.473 ±0.18 0.667±0.02 0.519±0.02 0.655±0.02 0.681 <0.0001 
Table 3.9. Heart and Body weights at necropsy of Ren and non-Ren mice.  All measurements 
were of fresh tissue. A) Heart/ Body Weight (He/BW) measurement was a percentage calculated by: 
(organ weight in grams/ total body weight in gram) x 100.  Error is standard error of the mean. B)  All 
p-values are from Student T-test.  The p-values were multiplied by 2 to correct for multiple testing. 
There were no statistically significant differences between 2 copy-Ren+ and 3 copy-Ren+. 
 
Similar to observations in the echocardiogram data, there were differences 
between the WT and the Ctgf 3 copy animals in the absence of the Ren background.  
The 3 copy animals had significantly increased heart and lung weights (Heart: Table 
3.9, p<0.05 and Lung: WT = 0.093g±0.003 and 3 copy =0.106g±0.004, p<0.01) as 
well as a suggestive increase in He/BW and a significant increase in Lu/BW ratio in 
the absence of a difference in total body weight (He/BW: Table 3.9 and Lu/BW WT = 
0.307%±0.02 and 3 copy =0.348%±0.01, p=0.01).  At 7 months of age results 
suggested small but significant differences in the 3 copy mice in echocardiogram 
parameters as well as in gross organ weights. 
The echocardiogram data suggested a moderate hypertrophic response to 
the Ren+ background for both WT and 3 copy mice, which is corroborated by the 
heart weight and He/BW ratio.  The histology results, however, suggested that at 7 
months of age, addition of the Ren background was not sufficient to cause a 
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 histologically measurable increase in cardiac fibrosis.  Both the echocardiograms 
and necropsy data suggested that while addition of the Ren gene does cause a 
hypertrophic response, the Ctgf 3 copy mice were not more sensitive to this stimulus 
than the WT mice.  In the absence of the Ren gene, however, we observed that the 
Ctgf 3 copy mice appeared in both echocardiograms and organ weights to be 
trending towards a more hypertrophic phenotype than the fully WT mice, but this 
effect was not observed in measures of cardiac fibrosis.  Interestingly, when 
compared to mice with and without the Ren gene, there was a separation between 
the clear affect on hypertrophy compared to the lack of an effect on cardiac fibrosis. 
 
D. Model 3. Transverse Arotic Constriction 
Introduction  
The AngII and Renin experiments above were focused on examining the role 
of varying Ctgf gene expression levels on a hypertensive mouse model.  The results 
suggest that increased Ctgf gene expression may have a small role in increasing 
hypertension-induced cardiac fibrosis but more likely increased cardiac hypertrophy.  
The experiments, however, only address the role Ctgf is playing in cardiac 
hypertrophy in the presence of RAS-induced hypertension and the direct effect of 
AngII on the vascular wall.  I, therefore, chose to induce hypertrophy through cardiac 
pressure overload using mechanical means.  Transverse aortic constriction (TAC or 
aortic banding) is a mechanical means to induce cardiac pressure overload where 
the role of the RAS can be downplayed.  Thus, how altered Ctgf gene expression 
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 affects hypertrophy can be examined in the absence of direct stimulation of Ctgf 
expression caused by exogenously applied AngII. 
TAC generates pressure overload on the heart by restricting blood flow to the 
left ventricle from the transverse aorta resulting in chronically increased systolic left 
ventrical (LV) blood pressure.  While TAC is a surgical method of inducing cardiac 
hypertrophy, the duration of experiments are generally longer than that of AngII 
infusion (4-8 weeks) giving animals longer to recover and minimizing the affect of 
surgery on the results.  In addition, unlike in AngII infusion most mouse strains will, if 
banded for a sufficient period of time, progress into heart failure [20, 42, 43].  Our lab 
has used TAC extensively and previous results suggested that it is a more robust 
method of inducing cardiomyocyte hypertrophy, increased heart to body weight ratio, 
cardiac fibrosis, and eventually cardiac dilation and heart failure [20, 43]. 
 
Results 
1. Echocardiogram 
Similar to the AngII minipump infusion experiments, mice were administered 
an echocardiogram before TAC.  Then they were remeasured after two weeks of 
TAC and after four weeks of TAC.  The intermediate time point was measured to 
detect differences in the temporal dynamics of hypertrophy between genotypes.  
After a total of 5 weeks of TAC, animals were sacrificed, necropsy was performed 
and then tissues were harvested for both mRNA gene expression assay and 
histological examination. 
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Measurement Week Ctgf 1 copy 
WT 
(2 copy) 
p-value 
1 copy vs. WT 
0 50.8±3.1 44.5±1.6 0.072 
2 59.0±4.0 45.1±2.3 0.008 
Fractional 
Shortening 
 4 59.3±5.7 50.4±3.4 0.165 
0 82.0±2.9 76.4±1.7 0.103 
2 88.0±3.5 76.7±2.2 0.014 Ejection Fraction  4 86.9±4.1 80.8±3.5 0.293 
0 28.1±3.0 32.2±1.0 0.174 
2 11.1±1.9 33.2±2.0 0.067 
Stroke volume 
(μL/beat) 
 4 22.1±3.3 24.9±1.9 0.432 
0 517±32 491±30 0.574 
2 622±36 530±48 0.158 
Heart Rate 
(beats/min) 
 4 587±38 594±21 0.882 
0 14131±1151 15802±1087 0.313 
2 16918±1949 17637±2179 0.812 Cardiac Output  4 12666±1782 14677±1077 0.061 
0 43.6±5.3 43.1±4.9 0.943 
2 35.8±7.6 45.5±6.0 0.328 
Posterior Wall 
Thickening 
 4 29.2±5.1 32.6±4.2 0.626 
0 1.11±0.16 0.82±0.053 0.071 
2 1.78±0.26 0.94±0.12 0.009 
Relative wall 
thickness; sys 
 4 2.57±0.75 1.47±0.18 0.090 
0 0.39±0.04 0.34±0.02 0.078 
2 0.52±0.07 0.35±0.04 0.043 
Relative wall 
thickness; dias 
 4 0.64±0.13 0.52±0.05 0.330 
0 7.27±1.9 10.2±1.2 0.184 
2 4.19±1.5 10.4±1.3 0.008 
Left Ventricle 
Volume; sys 
 4 4.67±2.1 7.78±2.7 0.440 
0 35.4±4.8 42.5±1.9 0.155 
2 31.1±3.1 43.6±2.7 0.009 
Left Ventricle 
Volume; dias 
 4 26.8±5.1 32.7±4.3 0.393 
0 124±15 127±7.0 0.882 
2 156±11 141±13 0.426 
Left Ventricle 
Mass 
 4 158±12 176±15 0.425 
 
Table 3.10. Echocardiogram parameters for 1 copy mice prior to, during and after TAC 
treatment.  1 copy: n=7 at all time points. At zero weeks is WT: n=9, at two weeks WT: n=8 and at 
four weeks WT: n=12.  Ejection fraction and fractional shortening were measured in percent, cardiac 
output is in μL/beat, LV volume is in μL and LV mass is in μg.  All other measurements are in units 
given or in arbitrary units.  Error values are standard error and p-values are from Student T-test.  All 
p-values were multiplied by 2 to correct for multiple testing (additional comparisons of change over 
time) and any p-value < 0.05 is bold.  Abbreviations: sys = sytole and dias = diastole.  
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 Prior to TAC surgery there were no differences in the echocardiogram 
parameters between any of the genotypes.  Throughout the experiment both the 1 
copy and WT mice showed a profile of increasing hypertrophic response to TAC 
treatment.  At both two weeks and four weeks after TAC surgery the 1 copy had 
increased FS, LV-EF, and RWT in systole and diastole as well as reduced left 
ventricle volume in systole and diastole compared to WT and at two weeks of 
treatment these differences were statistically significant (Table 3.10).  In addition, 
although not statistically signficicant 1 copy hearts had reduced PWTh and cardiac 
output compared to WT at two and four weeks.  Although not all of these differences 
were statistically significant, it is a pattern suggestive of a greater reduction in 
function due to hypertrophy in the 1 copy animals.  Interestingly, the differences 
were stronger at two weeks suggesting the 1 copy animals may have a stronger 
initial response to TAC treatment than WT animals.  An example of the temporal 
difference in response can be seen in Figure 3.3. 
In comparison to the 1 copy and WT mice, the Ctgf 3 copy mice had a 
distinctly different response to TAC treatment.  After two weeks of TAC, 3 copy mice 
had a hypertrophic response that was marginally bigger than WT.  The 3 copy mice 
had significantly increased LV mass and RWT in diastole as well as decreased 
PWTh (Table 3.11).  The changes in LV mass and PWTh were some of the biggest 
inter-genotype differences in the experiment with the LV mass a 25% increase and 
the PWTh a 30% decrease (Table 3.11).  At two weeks, the 3 copy mice appeared 
to have a larger, more hypertrophic heart with a less functional posterior wall.  
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 Measurement Week WT (2 copy) 
Ctgf 
3 copy 
p-value 
WT vs. 3 copy 
0 45.1±1.6 46.6±1.6 0.510 
2 48.0±3.4 50.8±3.4 0.584 
Fractional 
Shortening 
 4 52.6±2.9 49.1±3.4 0.452 
0 77.0±1.6 78.2±1.6 0.616 
2 78.4±3.3 80.1±3.5 0.738 Ejection Fraction  4 82.9±2.9 78.2±3.4 0.320 
0 30.7±1.2 29.1±1.5 0.410 
2 26.9±2.1 25.5±1.8 0.448 
Stroke volume 
(μL/beat) 
 4 25.0±1.6 26.8±1.8 0.839 
0 497±19 526±17 0.256 
2 544±36 632±24 0.021 
Heart Rate 
(beats/min) 
 4 603±18 658±15 0.021 
0 15142±715 15036±771 0.922 
2 16207±1648 15865±1096 0.731 Cardiac Output  4 14592±882 17494±1006 0.075 
0 44.1±4.4 41.9±2.9 0.666 
2 42.5±5.1 26.7±3.6 0.015 
Posterior Wall 
Thickening 
 4 37.3±4.3 31.3±3.9 0.302 
0 0.91±0.07 1.02±0.08 0.351 
2 1.22±0.20 1.60±0.25 0.270 
Relative wall 
thickness; sys 
 4 1.61±0.17 1.52±0.21 0.737 
0 0.34±0.02 0.37±0.02 0.320 
2 0.40±0.04 0.55±0.05 0.030 
Relative wall 
thickness; dias 
 4 0.52±0.04 0.049±0.04 0.552 
0 9.66±1.0 8.91±0.95 0.602 
2 9.71±2.2 8.80±2.7 0.805 
Left Ventricle 
Volume; sys 
 4 6.68±2.1 10.5±2.7 0.299 
0 40.5±2.0 38.0±2.2 0.422 
2 39.6±3.7 34.3±4.1 0.365 
Left Ventricle 
Volume; dias 
 4 31.7±3.3 37.3±3.8 0.299 
0 138±5.8 138±6.9 0.962 
2 145±12 185±11 0.022 
Left Ventricle 
Mass 
 4 168±12 189±10 0.182 
 
Table 3.11. Echocardiogram parameters for 3 copy mice prior to, during and after TAC 
treatment.  At zero weeks is WT: n=16, and 3 copy: n=23, at two weeks WT: n=12, and 3 copy: 
n=17, and at four weeks WT: n=16, and 3 copy: n=21.  Ejection fraction and fractional shortening 
were measured in percent, cardiac output is in μL/beat, LV volume is in μL and LV mass is in μg.  All 
other measurements are in units given or in arbitrary units.  All p-values are from Student T-test and 
multiplied by 2 to account for multiple testing.  Any p-value < 0.05 considered significant and is bold.  
Abbreviations: sys = systole and dias = diastole.  
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 After four weeks of treatment there were no significant differences in 
echocardiogram parameters between 3 copy and WT mice.  The 3 copy mice, 
however, were different in how the heart changed between week two and week four 
of TAC treatment.  Instead of continuing to become more hypertrophic like 1 copy 
and WT mice, many of the echocardiogram parameters for the 3 copy mice began to 
trend back towards baseline (see an example in Fig 3.3).  While none of the 3 copy 
values at four weeks were in the range of dilated cardiomyopathy, the reversal of 
hypertrophy does suggest that 3 copy mice may have been undergoing the earliest 
stages of cardiac dilation.  This distinctive pattern in the 3 copy mice held true for all 
echo parameters, except the LV mass, which is stable from two weeks to four 
weeks, consistent with the phenotype in early stages of cardiac dilation. 
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Figure 3.3. Left ventricle volume in systole from echocardiograms performed at zero, two and 
four weeks of TAC treatment.  Error values are standard error of the mean.  LV = left ventricle. 
 
Taken together, the data show that the largest genotypic differences were 
between Ctgf 1 copy and 3 copy animals after four weeks of TAC.  Although 
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 differences of 1 copy and 3 copy mice from their respective WT cohorts were not 
statistically significant, they suggested a gene dosage effect.  In addition, at the four 
week time point all of the echocardiogram parameters, except PWTh, were 
proportional to Ctgf copy number (Table 3.10 and 3.11, Fig 3.3).  Unfortunately, 
most of the changes between week two and week four as well as between 
genotypes in week two and four were not statistically significant because there were 
very large variations between individuals of the same genotype (see standard errors 
in Table 3.10 and 3.11 particularly for week 4).  Nonetheless, the genotype-
phenotype relationship at four weeks and the genotype-specific differences in 
response to TAC do suggest that Ctgf copy number is affecting the hypertrophic 
response to cardiac pressure overload. 
 
2. Necropsy and Histology 
After 5 weeks of TAC animals were sacrificed.  Upon removal of the heart, 
visual examination revealed that most of the Ctgf 3 copy animals had enlarged and 
fibrotic left atria as well as visibly enlarged hearts (Fig 3.5A is WT and 3.5B is 3 
copy).  Histological examination of sections of the left atria stained with Masson’s 
Trichrome show significant fibrosis in the wall of many of the left atria of 3 copy 
hearts (Fig 3.5D) and little or no fibrosis in the WT atrial wall (Fig 3.5C).  The left 
ventricle of each heart was also examined for fibrosis on Masson’s Trichrome 
stained slides and each slide was scored using the same method as the AngII 
treated hearts.  There was no statistically significant difference in fibrosis score 
between 1 copy, WT, and 3 copy hearts (1 copy = 2.1±0.2, n=6, WT = 1.8±0.3, 
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 n=12, and 3 copy = 1.7±0.2, n=14).  In addition, there was no difference in the 
distribution of scores (Fig 3.4) suggesting that Ctgf copy number did not alter the 
levels of cardiac fibrosis during TAC treatment. 
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Figure 3.4. Frequency of histology score for TAC treated mice by copy number.  Each diamond 
represents one heart with the score given on the left axis. 
 
Gross examination of the lungs showed that a few of the 3 copy mice also 
had enlarged lungs or blood pooling in the lungs, a phenotype not observed in the 
WT animals (data not shown).  Histological examination of Masson’s Trichrome 
stained slides of the lungs showed that many of the Ctgf 3 copy lungs had a loss of 
the normal open lattice-like morphology with signs of infiltrating cells and increased 
collagen deposition (Fig 3.5E is WT compared to 3.5F which is 3 copy).  In 
particular, note the increased amounts of collagen surrounding what appeared to be 
blood vessels and terminal bronchioles.  In addition, much of what is normally 
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 aveolar airspace is replaced by cell infiltrate (possibly inflammatory), fibrotic 
thickened alveolar ducts and alveolar sac walls. The Ctgf 1 copy hearts and lungs 
were similar to WT. 
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Figure 3.5. Organ morphology after five weeks of TAC treatment. A) & B) Gross heart 
morphology, 5x magnification. A) Left atria of a WT heart showing normal morphology.  B) Enlarged 
fibrotic left atria of a Ctgf 3 copy.  C) & D) Masson’s Trichrome stained sections of left atria, 100x 
magnification. C) Left atrial wall of a normal WT heart. D) Fibrotic left atrium of a 3 copy heart. E) & F) 
Masson’s Trichrome stained sections of lung tissue at 400x magnification. E) Wild type lung section 
showing normal lattice work of tissue and minimal surrounding vessels and airways. B) Ctgf 3 copy 
lung section showing loss of open lattice work and thickened collagen surrounding vessels and 
airways. 
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 At sacrifice, hearts were weighed as another method to determine the extent 
of hypertrophy.  Similar to the echocardiogram parameters at four weeks, the 
unadjusted heart weights and the He/BW ratios were proportional to Ctgf copy 
number (Table 3.12), with 1 copy the least massive and 3 copy the most massive.  
However, the genotype effect did not reach statistical significance at the level of 
p<0.05, and the comparison of 1 copy to 3 copy was only weakly significant (Heart: 1 
copy vs. 3 copy, p = 0.086, He/BW: 1 copy vs. 3 copy, p = 0.060, 1 copy n=7 and 3 
copy n=21 and values in Table 3.12).  Across genotypes this was a 15-28% increase 
in the He/ BW ratio compared to untreated animals, which is a relatively small 
increase (untreated He/ BW: 1 copy = 0.499±0.009, n=3; 2 copy = 0.515±0.013, 
n=24; and 3 copy = 0.510±0.009, n=16). 
 
 Mean Value ± Standard Error T-test p-value vs WT 
Genotype Heart Weight He/ BW Total Body 
Weight 
Heart 
Weight 
He/ BW 
1 copy 0.155±0.013 0.575±0.041 26.9±0.82 0.167 0.108 
Wild type 0.170±0.008 0.643±0.030 26.4±0.57 ---- ---- 
3 copy 0.175±0.006 0.654±0.025 26.8±0.46 0.323 0.390 
 
Table 3.12. Heart and Body weight measurements for TAC treated mice.  All measurements were 
of fresh tissue.  Heart/ Body Weight (He/BW) measurement is a percentage calculated by: (organ 
weight in grams/ total body weight in gram) x 100.  There were no statistically significant differences 
in total body weight between genotypes. 
 
In addition lung weights were compared as heavier lungs can be a sign of 
lung fibrosis and retention of fluid that is associated with poor heart function.  The 3 
copy lungs were significantly heavier than the 1 copy lungs whether as an 
unadjusted lung weight or the Lung/ Total body weight ratio (Lung: 1 copy  = 
0.094±0.003 and 3 copy  = 0.118±0.007, p = 0.032, and Lung/BW: 1 copy  = 
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 0.350±0.004 and 3 copy  = 0.428±0.030 , p = 0.045, 1 copy n=7 and 3 copy n=16).  
The heart weight of WT animals were similar to those of 3 copy mice and were not 
significantly different from either 1 copy or 3 copy. 
Generally, the pattern of heart parameters at necropsy varyied in proportion 
to Ctgf copy number.  In addition, Ctgf 3 copy animals had more extensive damage 
to the atria and lungs suggesting increased cardiac load and response to treatment. 
 
3. Gene expression profiling 
 To measure for changes in expression of genetic markers of cardiac 
hypertrophy and fibrosis, a portion of the apex of each heart was removed at 
sacrifice and RT-PCR was performed.  Levels of αMHC, βMHC, and ANP were 
measured as markers of hypertrophy and Ctgf and TGFβ levels were assayed as 
measure of active cardiac fibrosis.  No major differences were observed in the level 
of gene expression between TAC treated Ctgf 1 copy and WT mice for TGFβ, ANP 
or βMHC.  Expression levels in 1 copy mice of αMHC were slightly and fibronectin  
 
Gene: 1 copy (% of WT) Wild Type T-test p-value 
αMHC 143±7.5 100±11 0.043 
βMHC 142±19 100±28 0.402 
TGF-β1 family 95±19.7 100±9.3 0.434 
CTGF 38±5.0 100±12 0.046 
ANP 98±45 100±17 0.218 
Fibronectin 37±14 100±18 0.044 
 
Table 3.13. mRNA expression of markers of cardiac hypertrophy and fibrosis in TAC treated 1 
copy and WT hearts. Results are normalized to β-actin.  TAC treated 1 copy: n=3  and WT: results 
n=12.  Wild type TAC treated controls were set at 100%.  The p-values are from Student T-test. 
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 levels were reduced to about half of WT staying proportional to copy number despite 
treatment, but these differences were only weakly statistically significant (Table 
3.13).  Other than Ctgf expression levels, the 1 copy animals appear to have a gene 
expression profile very similar to WT for both makers of cardiac hypertrophy and 
fibrosis following TAC treatment. 
The 3 copy hearts were also compared to the WT hearts for differences in 
gene expression profile.  The 3 copy hearts had a significant increase in βMHC and 
a significant decrease in αMHC as well as a non-statistically significant increase in 
ANP, which altogether suggested an enhanced hypertrophic state (Table 3.14).  
Unexpectedly, the Ctgf expression levels in the 3 copy hearts were not 1.5-fold that 
of WT.  While fibronectin levels were increased some in 3 copy hearts, the difference 
was not statistically significant, and TGFβ levels were significantly reduced (Table 
3.14) suggesting it is unlikely that the 3 copy hearts were more fibrotic than the WT 
hearts. 
 
Gene: Wild Type 3 copy (% of WT) T-test p-value 
αMHC 100±9.4 55±8.4 0.003 
βMHC 100±23.1 308±60 0.006 
TGFβ-1 family 100±14.5 70±11 0.045 
CTGF 100±8.0 95±26 0.880 
ANP 100±10.8 141±26 0.220 
Fibronectin 100±15.7 164±62 0.362 
 
Table 3.14.  mRNA expression of markers of cardiac hypertrophy and fibrosis in TAC treated 
WT and 3 copy hearts. Results were normalized to β-actin.  TAC treated WT: n=12 and 3 copy: 
n=14.  Wild type untreated controls were set at 100% and all values were relative to that.  The p-
values are from Student T-test and were multiplied by 2 to correct for multiple testing.  A p<0.05 is 
considered significant and is in bold. 
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 Overall, the differences between 1 copy and WT hearts in genetic markers of 
cardiac hypertrophy and fibrosis were weak.  The differences between 3 copy and 
WT hearts in genetic markers of cardiac hypertrophy suggested 3 copy hearts had 
an enhanced phenotype while the markers of fibrosis were less conclusive.  
Interestingly, αMHC and fibronectin expression levels varied with Ctgf copy number 
(Table 3.13 and 3.14) suggesting, despite a relatively small effect, that altered basal 
Ctgf expression may impact cardiac response to pressure overload. 
 
E. Discussion 
Previous research and prevailing opinions in the field have indicated that 
CTGF is a key pro-fibrotic factor and it has been widely suggested that reduction of 
Ctgf expression is likely to be an effective method of reducing pathological cardiac 
damage [4, 37]. To better examine what function CTGF may have in CVD and 
directly test if genetic variations in Ctgf expression can alter the cardiac hypertrophy 
and fibrotic phenotypes under pathological conditions, Ctgf mutant mice were put 
under conditions of systemic hypertension or cardiac pressure overload.  
Surprisingly, across all the experiments, the Ctgf genotype-specific differences were 
small. 
Treatment of mice for two weeks with AngII was probably the most 
extensively analyzed.  The 1 copy mice showed a subtle increase in hypertrophy 
over WT, but it was clear that reduction of Ctgf expression to half of its normal levels 
is not sufficient to prevent hypertension-induced cardiac hypertrophy.  In addition, 
the Ctgf 1 copy mice had levels of cardiac fibrosis similar to WT animals suggesting 
90 
 reduction of Ctgf levels alone may not be sufficient to reduce cardiac fibrosis.  A 
mouse model with expression of Ctgf lower than 50% may be necessary to 
determine if reduction of Ctgf expression is an effective method of preventing or 
ameliorating hypertension-induced cardiac damage. 
The Ctgf 3 copy mice had moderately increased cardiac fibrosis compared to 
WT in response to hypertension induced by AngII infusion.  In addition, the 3 copy 
mice had an increase in cardiac fibrosis on histology slides and increased 
expression of pro-fibrotic markers.  Despite only a moderate increase in hypertrophy, 
excess Ctgf expression in the cardiac tissue does translate to a measurable increase 
in cardiac fibrosis.  Together, the data suggests that the level of Ctgf expression in 
cardiac tissue undergoing hypertrophy may be a partial determinant in the extent 
and severity of cardiac fibrosis. 
Surprisingly, and in contrast to previous findings, Ctgf, TGFβ, and fibronectin 
levels in the hearts of WT and 3 copy AngII treated animals were noticeably lower 
than that of untreated hearts of the same genotype.  Previous findings of increased 
Ctgf expression in response to pro-hypertrophic stimuli come from tissue culture 
assays, myocardial infarction models and measurements of response to acute 
treatment [1, 36, 44].  There is a lack of evidence as to how Ctgf expression levels 
may behave in an animal model of chronic hypertension.  A two-week experiment 
such as this was acute in that it was short in duration and there was a sudden 
increase in blood pressure (nearly 60 mmHg increase in less than seven days).  
However, compared to other models where much larger doses of AngII are given for 
only one to three days [35], a two-week experiment may represent a model that is 
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 more chronic in nature, thus, explaining why Ctgf and other markers of fibrosis were 
observed to be downregulated.  Over the short term increased Ctgf production has 
been shown to be important for stimulating cell migration, ECM turnover and other 
processes necessary in repairing damaged tissue [37, 45].  Specifically in the heart, 
prolonged CTGF production has been associated with cardiac scarring [36, 46].  
Therefore, as healing progresses decreased Ctgf production may be important 
adaptive mechanism in the prevention of scarring. 
As another model of hypertension, Ctgf mutant mice were crossed to renin 
over-expressor mice to examine how altering Ctgf copy number and gene 
expression modulates cardiac hypertrophy and fibrosis induced by lifelong 
hypertension.  While addition of the Ren background caused mild hypertrophy and 
cardiac fibrosis in both the WT and 3 copy mice, the overall phenotype at 7 months 
of age was much milder than AngII treatment.  Likely as a result of the milder 
phenotype, no differences were visible between Ctgf 3 copy and WT mice in the Ren 
background.  Nevertheless, it is worth noting that there was again a general trend 
toward increased hypertrophy in the 3 copy-Ren+ mice compared to the WT-Ren+.  
Aging the Ren mice longer until hypertrophy and fibrosis became more severe may 
have produced more pronounced differences between WT-Ren+ and 3 copy-Ren+ 
animals. 
In the Ren experiments, WT and 3 copy seven-month old mice were used as 
controls.  When these non-Ren mice were compared, the 3 copy mice appeared to 
have increased heart size and hypertrophy compared to fully WT mice.  This 
difference was not observed in younger 3-4 month old mice (observations of AngII 
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 and TAC animals prior to treatment).  This observation suggested that aging alone 
may be a viable stress for revealing the differences between 3 copy and WT mice, 
which will be examined in the next chapter. 
As a model of cardiac hypertrophy and fibrosis that is less dependent on the 
RAS, I also used trans-aortic banding.  TAC treatment is considered a more 
strenuous, so the expectation was a bigger difference between WT and Ctgf mutant 
mouse strains.  The results, however, cannot be summed up so simply.  Again, the 
difference between genotypes was small, but more importantly, the pattern of 
response was a linear association between phenotype and Ctgf copy number.  The 
largest genotypic differences were seen at the midpoint where the Ctgf 1 copy mice 
had increased hypertrophy compared to WT, but by four weeks of TAC, the 1 copy 
mice were still more hypertrophic than WT but the differences were no longer 
statistically significant.  At sacrifice, a few differences in genetic markers of cardiac 
hypertrophy or fibrosis suggested that by five weeks of treatment the phenotypic 
differences observed at two weeks by echocardiogram had largely evened out.  The 
evidence suggests that the 1 copy mice had an accelerated hypertrophic response 
to TAC treatment during the first two weeks, which leveled off and persisted over 
time without progressing to dilation, and by five weeks of treatment the 1 copy mice 
had a similar or only slightly more severe phenotype than WT mice. 
After two weeks of TAC the 3 copy mice were also more hypertrophic than 
WT, but by four weeks they appeared less hypertrophic than WT.  Similar to the 1 
copy mice, the 3 copy mice had a stronger initial response to TAC than WT, but in 
contrast to 1 copy appeared to be reversing towards cardiac dilation by week four.  
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 Further evidence for cardiac damage in the 3 copy mice comes from the gross 
morphology and histology of the heart.  In most of the Ctgf 3 copy mice there was 
significant atrial fibrosis and/or fibrotic lung damage, which was largely absent in 1 
copy and WT hearts.  Whether these pathologies were a cause of cardiac 
hypertrophy or a result of it is unclear, but it is worth noting that in human congestive 
heart failure this sort of lung damage, due to poor fluid clearance as a result of 
reduced heart function, is common [47].  While the 3 copy hearts were not 
sufficiently advanced in cardiac dilation to be causing congestion of the lungs, it is an 
interesting correlation. 
The comparison of Ctgf 1 copy mice to WT mice and Ctgf 3 copy mice to WT 
mice was originally conceived as two separate endeavors; analysis of the data 
suggested trends existed across the three genotypes in the TAC experiments.  After 
four weeks of TAC treatment in most echocardiogram parameters, the biggest 
genotype differences were between Ctgf 1 copy and 3 copy mice suggesting a gene 
dosage dependent effect.  The same effect could be seen in expression levels of the 
genetic markers of hypertrophy and in measurements of heart weight.  Overall, 
under conditions of TAC treatment Ctgf copy number had a greater influence on 
cardiac hypertrophy than cardiac fibrosis and appeared to be temporally altering the 
progression of hypertrophy. 
By utilizing multiple mechanisms to induce cardiac stress on mice with varying 
Ctgf gene copy number, the role of Ctgf in cardiac hypertrophy and cardiac fibrosis 
was examined. Reduction of Ctgf gene expression has been widely suggested as a 
target for anti-fibrotic drug development [37].  The phenotype of the Ctgf 1 copy mice 
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 indicates that, reduction of Ctgf gene expression by half was not sufficient to prevent 
cardiac damage and may have caused greater harm bringing into question its value 
as a target for anti-fibrotic drugs.  Increased CTGF levels were thought to be causal 
in fibrosis despite a dearth of direct evidence.  Altogether, the evidence from three 
different models of cardiac fibrosis indicated that variations in Ctgf gene expression 
within the physiological range that is likely to occur in the human population alone 
influences cardiac hypertrophy and cardiac fibrosis only mildly.  While the Ctgf 
genotype-specific response to treatment varied depending on the type of stress and 
the amount of time it was applied, the results indicate that Ctgf is more strongly 
associated with severity of cardiac hypertrophy than with severity of cardiac fibrosis.  
It is possible that larger changes in Ctgf gene expression will result in a more severe 
phenotype or that increased Ctgf expression is only pathological in the presence of 
other pro-fibrotic factors. 
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CHAPTER 4 
THE EFFECTS OF INCREASED CTGF GENE EXPRESSION ON AGING-
ASSOCIATED CARDIAC HYPERTROPHY AND CARDIAC FIBROSIS 
 
A. Introduction 
 Like so many other common diseases that face humans, cardiovascular 
disease (CVD) is largely an aging-associated disease.  Evolutionarily speaking, 
diseases that tend to occur after the prime reproductive years are not selected out of 
the population as evolution only acts on diseases that reduce the ability of a person 
to pass on their genes.  It has even been suggested that some of the alleles that 
increase likelihood of development of aging-associated diseases are an advantage 
to humans in fertility during child-bearing years [1].  For most people, the onset of 
clinically symptomatic CVD does not become evident until after prime child-bearing 
years [2].  Animal models of CVD, including Apolipoprotein E knockout and Low 
Density Lipoprotein receptor knockout models, follow a similar pattern in that CVD 
onset is not immediate [2, 3].  Chronic conditions like high blood pressure (HBP) and 
dyslipidemia require time to result in cardiovascular disease. 
 Previous studies of cardiac function in aged mice have shown that, without 
further intervention, as mice age the heart becomes mildly hypertrophic and fibrotic, 
thus establishing a naturally occurring model for cardiac aging [4, 5].  Experiments 
outlined in previous chapters suggested that inducing hypertension or cardiac 
  
pressure overload in the Ctgf mutant mice had a small but observable impact on 
severity cardiac hypertrophy and fibrosis.  It is possible that the mechanical stress of 
these treatments is too harsh to detect a small effect.  In addition, preliminary 
echocardiogram data from WT and Ctgf 3 copy controls (discussed in chapter 3) 
suggested that as young as 7 months old, there were differences in cardiac function 
between untreated Ctgf 3 copy and WT mice.  If altered Ctgf gene expression has a 
small effect, given time and the usual stress of aging, a difference in the normal 
cardiovascular aging process could become visible in the Ctgf mutant mice. 
In order to more closely examine any genotype-specific cardiovascular 
differences that may occur due to aging, Ctgf 3 copy and 4 copy mice as well as WT 
controls were aged to 12 to 14 months to determine how Ctgf expression levels 
affect the natural aging process of the heart. 
 
B. Materials and Methods 
1. Aged animals 
 Wild type and Ctgf duplication mice (3 copy and 4 copy) were aged to 12-14 
months then measured unanaesthetized by echocardiogram to determine functional 
cardiac parameters.  Animals were sacrificed and total body and organ weights were 
measured, femur length was measured by hand, approximate body fat was 
determined by weighing the inguinal and gonadal fat pads.  Tissue samples were 
taken for mRNA gene expression by RT-PCR and for histology as described in 
previous chapters.  In addition, a subset of mice were assayed by RT-PCR for one 
the gene smooth-muscle actin (SMA) using the primers 5’-GCA GGT GAT CAC CAT 
101 
  
TGG AA-3’ (forward), 5’-GCT GAC TCC ATC CCA ATG AA-3’ (reverse), and 5’-F 
CGA ACG CTT CCG CTG CCC AGA Q-3’ (probe).  Similar to the AngII mice, Ctgf 
copy number (2, 3 and 4 copy) and Ctgf gene expression levels were tested for a 
statistical association to the models of cardiac hypertrophy and cardiac fibrosis 
described in Chapter 3.  All other methods were the same as in previous chapters. 
 
2. Young controls 
In addition to aged mice, young control WT and Ctgf 3 copy mice were also 
measured by echocardiogram, necropsy, mRNA profiling, and histology.  As much 
as possible young animals were treated identically to the animals aged to one year.  
For echocardiogram data the large set of pre-treatment data from the Angiotensin II 
and TAC experiments was combined and acted as a set of young controls.  These 
animals generally ranged from 3 to 4 months old at the time of echocardiogram 
measurement.  A separate sample of young animals underwent necropsy at 3 to 5 
months old and had histological determinations performed in the same manner as 
the one year old animals.  Data from this set of young animals has not been 
previously presented. 
 
C. Results 
Mice aged to one year 
1. Echocardiogram 
 Wild type (WT), Ctgf 3 copy and Ctgf 4 copy mice were echoed at 12-14 
months of age to determine functional differences in cardiac parameters.  Compared 
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to WT the Ctgf 3 copy mice had significantly increased posterior wall thickening 
(PWTh) and cardiac output (CO) at one year of age (p<0.05, Table 4.1) and there 
were also suggestive increases in FS and LV-EF as well as a suggestive decrease 
in LV Vol in systole between WT and 3 copy mice (p<0.10,Table 4.1).  These 
changes in echocardiogram parameters show that the 3 copy mice had hearts with 
thicker walls that were beating harder, which suggests a more hypertrophic 
phenotype in 3 copy mice. 
The 4 copy mice had a similar phenotype to the 3 copy mice with even more 
pronounced increases in hypertrophy including significantly increased FS, RWT in 
systole, LV-EF, and LV mass compared to WT (p<0.05) and there was also a 
suggestive decrease in LV Vol in (Table 4.1, p<0.10).  In addition, the LV-EF value 
was above what is generally considered that normal range for mice (4 copy LV-EF = 
87.3±1.3, normal range = 55-85%). These changes in echocardiogram parameters 
show that 4 copy mice had larger, thicker-walled hearts that were beating harder 
than the WT controls, which does suggest an exaggerated hypertrophic phenotype 
in the 4 copy mice. 
Also worth noting was that nine of the twelve echocardiogram parameters had 
a proportional relationship to Ctgf copy number (FS, RWT in systole, PWTh, LV Vol 
in systole and diastole, LV-EF, Heart rate, Stroke Volume and CO).   As the Ctgf 
copy number increased, in genera,l the heart was larger and thicker walled, had 
reduced chamber volume, and was beating harder.  Overall, the changes in cardiac 
function suggested that increased Ctgf copy number aggravated age-related cardiac 
hypertrophy. 
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Measurement 
p-value 
3 copy 
vs. WT 
WT 
(2 copy) 
Ctgf 
3 copy 
Ctgf 
4 copy 
p-value 
4 copy 
vs. WT 
Fractional 
Shortening (%) 0.095 50.2±1.5 52.9±1.1 56.6±1.8 0.006 
Ejection 
Fraction (%) 0.084 81.6±1.4 84.0±0.97 87.3±1.3 0.008 
Stroke volume 
(μL/beat) 0.469 31.8±1.4 31.9±1.1 32.4±1.9 0.392 
Heart Rate 
(beats/min) <0.001 511±12 566±10 597±16 <0.0001
Cardiac Output 
(uL/min) 0.025 16033±662 18105±744 19351±1233 0.007 
Posterior Wall 
Thickening 0.032 40.5±2.6 47.6±2.6 50.2±3.1 0.014 
Relative wall 
thickness; sys 0.261 1.11±0.07 1.17±0.06 1.37±0.11 0.017 
Relative wall 
thickness; dias 0.157 0.381±0.02 0.360±0.01 0.385±0.02 0.450 
Left Ventricle 
Volume; syst 0.095 7.94±0.96 6.50±0.57 4.90±0.65 0.022 
Left Ventricle 
Volume; dias 0.313 39.7±2.2 38.4±1.6 37.3±2.3 0.256 
Left Ventricle 
Mass; Un 0.073 148±6.3 136±4.9 155±5.8 0.234 
Left Ventricle 
Mass/ BW 0.381 3.76±0.12 3.83±0.17 3.66±0.18 0.328 
 
Table 4.1. Echocardiogram parameters of mice aged to one year.  WT: n=27, 3 copy: n=35, and 4 
copy: n=13.  LV volume is measured in μL, LV mass is in μg and BW is in grams.  All other 
measurements are in units given or in arbitrary units.  Error values are standard error of the mean, p-
values are from Student T-test and any p-value < 0.05 is highlighted in bold.  Abbreviations: syst = 
systole, dias = diastole, Un = Uncorrected, and BW = body weight. 
 
Since for a majority of the measurements a relationship between copy 
number and severity of phenotype existed, it made sense to look for significant 
differences between all three means in a single test using analysis of variance 
(ANOVA).  The ANOVA test produced a highly significant p-value (p<0.0001) for 
heart rate, significant p-values (p<0.05) for FS, LV-EF, and CO as well as suggestive 
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p-values (p<0.10) for PWTh and LV Vol in systole.  The finding of significance by 
ANOVA for a genotype effect in so many parameters reinforces the conclusions that 
there is a genotype effect caused by altered Ctgf copy number. 
 
2. Necropsy 
Following echocardiogram animals were sacrificed, organs were weighed, 
and histology was evaluated.  The unadjusted heart weights between WT and 3 
copy mice (Table 4.2) were indistinguishable, but when heart weight was adjusted to 
body weight (He/BW), the 3 copy mice had on average heavier hearts than WT 
(p<0.05, Table 4.2).  The difference in the He/BW ratio may be in part because the 
total weight of the 3 copy mice was on average 2.8 grams less than WT.  If this 
difference in body weight is just fat weight then there is likely no difference in heart 
weight; however, if the difference is in body size, then the 3 copy animals have 
proportionally larger hearts.  For a subset of animals lean weight and femur length 
were measured at sacrifice.  There was not a statistically significant difference in fat 
weight (WT = 0.866g±0.12, n=8 and 3 copy = 0.927g±0.13, n=10, p=0.371), but 
there was a suggestive difference in femur length where 3 copy mice had shorter 
femurs (WT = 13.1mm±0.4, n=15 and 3 copy = 12.6mm±0.2, n=19, p=0.073).  
Altogether, the data indicated that 3 copy mice were smaller-bodied than WT and 
had slightly larger hearts in comparison to body size. 
There were no statistically significant differences in unadjusted heart weight 
between the WT and 4 copy mice, and the He/BW ratio for 4 copy mice was smaller 
than WT (Table 4.2).  The 4 copy mice weighed on average 5.1 grams more than 
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the WT mice (Table 4.2), may have had longer femurs than WT (WT = 13.1g±0.4, 
n=15 and 4 copy = 13.5g±0.2, n=11, p=0.227), but had similar amounts of body fat 
(WT = 0.866mm±0.12, n=8 and 4 copy = 0.965mm±0.21, n=6, p=0.339).  The 4 copy 
mice may have been bigger-bodied than the WT mice, and while it is hard to draw 
any definite conclusion about a genotypic difference in heart size, the data 
suggested that the 4 copy hearts were similar in size or smaller than WT. 
 
Measurement 
p-value 
3 copy 
vs. WT 
WT 
(2 copy) 
Ctgf 
3 copy 
Ctgf 
4 copy 
p-value 
4 copy 
vs. WT 
Body Weight 0.001 31.9±0.9 29.1±0.6 34.2±0.9 0.037 
Heart Weight 0.065 0.163±0.005 0.155±0.003 0.163±0.003 0.479 
Lung Weight 0.038 0.108±0.002 0.115±0.003 0.128±0.003 <0.0001 
Heart/ BW 0.014 0.511±0.01 0.535±0.01 0.480±0.01 0.018 
Lung/ BW <0.0001 0.345±0.01 0.394±0.01 0.376±0.01 0.016 
Lean BW 0.099 29.8±1.2 27.6±1.1 32.2±0.88 0.079 
Heart/ Lean BW 0.308 0.547±0.023 0.562±0.023 0.506±0.014 0.070 
Lung/ Lean BW 0.015 0.363±0.015 0.417±0.017 0.397±0.011 0.068 
Heart Fibrosis 
Score 0.011 0.7±0.2 1.3±0.2 0.4±0.1 0.414 
 
Table 4.2. Organ and body weight measurements at necropsy.  Error values are standard error of 
the mean and p-values are from Student T-test.  For WT n=29, 3 copy n=33, and 4 copy n=13.  
Except for lean BW where WT n=8, 3 copy n=10, and 4 copy n=6 and heart fibrosis score where WT 
n=22, 3 copy n=23, and 4 copy n=6.  Any p-value < 0.05 is highlighted in bold.  All weights are in 
grams.  All ratios were calculated as: (organ weight in grams x body weight in grams) x 100.  
Abbreviations: BW = total body weight in grams. 
 
Generally a heavier heart suggests increased hypertrophy and/or increased 
fibrosis, which can be associated or causal of lung damage.  Generally, heavier 
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lungs indicates damage including fibrosis and/or cell infiltrate, but can also be a sign 
of fluid retention in the lungs possibly because of reduced cardiac function  [6, 7].  
To screen for lung damage unadjusted lung weights and lung to body weight 
(Lu/BW) ratios were determined (Table 4.2).  For both the 3 copy and 4 copy mice in 
unadjusted and BW adjusted measurements, the Ctgf mutant mice had significantly 
heavier lungs than WT (Table 4.2).  Since both 3 copy and 4 copy mice have 
elevated LV-EF, heavier lungs were not likely to be due to fluid retention caused by 
congestive heart failure but may indicate the presence of fibrosis or other disease. 
 
3. Histology 
In order to better understand the pathology of the heart in these animals, thin 
heart sections were stained using the Masson’s Trichrome method to examine 
extent of fibrosis and other pathology in the heart and lungs.  Hearts were given a 
score based on extent of fibrotic tissue.   Each genotype had a range of cardiac 
damage with noticeable individual variation within each genotype.  On average, the 
3 copy mice had almost twice the fibrosis as WT (Table 4.2).  There was no 
difference in extent of fibrosis in 4 copy hearts compared to WT further suggesting 
that hypertrophy in 4 copy mice was not pathological. 
Due to the significantly increased lung weight in the 3 and 4 copy mice 
compared to WT, Masson’s Trichrome stained slide of lung tissue for all three 
genotypes was examined for histological differences (Fig 4.1).  The 3 copy animals 
were largely similar to WT (Fig 4A and 4B) with a few 3 copy animals appearing to 
have reduced airspace suggestive of thickening of the alveolar walls, fibrosis, or cell 
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infiltrate, but variation between individuals was large, preventing a conclusive 
finding.  The 4 copy animals, however, had a much more dramatic phenotype where 
all six of the 4 copy animals examined had increased levels of cell infiltrate and 
fibrosis with 10% or more occlusion of the airspace and areas in or around the 
terminal bronchioles and blood vessels with near 100% occlusion (Fig 4.1C and 4D).  
The extent of damage to the lungs of 4 copy animals did vary, but it was ubiquitously 
more severe than the average WT animal.  
 
                  
A B 
 
                  
C D 
Figure 4.1. Morphology of lung at one year of age of WT and 4 copy mice.  Masson’s Trichrome 
stained showing collagen and elastin in blue. A) WT lung showing normal some age associated 
thickening of alveolar walls.  B) Magnified image of section in A showing some thickened collagen 
network an artery.  C) Ctgf 4 copy lung section showing loss of open latticework, cell infiltrate and 
fibrosis.  D) Magnified image of section in C showing extensive collagen surrounding vessels and 
airways as well as infiltrating cells. 
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Overall the organ weights and histology suggest that hearts of the 3 copy 
mice w
but 
. Expression of hypertrophic and fibrotic markers 
ayed for genetic markers of 
, 
evere 
P 
s 
 While 
ere more hypertrophic and more fibrotic than WT.  The lung weights and 
histology also suggested that the 3 copy animals may have some lung damage, 
the severity varied and may not be greater than WT.  The 4 copy mice had a more 
clear case of damage to the lungs, but the data in respect to the heart was less 
conclusive. 
 
4
 A small portion of the apex of each heart was ass
cardiac hypertrophy and fibrosis by RT-PCR.  αMHC, βMHC, ANP and smooth 
muscle actin (SMA) were all used as markers of cardiac hypertrophy and CTGF
TGFβ, fibronectin and collagens I, III, and IV were used as markers of cardiac 
fibrosis.  Increases in all of these genes are generally associated with a more s
phenotype, except for αMHC where a decrease can be associated with increased 
hypertrophy but is not required [8].  Many of the same genes were increased in 
expression in the 3 and 4 copy mice when compared to WT including αMHC, AN
and TGFβ (Table 4.3).  There was also a significant increase in the fibronectin level
in the 3 copy mice, and levels of collagens I and III were increased 2 to 2.5-fold, but 
the difference was not significant due to large variations within each genotype.  In 
the 4 copy mice, there was a significant increase in collagen IV, although this 
difference was so small, it was somewhat doubtful that it was real (Table 4.3). 
reaching statistical significance, many of the differences in genetic markers are 
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small.  These changes are, however, commensurate with the small differences that 
have been observed between these genotypes in other assays. 
 
Gene 
p-value 
3 copy 
vs. WT 
WT 
(2 copy) 
Ctgf 
3 copy 
Ctgf 
4 copy 
p-value 
4 copy 
vs. WT 
αMHC 0.041 100±8.2 124±10 159±19 0.002 
βMHC 0.133 100±20 75.0±12 140±25 0.326 
ANP 0.033 100±12 152±23 144±20 0.048 
CTGF 0.311 100±16 90.0±11 68.5±11 0.092 
TGFβ 0.037 100±7.1 126±11 114±12 0.002 
Fibronectin 0.031 100±8 281±84 122±18 0.153 
Collagen I 0.180 100±9 260±149 116±12 0.140 
Collagen III 0.169 100±8 222±109 115±17 0.200 
Collagen IV 0.188 100±6.9 110±13 125±11 0.023 
SMA 0.164 100±28 148±38 ND ND 
 
Table 4.3. mRNA expression of genetic markers of cardiac hypertrophy and fibrosis in mice 
aged to one year.  For Ctgf, bMHC, ANP and fibronectin WT n=27, 3 copy n=33, and 4 copy n=13.  
For TGFB, aMHC, and the Collagens WT n=18, 3 copy n=24, and 4 copy n=13.  For SMA WT n=13 
and 3 copy n=13.  Samples were normalized to β-actin and were relative WT, which was set to 100%.  
Any p-value<0.05 is highlighted in bold.  Error values are standard error of the mean and p-values are 
from Student T-test.  Abbreviations: SMA is smooth muscle actin and ND is not determined. 
 
 
5. Statistical Modeling of Cardiac Hypertrophy and Fibrosis in Aged mice 
 In order to better determine if there was an association between Ctgf copy 
number or Ctgf expression levels and cardiac hypertrophy and/or fibrosis, multiple 
factors were combined into a statistical model to increase the power to detect an 
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association.  Data from echocardiography, necropsy, histology, and gene expression 
profiling were combined for WT, 3 copy, and 4 copy mice.  Cardiac hypertrophy was 
associated with copy number with a suggestive p-value (p=0.10), but Ctgf gene 
expression levels irregardless of copy number was not associated with cardiac 
hypertrophy (p=0.80).  In addition, similar to previous experiments, Ctgf copy 
number was not associated with cardiac fibrosis.  However, Ctgf gene expression 
levels were highly correlated with cardiac fibrosis (r2 = 0.327, p<0.0001) explaining 
about 33% of the variation.  Ctgf gene expression levels may have been associated 
with fibrosis, even though Ctgf copy number was not, because Ctgf gene expression 
levels varied widely within each genotype. 
 
Comparision of one year old mice to young mice 
To better understand the progression of the hypertrophy in Ctgf 3 copy 
animals, “young” (3-5 month old) WT and 3 copy mice were compared to the 12-14 
month aged counterparts.  In particular, examining young animals can help delineate 
between the possibilities that: 1) Ctgf 3 copy animals are different from WT starting 
from a young age and the hypertrophic phenotype observed has a developmental 
origin prior to adulthood or 2) Ctgf 3 copy animals have an accelerated or more 
severe hypertrophic phenotype as a result of the normal aging process.  As Ctgf has 
been described to have roles in both development and aging, the answer could also 
be a combination of both 1) and 2). 
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1. Echocardiogram 
 By combining the echocardiogram data for the pre-treatment animals in both 
the AngII and TAC experiments, a large data set could be examined to detect even 
small differences between genotypes.  The majority of these animals were 
measured between three to four months old (slightly younger than the necropsy 
data).  As in previous experiments, no differences existed in any of the 
echocardiogram parameters between young untreated WT and 3 copy animals (data 
not shown).  Therefore, any differences in cardiac function between WT and 3 copy 
mice are occurring after four months of age. 
 In addition, the result of echocardiograms of young WT animals, shown 
above, was compared to the data from one year old WT animals and there were no 
significant differences in echocardiogram parameters between young and 1 year old 
WT animals (data not shown).  The young 3 copy animals were also compared to 
their one year old counterparts and there were significant increases in PWTh, FS, 
EF and CO (PWTh: young 3 copy = 40.5%±2.2 and 1 year 3 copy = 47.6%±2.6, 
p=0.20; FS: young 3 copy = 48.9%±1.2 and 1 year 3 copy = 52.9%±1.1, p= 0.027; 
EF: young 3 copy = 80.5%±1.1 and 1 year 3 copy = 84.0%±1.0, p=0.031; and CO: 
young 3 copy = 15300±580 and 1 year 3 copy = 18105±744, p=0.004, young n=43 
and 1 year n=35, Fig 4.2).  The young WT and 3 copy mice start out the same, but 
as the 3 copy mice age, they undergo changes in heart function that were 
suggestive of cardiac hypertrophy (Fig 4.2). 
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Figure 4.2.  Echocardiogram parameters in young verses old 3 copy mice. A) Parameters 
expressed in percent. B) Cardiac output expressed in microliters per minute.  All parameters shown 
were statistically significantly different between young 3 copy and 1 year old 3 copy animals. Young 3 
copy n=43 and 1 year old 3 copy n=35.  The p-values are from Student T-test and were multiplied by 
2 to correct for multiple testing. 
 
 
2. Necropsy and Histology 
As both the WT and 3 copy mice aged there were significant increases in the 
weight of both the heart and the lungs (Table 4.4).  Concordantly, in the WT mice 
body weight also increased about 6 grams as the animals aged keeping the He/BW 
and Lu/BW ratio constant (Fig 4.3).   The 3 copy mice had a smaller increase in 
heart and lung weight but also gained proportionally less total body weight over the 
same time period (Table 4.4).   
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Param. 
p-value 
Young 
vs. Old 
WT 
Young WT 
(2 copy) 
Old WT 
(2 copy) 
Young Ctgf
3 copy 
Old Ctgf 
3 copy 
p-value 
Young 
vs. Old 3 
copy 
Body 
Mass 4.2x10
-8 26.2±0.45 31.9±0.9 27.8±0.8 29.1±0.6 0.085 
Heart 1.0x10-6 0.134±0.003 0.163±0.005 0.141±0.002 0.155±0.003 0.002 
Lung 0.001 0.094±0.005 0.108±0.002 0.102±0.002 0.115±0.003 0.005 
 
Table 4.4. Organ and body weight measurements at necropsy of young and old WT and 3 copy 
mice.  For young WT n=24, old WT n=29, young 3 copy n=16, and old 3 copy n=33.  Any p-value < 
0.05 is highlighted in bold.  All weights are in grams.  Error values are standard error of the mean and 
p-values are from Student T-test.  Abbreviations: Param = Parameter. 
 
Subsequently, the He/BW and Lu/BW ratio for the 3 copy animals increased 
significantly as the animals age suggesting a difference in the affects of aging on 
these organs in 3 copy mice (He/BW: young Wt = 0.515±0.01, n=24 verses young 3 
copy = 0.510±0.009, n=19, p = 0.305 and Lu/BW: young Wt = 0.358±0.02, n=24 
verses young 3 copy = 0.371±0.01, n=16, p = 0.333).  In addition, when the He/BW 
and Lu/BW ratio were compared between young WT mice and young 3 copy mice, 
there were no statistically significant differences suggesting that the changes were 
not occurring prior to adulthood. 
As shown by examination of histology in the previous section, at one year of 
age the 3 copy hearts had significantly more fibrosis than WT animals.  Similar to the 
mice aged to one year, for a subset of the young controls heart tissue was taken and 
stained with Masson’s Trichrome in order to examine levels of cardiac fibrosis.  After 
examining five to ten slides of each genotype, it was clear that the histology score 
for almost every WT and 3 copy young animal was 0.5 or less and in general hearts 
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from both genotypes had little or no fibrosis.  These results are further evidence that 
the fibrotic damage to 3 copy hearts was the result of the aging process.  
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Figure 4.3. Organ to body weight ratios as mice age.  For young WT n=24, old WT n=29, young 3 
copy n=16, and old 3 copy n=33.  Error bars are standard error of the mean.   
 
 
3. Genetic markers of cardiac hypertrophy and fibrosis compared to young 
mice 
  
A set of young WT and young 3 copy mice were assayed for mRNA gene 
expression along with a subset of the 1 year old animals (for which data is also 
shown above) for the same set of genetic markers of cardiac hypertrophy and 
fibrosis.  The purpose of examining gene expression profiles of young mice was to 
see how each genotype adapted to the natural aging process. Expression levels 
were set to 100% for each genotype of young animals and aged animals were 
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compared to the young controls separately because the comparison of interest was 
not WT verses 3 copy, but was young animals to 1 year old animals within each 
genotype. 
 
Gene 
WT 
Young  
vs Old   
p-value 
Young 2 
copy 
(WT) 
1 year 
WT 
(2 copy)
Young 
Ctgf 
3 copy 
1 year 
Ctgf 
3 copy 
3 copy 
Young 
vs Old  
p-value 
αMHC 0.049 100±12 150±12 100±7 167±13 0.006 
βMHC 0.001 100±25 665±60 100±22 626±27 0.010 
ANP 0.226 100±24 174±22 100±8 229±72 0.012 
CTGF 0.267 100±24 187±29 100±11 249±23 0.0008 
TGFβ 0.881 100±11 100±6 100±9 132±23 0.177 
Fibronectin 0.603 100±24 97±13 100±9 183±89 0.052 
Collagen I 0.403 100±14 165±37 100±14 142±59 0.502 
Collagen III 0.891 100±16 112±22 100±16 133±138 0.676 
Collagen IV 0.902 100±16 110±6 100±10 103±26 0.930 
 
Table 4.5. mRNA expression levels of genetic markers of cardiac hypertrophy and fibrosis in aged 
WT and 3 copy hearts verses young controls of the same genotype.  Young WT: n=7, 1 year WT: 
n=20, young 3 copy: n=8, and 1 year 3 copy: n=23.  Samples were normalized to β-actin and each 
genotype’s young controls, which were set to 100%.  Error values are standard error of the mean and 
p-values are from Student T-test but were multiplied by 2 to adjust for multiple testing.  Any p-value < 
0.05 is highlighted in bold. 
 
There were few significant changes in gene expression in the hearts of WT 
animals were as they aged.  There was a mild increase in αMHC, a sizeable 6-fold 
increase in β-MHC, and no significant changes in cardiac fibrosis-related genes.  
This profile suggested a mild hypertrophy and little or no signs of cardiac fibrosis 
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(Table 4.5).  The 3 copy hearts had similar increases in αMHC and βMHC to WT but 
also had increased ANP levels.  In addition, the profile of cardiac fibrosis-related 
genes in 3 copy mice was altered by aging.  Both Ctgf and fibronectin were 
significantly increased and TGFβ as well as collagens I and III were increased in the 
aged 3 copy animals (Table 4.5).  The genetic profile of the 3 copy hearts suggests 
the presence of active cardiac hypertrophy and fibrosis. 
 
D. Discussion 
 Cardiovascular disease is generally recognized as an aging-associated 
disease and has an age-related component.  Even in WT mice aged to one year 
there were visible signs of age-related cardiovascular damage in the form of small 
amounts of cardiac fibrosis.  The one-year old WT mice, however, did not have 
changes in cardiac function and any increase in heart weight over young WT mice 
disappeared when adjusted to body weight.  Altogether the data suggests the WT 
mice had a subtle age-related hypertrophy along with small amounts of cardiac 
fibrosis, which is part of the normal aging process. 
 Ctgf has long been thought to be a primary pro-fibrotic factor because of its 
strong association to pathological fibrosis as well as its known function in ECM 
maintenance [9, 10].  The association has been so strong that it has even been 
widely suggested as a primary target for anti-fibrotic drug intervention [10].  To better 
understand whether Ctgf is truly causal in cardiac hypertrophy and fibrosis, I aged 
mice that had one or two extra copies of the Ctgf gene to one year of age.  If 
increased Ctgf expression was truly a major cause of cardiac fibrosis, the Ctgf 3 
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copy and 4 copy mice should have had a dramatic increase in fibrosis.  However, 
this was not the case; the increases in hypertrophy and fibrosis were small.  Three 
copies of the Ctgf gene mildly increased cardiac fibrosis and cardiac hypertrophy 
and four copies of the Ctgf gene incrementally exacerbated the cardiac hypertrophy.  
Interestingly, the 4 copy mice did not have an increase in cardiac fibrosis, 
suggesting that increased hypertrophy does not necessitate increased fibrosis. 
In addition, increased Ctgf expression for the most part had a larger impact 
on cardiac hypertrophy than cardiac fibrosis.  Recent studies in tissue culture using 
rat cardiomyocytes show that treatment with Ctgf alone is sufficient to induce 
cardiomyocyte hypertrophy and that knockdown of Ctgf function can abrogate the 
pro-hypertrophic effects of both free fatty acids and high glucose treatment [11, 12].  
This finding brings up the possibility that the effect of Ctgf on fibrosis is indirect and 
occurs through modulation of hypertrophy or metabolism. 
While the 3 copy and 4 copy animals had increased cardiac hypertrophy 
and/or fibrosis the increase was moderate.  The small difference that additional Ctgf 
makes implies that Ctgf is likely a regulator of fibrosis at some level but increased 
Ctgf expression is not the primary factor in causing pathological fibrosis.  It is 
tempting to conclude that increased Ctgf has little to do with fibrosis and it is just a 
result of the pathological process, but this conclusion seems unlikely as increased 
Ctgf gene expression does have some effect on fibrosis.  It is more likely that CTGF 
is actually a co-factor and not a causal factor.  Ctgf has been shown to work in 
conjunction with and directly bind to a number of pro-fibrotic or ECM associated 
molecules including TGFβ, integrins, proteoglycans, and others [13, 14].  If Ctgf is a 
118 
  
co-factor, then increased Ctgf would result in some increase in fibrosis, such as what 
we have observed, but not as large as an increase as in a gene that is a primary 
cause of fibrosis.  As increased Ctgf is not a major cause of fibrosis, it may not be an 
ideal target for anti-fibrotic treatments. 
While Ctgf may or may not be causal in pathological fibrosis, it has a well 
established role in wound healing and ECM maintenance [15-17].  As we age the 
amount of maintenance and repair needed in the upkeep of our tissues increases so 
it is logical that the expression of genes that are important for the maintenance and 
repair of tissues will also increase.  In comparing young animals to old animals it 
was clear that, regardless of genotype, Ctgf expression increased with age 
suggesting that Ctgf may be important in regular tissue maintenance.  Having a role 
in healing and maintenance of ECM, along with a role in collagen production, Ctgf 
could be a suitable target for therapeutics aimed at improving wound healing (such 
as in burn victims), preventing hypertrophic scarring (keloids), and the never-ending 
pursuit of a youthful appearance in the cosmetics industry. 
There is also the distinct possibility that because the increases in gene 
expression we generated were small, they only produced small phenotypic results.  
The natural variations in gene expression levels seen in humans for the CTGF gene 
are unknown.  However, basal differences of 1.5 to 2-fold, which we generated, are 
modest and likely to be well within the range seen in the human population.  In order 
to see a large increase in fibrosis, model systems with much greater increases in 
Ctgf gene expression may need to be made.  Whether a much larger increase is 
realistically within the realm of human variation is hard to predict. 
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In conclusion, moderately increased Ctgf expression levels are not sufficient 
to drastically increase cardiac fibrosis shedding doubt on Ctgf as a primary pro-
fibrotic factor.  In light of these results, Ctgf may or may not be an ideal target for 
anti-fibrotic therapy. 
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A. Abstract 
Connective tissue growth factor (CTGF) is a signaling molecule that primarily 
functions in extracellular matrix maintenance and repair.  Increased Ctgf expression 
is associated with fibrosis in chronic organ injury.  Studying the role of CTGF in 
fibrotic disease in vivo, however, has been hampered by perinatal lethality of the 
Ctgf null mice as well as the limited scope of previous mouse models of Ctgf 
overproduction.  Here, we devised a new approach and engineered a single mutant 
mouse strain where the endogenous Ctgf-3’ untranslated region (3’UTR) was 
replaced with a cassette containing two 3’UTR sequences arranged in tandem.  The 
modified Ctgf allele uses a 3’UTR from the mouse FBJ osteosarcoma oncogene (c-
Fos) and produces an unstable mRNA, resulting in 60% of normal Ctgf expression 
(Lo allele).  Upon Cre-expression, excision of the c-Fos-3’UTR creates a transcript 
utilizing the more stable bovine growth hormone (bGH) 3’UTR, resulting in increased 
Ctgf expression (Hi allele).  Using the Ctgf Lo and Hi mutants, and crosses to a Ctgf 
knockout or Cre-expressing mice, we have generated a series of strains with a 30-
fold range of Ctgf expression.  Mice with the lowest Ctgf expression, 30% of normal, 
appear healthy, while a global nine-fold over-expression of Ctgf causes 
abnormalities, including developmental delay and craniofacial defects, and 
embryonic death at E10-12.  Overexpression of Ctgf by tamoxifen-inducible Cre in 
the postnatal life, on the other hand, is compatible with life.  The Ctgf Lo-Hi mutant 
mice should prove useful in further understanding the function of CTGF in fibrotic 
diseases.  Additionally, this method can be used for the production of  mouse lines 
with quantitative variations in other genes, particularly with genes that are broadly 
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expressed, have distinct functions in different tissues, or where altered gene 
expression is not compatible with normal development. 
 
B. Introduction 
Many of the diseases that have a major impact on human health and pose a 
major burden on healthcare costs have a fibrosis-related component.  Coronary 
heart disease (CHD) was the single largest killer in the United States in 2003, 
accounting for 1 in every 5 deaths [1].  Forty percent of acute CHD incidents result in 
death, but for those who survive an ischemic event, permanent scarring of heart 
tissue is largely unavoidable.  Both myocardial infraction (MI) and chronic high blood 
pressure result in scarring of the myocardium known as cardiac fibrosis [2].  Cardiac 
fibrosis is characterized by necrosis of myocardial tissue, collagen buildup, and scar 
tissue contraction often resulting in ventricular diastolic dysfunction and a poor long 
term prognosis [3-5].  Similarly, both diabetic nephropathy and cirrhosis of the liver 
have been identified as diseases with a large burden on the healthcare system and 
are characterized by fibrotic tissue damage [6, 7].  Prevention of cardiac fibrosis and 
fibrotic disease in other organs (kidney, liver, lung and others) is a promising 
strategy of intervention for improving long term prognosis and quality of life. 
All of the fibrosis-related diseases mentioned are characterized by 
overexpression of connective tissue growth factor (CTGF or CCN2, 
ENSMUSG00000019997), a primary fibrosis-related signaling molecule [8].  CTGF 
is a member of the CCN (Cyr61, Ctgf, and Nov) family of extracellular matrix (ECM) 
associated proteins.  Ctgf is widely expressed during development, and in adulthood 
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it is expressed in all major organs including the vasculature and the skeletal system 
[9, 10].  In the adult, expression is nearly ubiquitous and promotes normal turnover 
and maintenance of ECM.  As part of normal wound healing following injury, there is 
a marked induction of Ctgf expression [11].  Essentially, CTGF acts as a central 
coordinator of multiple pro- and anti-fibrotic signals and misregulation of CTGF is 
believed to result in tissue fibrosis and scarring [11, 12].  Increased Ctgf expression 
is clearly associated with fibrosis in multiple tissues including skin, liver, heart, lung, 
and kidney (reviewed in [11, 12]).  In addition, CTGF is a diffusible protein and can 
be detected in urine and blood [13, 14].  A critical difference between healthy healing 
and pathological fibrosis may be the temporal regulation of, and/or the level and 
duration of, Ctgf expression.  Thus, it is postulated that tight regulation of Ctgf 
expression is necessary to maintain healthy tissues and induce healthy, non-fibrotic 
healing [15]. 
To examine the role of CTGF in vivo, several animal models have been 
created.  The first is a traditional knockout, which when homozygous, is perinatally 
lethal.  The pups are born, but do not survive due to skeletal deformity, including a 
malformed rib cage which causes an inability of pups to breathe properly.  The 
heterozygous knockouts survive and have little discernable fibrosis-related 
phenotype [16].  Transgenic models of Ctgf overproduction in bone and cartilage, 
cardiomyocytes, kidney podocytes, hepatocytes, lung epithelia and fibroblasts have 
also been made using promoter-enhancers constructs specific to each cell type [17-
23].  The fibrotic phenotypes of these strains vary widely ranging from no increase in 
fibrosis to a clear fibrotic phenotype.  In all of these models the relationship between 
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gene expression level and phenotype is not clear since the normal control of Ctgf 
gene expression is disrupted and the mechanism by which altered steady state Ctgf 
gene expression influences non-target tissues has not been described.  Thus, the 
role of Ctgf expression in fibrosis remains unclear and there is a need for animal 
models with variable Ctgf expression in which there is minimal alteration in the 
natural transcriptional regulation to clarify how altered Ctgf expression levels may 
predispose or change the progression of heart disease and other fibrotic diseases. 
Here we describe an innovative method of modulating gene expression by 
making one animal that can express either low or high levels of a gene. This is made 
possible by use of Cre-recombinase to alter expression in vivo from low to high. The 
endogenous 3’-untranslated region (3’UTR) is replaced with a cassette containing 
the 3’UTR from the FBJ osteosarcoma oncogene (c-Fos, ENSMUSG00000021250) 
and the 3’UTR from the bovine growth hormone (bGH) gene, also known as 
somatotropin (ENSBTAG00000017220), placed in tandem.  Each 3’UTR modulates 
the stability of the mRNA transcript and can respectively decrease (c-Fos) or 
increase (bGH) steady state levels of mRNA in both cells and whole animals [24-27]. 
Using this method, we have created a single construct that allows the 
examination of the role of Ctgf when it has reduced expression, increased 
expression, or when expression is altered in a tissue-specific manner.  Our results 
show that Ctgf expression reduced to 30% of wild type is survivable, while 
expression nine fold higher than wild type leads to embryonic lethality by day E12.5.  
Thus, we have created a 30-fold range of Ctgf expression in vivo, which should 
prove useful in further understanding the function of CTGF in fibrotic disease. 
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C. Results 
1. Global, conventional KO of the Ctgf gene. 
In order to inactivate the Ctgf gene, we have made a targeting construct to 
delete exons 3 through 5 of the Ctgf gene in the genome in ES cells as illustrated in 
Figure 5.1A.  The 5’ and 3’ arms of homology are a 4.7kb BamH1/Nhe1 fragment 
and a 1.4kb Nsi1/Bgl2 fragment, respectively.  A neomycin resistant gene was used 
as a selection marker.  Mice heterozygous for an inactivated Ctgf KO allele appear 
normal and express the Ctgf gene at approximately 50% levels.  As reported by 
Ivkovic et al., homozygous mice completely lacking CTGF are born but die within 16 
hours [16]. 
 
2. Strategy to generate the Ctgf-Lo and Ctgf-Hi alleles. 
Our initial attempts to increase the stability of Ctgf transcripts in vivo using 
3’UTR replacement with the bGH-3’UTR [24] met with difficulties.  Chimeric mice 
with a modified allele tended to be runted and did not transmit the modified allele 
(data not shown).  In order to circumvent the potential embryonic lethality of high 
Ctgf expression and generate adult mice overexpressing the Ctgf gene, we devised 
a novel strategy using a low-high cassette (Lo-Hi) that allows us to change gene 
expression levels from low to high by altering mRNA stability (Fig 5.1B).  The second 
line in Figure 5.1B illustrates the Ctgf-Lo allele made by a replacement of the 
endogenous Ctgf gene 3'UTR sequence with a cassette that includes a loxP site, 
followed by the 3'UTR sequence from the FBJ osteosarcoma oncogene (c-Fos-
3'UTR), the neomycin resistant gene (neo), a second lox P site, and the bGH-3’UTR.  
129 
 Figure 5.1. Ctgf KO and Ctgf Lo-Hi allele.  A) Ctgf KO allele.  Line 1 is the endogenous Ctgf locus.  
Line 2 is the Ctgf KO allele construct.  Line 3 is the result following homologous recombination where 
exons 3-5 of the Ctgf gene were replaced with a neo cassette to generate the Ctgf KO allele.  Black 
boxes indicate coding exons and a white box indicates the endogenous 3’UTR.  B) Ctgf Lo-Hi allele. 
Line 1 is the endogenous Ctgf locus. The Ctgf Lo-Hi allele was generated by replacement of the 
endogenous Ctgf-3’UTR with a construct containing the c-fos-3’UTR and a Neo cassette flanked by 
loxP sites, followed by the bGH-3’UTR.  In line 2, the modified Ctgf gene uses the less stable c-Fos-
3’UTR which reduces gene expression (Ctgf Lo allele).  In the bottom line, following Cre-mediated 
recombination, the c-Fos-3’UTR and Neo cassette are excised and the Ctgf gene uses the more 
stable bGH-3’UTR which increases gene expression (Ctgf Hi allele).  TAA indicates a stop codon  
Restrcition sites are abbreviated B is BamH1, Bc is Bcl1, Nhe is Nhe1, Nsi is Nsi1, and Bg is Bgl2. 
 
The modified allele, Ctgf-Lo, uses the c-Fos-3'UTR and so its transcripts are less 
stable than those from the wild type Ctgf allele.  However, a bGH-3’UTR (Fig 5.1B, 
third line).  The transcript with the bGH-3’UTR is more stable Cre-mediated 
recombination between the two loxP sequences in the Lo-Hi cassette excises the c-
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Fos-3'UTR and the neo gene and generates the Ctgf-Hi allele that uses than normal 
and consequently steady state levels of Ctgf mRNA increase. 
 
3. Mice with low Ctgf expression. 
Heterozygotes for the Ctgf-Lo (Ctgf Lo/+) allele are born and appear normal.  
Ctgf Lo/+ mice were first intercrossed to determine if the Ctgf Lo/Lo phenotype is 
viable.  Pups were born from this cross at a 10:18:5 genotypic ratio (+/+: Lo/+: 
Lo/Lo).  The number of Ctgf Lo/Lo pups was about half the expected Mendelian ratio 
of 1:2:1 for the cross, but the Chi square test was not significant (p = 0.409, n = 33).  
The Ctgf Lo/+ and Ctgf Lo/Lo pups are healthy, reproduce normally, and are 
indistinguishable from their wild type and heterozygous littermates. 
The Ctgf Lo/Lo mice are expected to have reduced Ctgf mRNA expression 
throughout the body.  Tail snips from 10-day old pups were used to assay for Ctgf 
mRNA expression.  Ctgf Lo/Lo mice express about 60% of wild type levels of Ctgf.  
The Ctgf Lo/Lo mice are similar in Ctgf expression level to the Ctgf heterozygous 
knockout (Ctgf KO/+) mice which express 50% of wild type Ctgf.  Ctgf Lo/+ 
heterozygotes have an intermediate Ctgf expression level that is 85% of wild type 
mice (+/+: 100% ± 6.8, n = 21, Lo/+:  85% ± 5.1, n = 25, p < 0.05, Lo/Lo: 60% ± 
11.4, n = 5, p < 0.005, Fig 5.2A).  
 
4. Mice with very low Ctgf expression. 
Ctgf Lo/Lo mice were crossed to Ctgf heterozygous knockouts (Ctgf KO/+) to 
generate mice with very low Ctgf expression (Ctgf Lo/KO).  Ctgf Lo/KO mice were  
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 Figure 5.2. Ctgf mRNA levels by quantitative RT-PCR.  A) Ctgf mRNA expression from tail 
samples of 10 day pups from a cross of Ctgf Lo/+ parents.  All mice are siblings.  The mean of Ctgf 
+/+ (wild type) expression is set to 100% expression LoLo: n = 5, Lo/+: n = 25, and +/+: n = 21.  B) 
Ctgf mRNA expression from tissues of five month old mice.  Ctgf Lo/+ mice are the control with Lo/+ 
expression set to 85% based on results from Figure 5.2A.  For each organ Lo/+:  n = 14 and Lo/KO: n 
= 8.  C) Ctgf mRNA expression from whole mouse embryos at day points E11.5, normalized to Lo/+ 
the same as Figure 5.2B.  Lo/+:  n = 8 and Hi/+: n =13  D) Ctgf mRNA expression from tissues of 10-
month old mouse tissues normalized to a combined control of animals of the genotypes +/+;Cre-, 
Lo/+;Cre-, and +/+;Cre+.  E) Neo gene copy number in embryos at day E11.5.  Copy number is in 
arbitrary units and normalized to Lo/+ = 100%.  Lo/+: n = 18 and Hi/+: n = 28.  For all graphs the Lo/+ 
animals are heterozygous for the Ctgf Lo allele and do not have a Cre allele. The Hi/+ animals are 
heterozygous for the Ctgf Hi allele and have one EIIa-Cre allele. 
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born at the expected Mendelian ratio of 1:1 (17 Lo/+: 15 Lo/KO).  Tissues from adult 
siblings (males and females) were assayed for Ctgf mRNA expression by RT-PCR.  
Ctgf Lo/KO heart tissue had significantly lower Ctgf expression (heart: Lo/KO: 30% ± 
4.2, n = 7, Lo/+: 85% ± 14.3 for, n = 14, p = 0.002, Fig 5.2B).  Similarly, both kidney 
and lung had significantly reduced Ctgf expression (kidney: Lo/KO: 33% ± 23.5, n = 
8, Lo/+: 85% ± 15.0, n = 14, p = 0.01 and lung: Lo/KO: 23% ± 11.9, n = 8, Lo/+: 85% 
± 27.9, n=14, p = 0.02, Fig 5.2B).  When the results from various tissues are 
combined, Ctgf expression in Lo/KO mice is on average 29% of wild type ((30% + 
33% + 23%)/3 = 28.7%).  The Ctgf Lo/KO animals reproduce adequately, are 
healthy, phenotypically normal in appearance, and display no overt structural 
phenotypes. 
 
5. Embryonic lethality in mice with high Ctgf expression on a B6.129 mixed 
background. 
 
When Cre is present, a Cre-mediated recombination between the two loxP 
sequences within the Ctgf-Lo allele excises the c-Fos-3'UTR and the neo gene, this 
generates the Ctgf-Hi allele that uses the bGH-3’UTR.   To generate mice carrying a 
Ctgf-Hi allele, Ctgf Lo/+ mice on a B6.129 mixed genetic background were crossed 
to a heterozygous whole body Cre expressing mouse line 129.Tg(Ella-Cre) (from 
B6.FVB-Tg(EIIa-cre) C5379Lmgd/J stock that was backcrossed to 129/SvEv for 18 
or more generations).  Heterozygotes for the Ctgf Hi allele (Ctgf Hi/+ mice) were 
defined as presence of the bGH-3’UTR, presence of a Cre allele and low Neo gene 
copy number.  After seven litters and 40 pups, no live mice carrying both the 
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modified Ctgf allele and the EIIa-Cre transgene were recovered, suggesting the 
Ctgf-Hi allele causes an embryonic lethal phenotype. 
To examine the timing and nature of the lethality, we used timed matings and 
recovered embryos between E13.5 and E14.5.  At this embryonic age, Ctgf Hi/+ 
embryos were recovered at a ratio of 10:15:11:7 (+/+;Cre-: Lo/+;Cre-: +/+;Cre+: 
Hi/+;Cre+) which was not different from the expected Mendelian genotypic ratio of 
1:1:1:1 (Chi Square, p = 0.385, n = 43). 
 
 
Figure 5.3. Phenotype of E13.5 embryos.  Embryos are from a cross between Ctgf Lo/+ and EIIa-
Cre +/- parents. The number of embryos for each genotype classified as Normal, Small, or Small 
atypical. +/+ n = 9, Lo/+ n = 15, Cre+ n = 11, Hi/+ n = 7.  The +/+ animals are wild type for Ctgf and do 
not have a Cre allele; Lo/+ animals are heterozygous for the Ctgf Lo allele and do not have a Cre 
allele.  Cre+ are wild type for Ctgf and have one Cre allele.  Hi/+ are heterozygous for the Ctgf Hi 
allele and have one Cre allele. 
 
 
At recovery, embryos were weighed and phenotypically classified as normal, 
small, or small atyical without knowledge of the genotype.  Normal embryos were 
nondysmorphic in appearance, of the expected developmental stage for the 
embryonic age, and were within two standard deviations of the mean embryo weight 
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for that litter.  Small embryos were nondysmorphic in appearance and of the 
expected developmental stage for the embryonic age, but small in size with a body 
weight below two standard deviations of the litter average (litter averages include all 
pups that were sufficiently intact to be weighed).  Small atypical embryos were 
developmentally delayed, macerated, or poorly vascularized with a body weight 
below two standard deviations of the litter average.  By this classification method, no 
normal Ctgf Hi/+ embryos were present among 43 embryos at E13.5-E14.5 (Fig 5.3).  
All of the Ctgf Hi/+ embryos were either small or small atypical and were similar in 
appearance to the examples in Fig 5.4E, which would be classified as small atypical 
(Fig 5.4A is a normal embryo from the same litter).  In addition to small size and 
weight, the Ctgf Hi/+ embryos generally lacked clearly visible vasculature, lagged 
behind in development, and many were macerated and likely to be in the process of 
reabsorption (Fig 5.4E).  This suggests that the embryos begin to die before E13.5.  
While the reason for the lethality is unclear, we observed a less developed eye (4e 
top arrow), as a mark of developmental delay and craniofacial defects including both 
lateral and midline facial clefting (4e middle and bottom arrow, respectively).  No 
Ctgf Hi/+ embryos were recovered from the litters older than embryonic day point 
14.5. 
 
6. Embryonic lethality in mice with high Ctgf expression on a 129/SvEv 
background. 
In order to investigate the timing of the lethality more closely and to examine 
embryo viability in a pure 129/SvEv background, Ctgf Lo/Lo mice on a 129/SvEv  
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 Figure 5.4. E14.5 and E10.5 embryos.  A) and E) are fixed embryos at E14.5 from a cross between 
Ctgf Lo/+ and EIIa-Cre +/- B6.129 mixed background parents. A) is a normal Lo/+ and E) is a small 
atypical Hi/+ at higher magnification.  Top arrow denotes less developed eye in E) and the lower two 
arrows point to lateral and midline facial clefting, respectively.  Embryos B) to D) and F) to H) are 
E10.5 embryos from a cross between Ctgf Lo/Lo and EIIa-Cre +/- 129/SvEv background parents.  B), 
C), and F), G), are unfixed embryos.  B), C) and D) are normal Ctgf Lo/+ embryos.  F), G), and H) are 
Ctgf Hi/+ embryos.  The top arrow in B) and F) points to the forebrain which appears smaller in F) and 
the lower arrow points to the mouth gape in F) also indicative of a small forebrain.  The top arrow in 
C) and G) points to the eye and the bottom arrow points to the hindbrain which both appears 
abnormal in G).  The pictures in D) and H) are from scanning electron microscopy.  The arrows in D) 
and H) point to the first (top) and second (bottom) pharangeal (branchial) clefts.  In D) there is normal 
closure of the clefts and in H) the clefts are abnormally patent (open).  B) and C) are the same 
embryo and F) to H) are the same embryo.  The bars in A), B), E), and F) represent 1000 μm and in 
C), D), G), and H) the bars represent 250 μm. 
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background were crossed with 129.Tg(Ella-Cre) mice.  After genotyping three litters, 
no Ctgf Hi/+ embryos were recovered at E13.5, suggesting an earlier lethality in the 
fully inbred background.  Embryos on a 129/SvEv background were then harvested 
at E10.5 (Fig 5.4 B-D and F-H) for examination of morphology. 
The Ctgf Hi/+ embryos at E10.5 display developmental delay and a number of 
morphological defects.  The gapping open mouth posture seen in Figure 5.4F 
(bottom arrow) and 5.4G is suggestive of a small forebrain (also 4B and 4F top 
arrow) and the abnormal indentation of the back of the head seen in Figure 5.4G 
(bottom arrow) suggests an abnormal hindbrain.  The embryo in Figure 5.4G also 
appears to have less visible microvasculature in the face and possibly elsewhere 
and has a less developed eye (top arrow 5.4g) suggesting possible developmental 
delay.  Additionally, the closure of the pharyngeal (branchial) arches, particularly 
between the first and second (pharyngeal cleft one) and second and third arch 
(pharyngeal cleft two), were abnormally patent (compare Figure 5.4D-H). 
No Ctgf Hi/+ embryos on a 129/SvEv inbred background were recovered 
beyond E12.5 suggesting the lethality on the 129/SvEv background is earlier than 
that of the B6.129 background, at around day E11.5-E12.  Despite the earlier time 
point of lethality in the 129/SvEv background, developmental delay and craniofacial 
defects were present in both backgrounds. 
 
7. Gene expression levels of Ctgf Hi/+ embryos. 
In order to examine the expression levels of the Ctgf-Hi allele, Ctgf Lo/Lo 
females were crossed to 129.Tg(Ella-Cre) Cre+ males and the embryos were 
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harvested at E11.5 and assayed for whole body Ctgf gene expression using RT-
PCR.  Ctgf expression varied greatly in Ctgf Hi/+ embryos, ranging between two and 
fifty times greater than the mean of Ctgf Lo/+ embryos.  Most likely this is due to 
variations in developmental stage, embryo condition, and variations in Cre 
expression.  On average the Ctgf Hi/+ embryos had a greater than ten fold increase 
in Ctgf mRNA levels compared to the Ctgf Lo/+ littermate controls, which is a nine 
fold increase in Ctgf expression over WT (Lo/+: 85% ± 34, n = 8 and Hi/+: 930% ± 
506, n = 13, p<0.05, Fig 5.2C). 
 To validate that excision of the c-fos-3’UTR and neo gene was occurring, 
whole embryos were assayed for neo gene copy number as a measure of excision 
efficiency.  On average Ctgf Hi/+ embryos had less than one eighth the amount of 
neo alleles than the Ctgf Lo/+ embryos (Lo/+:  100% ± 7.8, n = 18 and Hi/+: 11.6% ± 
1.7, n = 28, p < 1 x 10-7, Fig 5.2E).  While the excision of the c-fos-3’UTR and neo is 
not complete, the switch from the Lo allele to the Hi allele is occurring efficiently and 
in the large majority of cells.  There did not appear to be a direct relationship 
between reduction in neo copy number and increase in Ctgf gene expression levels 
suggesting that mechanisms other than just efficiency of c-fos-3’UTR and neo 
excision were regulating Ctgf gene expression levels in the embryos (data not 
shown). 
 
8. Pattern of CTGF protein in embryos. 
Increased Ctgf mRNA levels may be causing changes in the levels or pattern 
of CTGF protein in Ctgf Hi/+ embryos.  Thin sections of embryos were stained with a  
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 Figure 5.5. Immunofluorescence of E11.5 Ctgf Lo and Hi embryos.   Panels A) – D) are stained 
with an anti-CTGF antibody and a Alexa 594 (Texas Red) secondary.  Panels E) – H) are stained with 
DAPI to highlight nuclei.  Panels I) – L) are a merge of the Red and the DAPI layer.  Genotypes for 
each panel are as marked on the panel.  The panels in each row are from the same section.  All 
panels are at 5x magnification. 
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CTGF antibody and a fluorescent seconday then counterstained with DAPI to 
visualize the level and pattern of CTGF protein.  CTGF was visible in almost evey 
tissue of the embryos and appeared to be primarily staining the extracellular matrix 
and the cell surface (Fig 5.5I-L).  The Hi/+ embryo in Figure 5.5D has the highest 
CTGF staining and the Lo/+ embryo in Figure 5.5A the lowest staining, suggesting a 
genotype dependent difference CTGF levels.  Although the heart in Figure 5.5A is 
staining strongly, this likely represents a different genotypes suggesting CTGF levels 
vary substantially within each genotype.   
For the most part individual differences in staining were greater than the 
differences between genotypes, and there was not a distinct difference in the pattern 
of CTGF staining nor a dramatic difference in the overall intensity of CTGF staining 
between Ctgf Lo/+ and Ctgf Hi/+ (Fig 5.5).  Immunohistochemistry (IHC) with a 
higher antibody concentration and E13.5 mixed genetic background embryos yielded 
a similar result (data not shown). 
 
9. Survivors with high Ctgf gene expression. 
 After many matings, four Ctgf Hi/+ animals (out of 81 that were genotyped) 
escaped embryonic lethality and survived to adulthood (26:28:23:4 ratio of +/+,Cre-: 
Lo/+,Cre-: +/+,Cre+: Hi/+,Cre+).   One male and one female of the surviving animals 
were siblings from a mixed B6.129 mating.  Two additional male survivors came one 
year later, one from a mixed B6.129 mating and one from a 129/SvEv mating.  All 
four mice exhibited the same phenotype: a shortened face, small ears, a shortened 
and kinked or curled tail, and a shortened overall body length (Fig 5.6). 
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 Figure 5.6. Survivors of Ctgf Hi/+ embryonic lethality.  Gross morphology of high Ctgf-expressing 
survivors at 10 months old.  Males are shown in A) and B) and females are shown in C) and D).  In A) 
and B) the Ctgf Hi/+ mice (foreground) have small ears, shortened face and short body length.  B) 
The short curly tail of the Hi/+ male. D) Short kinked tail and short body of the Hi/+ female (top) 
compared with a control sibling (bottom).  All the animals shown are siblings from a cross between 
Ctgf Lo/+ and EIIa-Cre +/- animals on a mixed B6.129 background.  The controls (background of A) 
and C) and bottom of D)) are of the genotype Ctgf Lo/+.  
 
 The surviving Ctgf Hi/+ animals and their sibling controls were further 
characterized by dual energy x-ray absorptiometry (DEXA) to assess whole body: 
bone mineral density (BMD), bone mineral content (BMC) and body composition 
(lean, fat and % fat mass).  Although the number of samples was small and the 
animals were in different genetic backgrounds, all of the Ctgf Hi/+ animals had 
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significantly smaller bone area and lean mass than controls (bone area: controls: 
9.87 ± 0.33 cm2 and survivors: 8.35 ± 0.57 cm2; lean mass: controls: 25.4 ± 1.1 
grams and survivors: 21.0 ± 0.95 grams, controls: n = 9 and survivors: n = 4, p < 
0.05, Table 1) indicating a smaller overall body size as suggested by their outward 
appearance.  The BMC of Ctgf Hi/+ survivors was low suggesting changes in the 
bone mineralization or morphology (controls: 0.642 ± 0.033 grams, n = 9 and 
survivors: 0.532 ± 0.052 grams, n = 4, p < 0.05, Table 1). 
At sacrifice several tissues including fat pads were collected and weighed to 
determine any gross differences.  There were no differences in total amount or 
relative amounts of renal, inguinal, or mesenteric fat (data not shown).  Organ 
weights tended to be smaller with both kidney and lung significantly smaller in the 
Ctgf Hi/+ survivors (Kidney: controls: 0.221 ± 0.010 grams and survivors: 0.170 ± 
0.013 grams; Lung: controls: 0.133 ± 0.009 grams and survivors: 0.097 ± 0.008 
grams, controls n = 9 and survivors n = 4, p < 0.05, Table 1).  However, organ 
weights as a ratio of total body weight tended to be smaller in Ctgf Hi/+ survivors but 
were not significantly different from the controls (Table 1).  The organ weight ratios 
were not different from controls because at sacrifice the Ctgf Hi/+ survivors were 
smaller in total body weight than controls (controls: 35.720 ± 1.65 grams, n = 9 and 
survivors: 29.057 ± 3.57 grams, n = 4, p < 0.05, Table 1) suggesting that Ctgf Hi/+ 
survivors have a normally proportioned but smaller body size. 
Heart, kidney and lungs from Ctgf Hi/+ survivors and siblings or age-matched 
controls were harvested and assayed for Ctgf gene expression using RT-PCR.  
There was a significant increase in Ctgf expression in each tissue (Fig 5.2D).  The  
142 
  Measurement Control Hi/+; Cre + T-Test  p-value 
Bone (DEXA) BMD (g/cm2) 0.0648 0.0635 0.357 
 BMC (grams) 0.642 0.532 0.048 
 Area (cm2) 9.87 8.35 0.016 
Tissue (DEXA) Lean (grams) 25.4 21.0 0.013 
 Fat (grams) 11.3 9.9 0.312 
 Total (grams) 36.7 30.8 0.072 
 % Fat 30.0 30.0 0.485 
Weight (Fresh) Total 35.720 29.057 0.037 
 Kidney 0.221 0.170 0.007 
 Heart 0.167 0.142 0.081 
 Lung 0.133 0.097 0.017 
% of Body Weight Heart/ Total 0.475 0.485 0.347 
 Kidney/ Total 0.311 0.300 0.329 
 Lung/ Total 0.381 0.343 0.268 
 
Table 5.1. DEXA and necropsy measurements of Ctgf Hi/+ survivors and sibling controls.   
The top half of table is DEXA measurements of live mice at 10 months of age and the bottom is 
necropsy data.  Mice were euthanized at 10 months of age and total body weight and organ weights 
were measured.  Males and females were pooled.  The p-value for each measurement is from 
Student T-test.  Statistically significant p-values are shown in black. Controls: n = 9 and Hi/+: n = 4.  
Genotype of controls: Lo/+: n = 4, Cre+: n = 3, and +/+: n = 2.  Cre+ animals are wild type for Ctgf and 
+/+ animals are wild type for Ctgf and do not have a Cre allele.  BMD = bone mineral density and 
BMC = bone mineral content. 
 
heart had a modest increase at two-fold above controls, kidney is three-fold 
increased, and lung had the largest change at nearly five-fold increased Ctgf 
expression over sibling controls (Heart: Lo/+: 85% ± 9.6, Hi/+: 190% ± 16.6, 
p<0.0001; Kidney: Lo/+: 85% ± 11.6, Hi/+: 286% ± 67.9, p<0.001; Lung: Lo/+: 85% ± 
10.1, Hi/+: 482% ± 111.6, p<0.0001, n = 9 controls and n = 4 survivors, Fig 5.2D).  
At the time of sacrifice, 10 months of age, the Ctgf Hi/+ survivors appeared healthy 
and did not seem to have accelerated aging.  Histological evaluation of sections of 
heart, kidney, and lung was not remarkable and not different from age matched 
controls (data not shown). 
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10. Global increase of Ctgf gene expression in adult mice. 
The survival of several animals with very high Ctgf expression suggests that while 
high Ctgf expression is embryonic lethal, in an adult it is compatible with survival.  To 
test this hypothesis, we crossed Ctgf Lo/Lo mice with CAG-Cre mice, which are a  
 
 
Figure 5.7. Ctgf mRNA levels in tamoxifen treated adults and CTGF protein abundance in 
plasma.  A) Ctgf mRNA determined by RT-PCR in tamoxifen treated mice from a cross of Ctgf Lo/Lo 
and CAG-Cre +/- animals on a B6.129 F1 background.  All animals were treated with tamoxifen and 
Lo/+ is set to 85% as a control.  Lo/+: n = 23 and Hi/+: n = 20.  B) Quantification of CTGF protein 
abundance in plasma as calculated using ImageJ.  Lo/Lo: n = 5, +/+: n = 5, and Hi/+: n = 7 animals 
for each genotype.  C)  A 330 bp band corresponds to the Ctgf Lo allele and a 240 bp band 
corresponds to the Ctgf Hi allele.  The PCR reaction is not quantitative but the presence of the 240bp 
band indicates that Cre-mediated excision of DNA flanked by the loxP sequences has taken place.  
Presence of 330bp band in animals with Ctgf Hi allele (Hi) indicates that the excision is not complete.  
DNA from the wild type animal (WT) does not amplify with these primers indicating the absence of the 
Ctgf Lo allele.  The lane of size markers is indicated by M.  D) A representative western showing a 
doublet band for CTGF just above 31kDa for three Ctgf Lo/Lo mice, three WT mice and three Ctgf 
Hi/+ mice.  In A) Lo/+ animals are heterozygous for the Ctgf Lo allele and do not have a Cre allele.  In 
A), B), and D) Hi/+ animals are heterozygous for the Ctgf Hi allele, have one tamoxifen-inducible 
CAG-Cre.  All animals have been treated with tamoxifen. 
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tamoxifen-inducible global Cre expresser strain [28].  At four to six weeks of age, 
offspring were treated with tamoxifen to induce Cre expression.  PCR of small skin 
biopsy of tamoxifen-treated animals showed that the Lo-Hi allele functioned as 
predicted with excision of the c-fos-3-UTR and neo (Lo allele) to generate the 
smaller the Hi allele in the presence of tamoxifen and the inducible Cre gene (Fig 
5.7C).  Similar to Hi/+ survivors and embryos, Ctgf gene expression in Cre 
expressing mice (Ctgf Hi/+ mice, after tamoxifen treatment) was approximately four-
fold higher than in Ctgf Lo/+ mice without the Cre gene (Lo/+: 85% ± 15.3, n = 23 
and Hi/+: 357% ± 63.4, n = 20, p >0.00005, Fig 5.7A). 
Three months after tamoxifen treatment both males and females remained 
indistinguishable from the non-Cre carrying littermates, suggesting that high levels of 
Ctgf expression in the adult are survivable.  This experiment also shows that our 
construct can be used in an inducible fashion to study fibrotic disease in adult 
animals. 
 
11. CTGF protein levels in plasma. 
To confirm that changes in Ctgf mRNA expression translated to changes in 
CTGF protein abundance, a Western blot of plasma samples with a mouse-specific 
CTGF antibody was performed for quantitation.  CTGF is a secreted protein and is 
known to circulate in plasma at measurable levels.  Recent human and mouse 
research has suggested that CTGF protein levels in the plasma can be used as a 
non-invasive marker of Ctgf gene expression levels [29, 30].  Band sizes ranging 
from 11 kDa to the full length 38 kDa have been reported in Western blots for CTGF, 
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including multiple reports of a doublet around 31 kDa [31, 32].  The primary band we 
observed for CTGF in adult plasma was a doublet around 31 kDa (Fig 5.7D).  
Quantitation by densitometry showed that the Ctgf Lo/Lo mice had significantly 
reduced CTGF protein to a level that was about 60% of wild type (Lo/Lo: 0.62 ± 
0.077, n = 5, +/+: 1.00 ± 0.135, n = 5, p < 0.05, Fig 5.7B), which is similar to the Ctgf 
Lo/Lo mRNA expression levels (Fig 5.2A).  In contrast, tamoxifen-treated Ctgf Hi/+ 
animals had significantly increased CTGF protein abundance of about 170% of wild 
type (Hi/+: 1.72 ± 0.037, n = 7, p < 0.0001, Fig 5.7B).  While this is not as high as the 
mRNA expression levels, it is a significant and very consistent increase in CTGF 
protein levels. 
 
C. Discussion 
Previous studies have shown that altering or interchanging the 3’UTR of a 
gene is an effective method for altering gene expression in cells and in animals [24-
27].  The method takes advantage of the idea that the 3’UTR, in part, regulates 
mRNA abundance primarily through modulating mRNA stability.  In altering the 
stability of a gene’s mRNA, the mRNA abundance and thus the protein abundance 
can be modulated in a qualitatively predictable manner.  By combining Cre-lox 
technology with the use of two well-characterized 3’UTR sequences, c-Fos-3’UTR 
and bGH-3’UTR, a single allele that can decrease or increase gene expression has 
been assembled.  This method was applied to the gene Ctgf to generate an allelic 
series that has a 30-fold range of Ctgf expression as summarized in Table 2.  In 
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addition, in line with previous reports by Ivkovic et al [16], our Ctgf KO/KO 
(homozygous knockout) are born but die within a day. 
We found that embryos with a Ctgf Hi allele had increased Ctgf mRNA levels 
that were nine-fold higher than WT in embryos, and the increase in Ctgf expression 
was embryonic lethal, depending on genetic background, between day E11 and 
E13.5.  The lethality of the Ctgf Hi allele, made from the Lo-Hi allele, recapitulates 
the lethality observed in our previous attempts to directly generate a Ctgf Hi allele 
with the bGH-3’UTR.  Embryos from both 129/SvEv and B6.129 mixed backgrounds 
display craniofacial defects consistent with alterations to the first and second 
pharyngeal arches.  The fissures between the arches in the mutant E10.5 embryo in 
Figure 5.4H do not have a jagged border or other morphology that indicated a 
handling-related tear. 
 
Ctgf genotype Allele Ctgf mRNA Expression 
KO/KO del/del 0% 
Lo/KO c-fos-3’/del 30% 
+/KO WT/del 50% 
Lo/Lo c-fos-3’/c-fos-3’ 60% 
Lo/+ c-fos-3’/WT 85% 
+/+ (WT) WT/WT 100% 
Hi/+ inducible bGH-3’/WT 360% 
Hi/+ embryos bGH-3’/WT 930% 
 
Table 5.2. Strains in the Ctgf allelic series.  Ctgf expression levels are relative to WT.  A single WT 
allele expresses 50% (2 x 50% = 100%).  Each copy of the Ctgf Lo allele expresses about 30% of WT 
(Lo/+ = 30% + 50% ≈ 85%).  Each copy of the Ctgf Hi allele expresses about 300% to 860% of WT.  
Abbreviations: KO is knockout, del is exon 3-5 deletion, and 3’ is 3’UTR. 
 
 
In addition, similar fissures were observed in two other Ctgf Hi/+ embryos, 
suggesting that this defect was a result of high Ctgf gene expression.  Defect of the 
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pharyngeal arches, rostrum and midline in Ctgf Hi/+ embryos are in congruence with 
previous reports that Ctgf is highly expressed in these regions at E9.5-E10.5 [16].  In 
humans, altered development of the first and second pharyngeal arches is known to 
cause malformations of the ear, cheekbone, upper and lower jaw, soft palate, eye, 
and facial muscles and nerves [33].  In particular, closure defects of the first and 
second pharyngeal clefts (the spaces between the arches) are associated with 
oblique or lateral clefting and cervical/branchial (neck) fistula [34]. 
The generalized developmental delay and craniofacial defects like those seen 
in Ctgf Hi/+ embryos by themselves are not necessarily lethal [35], so it remains 
unclear why the Ctgf Hi allele is embryonic lethal.  Craniofacial defects are often 
observed in conjuction with cardiac defects and both phenotypes are thought to be 
caused by improper migration and differentiation of neural crest cells [36, 37].    
Defects including craniofacial dysmorphism and abnormal pharyngeal arches as well 
as cardiac defects were observed in transforming growth factor (TGFβ) family 
knockout mutant mouse strains and were thought to be caused by defective neural 
crest cell migration [36].  Although, TGFβ isoforms are most commonly thought to 
increase Ctgf expression [38], there are recent reports that suggest Tgfβ2 can inhibit 
Ctgf expression [39].  If TGFβ2 is regulating CTGF in utero, loss of Tgfβ2 could lead 
to increased levels of CTGF, creating a similar phenotype to our model of increased 
Ctgf expression. Therefore, dysfunction of neural crest cells, which likely causes the 
craniofacial defects in Ctgf Hi/+ embryos, may be the ultimate reason for the 
embryonic lethality.  No overt defects were observed in the heart in our limited 
histological analysis, and immunohistochemical staining revealed that Ctgf 
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expression may be generally increased in Hi/+ embryos but is not consistent.  
Despite the large increase in mRNA, immunohistochemistry (IHC) does not show 
large differences in CTGF levels suggesting that IHC may not be sufficiently 
sensitive or that translational regulation may be occurring.  Future experiments using 
in situ hybridization and/or tissue-specific overexpression of Ctgf should focus on 
defects in neural crest cells, especially in the heart, as a possible cause for the Ctgf 
Hi/+ embryonic lethality. 
Alternative causes for lethality in Ctgf Hi/+ embryos include failures of 
vasculogeneis or erythropoeisis, both are crucial developmental milestones of E10-
E12 embryos [40].  Many of the Ctgf Hi/+ embryos recovered appeared generally 
pale and may have lacked proper circulation.  Vascular endothelial growth factor 
(VEGF) is known to be an essential factor in vasculogenesis and is thought to have 
a complex regulatory relationship with CTGF [41-43].  Disruption of VEGF signaling 
caused by high CTGF levels could be the cause of this defect.  Failures in placental 
development, cell migration, or hematopoietic proliferation at this embryonic stage 
are also common reasons for embryonic lethality and could be the cause of lethality 
in the Ctgf Hi/+ embryos [44-46]. 
An unexpected benefit of the uneven penetrance of the EIIa-Cre has been the 
few animals that have escaped the embryonic lethality.  Genotyping showed that the 
survivors do not have complete neo excision in tail DNA suggesting they are 
mosaics for the Ctgf Lo and Ctgf Hi alleles and likely escaped lethality due to low 
Cre expression during embryogenesis.  Like the embryos, the survivors express 
significantly increased Ctgf as well as exhibit craniofacial defects in the form of a 
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shortened rostrum.  In addition, similar to previously reported Ctgf high expression 
transgenics, [17, 18] the survivors have skeletal defects in the form of shorted body-
length, shortened or kinked tails, and reduced bone mineral content.  All of these 
similarities as well as mRNA expression levels suggest that the Ctgf Hi/+ survivors 
are true high expressers. 
The EIIa-Cre line is known to have a mosaic pattern of Cre expression with 
varying excision efficiency in different tissues as well as large variability between 
animals in the amount of Cre-mediated excision.  Previous reports have shown that 
with the Ella-Cre as few as 50% of animals undergo high levels of Cre-mediated 
excision in the first generation [47, 48].  The EIIa-Cre expression profile reported by 
The Jackson Laboratory shows that certain organs such as lung and kidney have 
very high Cre expression in adults and other organs such as heart have much lower 
Cre expression [49].  It is noteworthy that the pattern of gene expression observed in 
our survivor mice is similar to the report of Cre expression by The Jackson 
Laboratory and shows that Ctgf expression is moderately increased in heart (two-
fold) and substantially increased in the kidney and lung (three-fold and five-fold, 
respectively).   
These surviving animals are rare with only four animals surviving the 
embryonic lethality in two years of breeding.  Matings of survivor males never 
produced offspring that carried a fully floxed (neo negative) high expressing allele, 
reinforcing that the Ctgf Hi/+ allele is embryonic lethal.  Therefore, due to their rarity 
and lack of direct transmission of the Ctgf Hi/+ allele, these animals are not a 
tenable model for Ctgf overexpression. 
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We then used a mouse strain that expresses tamoxifen-inducible Cre gene 
and showed that high Ctgf expression in an adult is not lethal.  With only a moderate 
dose of tamoxifen, these animals express a four-fold increase in Ctgf mRNA and a 
nearly two fold increase in CTGF protein abundance in plasma and do no appear to 
suffer any immediate ill effects.  Unlike the low Ctgf expression models where 
decreases in protein levels paralleled that of mRNA, in the Ctgf Hi/+ there is a two-
fold difference between the protein abundance in plasma (1.7-fold increased) and 
the tissue mRNA gene expression (3.6-fold increased).  The discrepancy may be 
due to the inaccuracy of the method used to quatitate the protein or to unknown 
regulation at the translational level.  The increase in Ctgf mRNA was not as high as 
in the embryos so a higher tamoxifen dose, or treatment at a younger age, may 
increase Ctgf expression to a level closer to the nine-fold increase we observe in 
embryos. 
Previous reports have implicated CTGF as a profibrotic signaling molecule 
leading to the suggestion that reducing Ctgf expression by treatment with a drug or a 
monoclonal antibody may be a worthwhile therapeutic strategy in treating fibrotic 
disease [11, 29, 30].  This therapeutic strategy, however, remains largely untested.  
The lack of overt fibrotic phenotype in histological analysis of the Ctgf Hi/+ survivors 
and the externally normal phenotype of the tamoxifen treated Ctgf Hi/+ animals 
suggests that genetically increasing Ctgf expression by itself is not sufficient to 
cause fibrosis.  This is consistent with a report which showed that exogenous 
application of CTGF to the skin alone is not sufficient to cause fibrosis [50].  
Transgenic mice overexpressing Ctgf in cardiomyocytes [19], kidney podocytes [20], 
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and hepatocytes [21] show no spontaneous fibrosis of tissue while transgenic mice 
overexpressing Ctgf in lung respiratory epithelial cells [22], and fibroblasts [23] show 
abnormal thickening of the alveolar septa or dermis and fibrotic alterations [22, 23].  
However, fibrosis in the lung-specific model is a largely development-related 
phenotype [22] and in the fibroblast-specific model the in vivo level of Ctfg 
expression was not established [23], so these results may differ from ours because 
of differences in levels of Ctgf expression or that the transgene is not responsive to 
normal transcriptional regulation of the Ctgf allele at the endogenous locus.  
Altogether, the current literature does not preclude a role for CTGF in fibrotic 
disease, but it suggests that activation of other factors or the application of stress 
may be required in addition to Ctgf overexpression in order to cause fibrosis. 
Increased Ctgf expression has been observed in conjunction with fibrotic 
pathology in a number of organs and disease conditions.  However, an unequivocal 
role for Ctgf as a causal factor in pathological fibrosis remains questionable.  An 
allelic series with a wide range of genetically altered Ctgf gene expression provides 
a tool to test the effectiveness of reducing Ctgf expression, in vivo, to prevent fibrotic 
disease, and determining if increased expression of Ctgf is causal in fibrotic disease.  
In addition, by generating mouse lines with varying Ctgf expression using the 
endogenous locus, the function of Ctgf in fibrotic disease can be tested more 
effectively. 
We note that this method of altering gene expression, through altering a 
gene’s 3’UTR, avoids many of the issues of random insertion transgenes including 
insertional mutagenesis.  Additionally, a single founder with the Lo-Hi allele in 
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combination with existing resources allows the production of an allelic series of 
quantitative variants.  We also note that, the construct can be arranged to produce a 
Hi-Lo allele which high expression allele can be switched to low expression allele. 
Altogether, this method will likely be particularly useful for genes with multiple 
separate functions, genes expressed in many tissues, as well as in cases where 
altered gene expression causes embryonic lethality. 
 
D. Methods 
1. Ethics statement 
All animals were cared for in accordance with guidelines set forth by the 
Association for Assessment and Accreditation of Laboratory Animal Care. The 
University of North Carolina – Chapel Hill’s “Institutional Animal Care and Use 
Committee” (IACUC) approved all studies (protocol #08-045 and #07-228). 
 
2. Modifications of the Ctgf gene 
In order to inactivate the Ctgf gene, we have made a targeting construct to 
delete exons 3 through 5 of the Ctgf gene in the genome in ES cells as illustrated in 
Figure 5.1A.  The 5’ and 3’ arms of homology were a 4.7kb BamH1/Nhe1 fragment 
and a 1.4kb Nsi1/Bgl2 fragment, respectively, and a neomycin resistant gene (neo) 
was used as a selection marker. The Ctgf-Lo allele (Fig 5.1B) was made by 
replacing the endogenous Ctgf gene 3'UTR sequence with a cassette that includes a 
loxP site, followed by the 3'UTR sequence from the c-Fos gene (c-Fos-3'UTR), neo, 
a second lox P site, and the 3’UTR from the bovine growth hormone gene (bGH-
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3’UTR).  A 1060bp fragment of DNA including the Ctgf-3’UTR sequence, 510 bp of 
3’flanking and the polyA addition signal were removed from the endogenous locus 
leaving the 20 bp immediately following the TAA stop codon intact. 
Gene targeting in mouse ES cells (TC1) from 129S6/SvEvTac (129/SvEv) 
was carried out using the procedures described previously [27, 51].  Cells with 
planned mutations were identified with PCR, followed by confirmation with Southern 
blot analyses, and used for generating mice carrying the mutations. 
 
3. Mice 
Both the Ctgf KO and Ctgf Lo-Hi mice were established and maintained on a 
129S6/SvEvTac (129/SvEv) background.  The Ctgf Lo-Hi mice were also 
backcrossed to C57BL6/J (B6) then intercrossed two to three generations to create 
a mixed B6.129 background.  Initial experiments were with these mixed background 
animals as noted. 
The B6.FVB-TgN(EIIa-Cre)C5379Lmgd/J (EIIa-Cre) constitutive global Cre 
expressing mice were a gift from Dr. Westphal at the NIH [48].  The EIIa-Cre mice 
were backcrossed to 129/SvEv mice for at least 18 generations before being bred to 
the Ctgf Lo-Hi mice. 
The inducible global Cre expressing mice are B6.Cg-Tg(CAG-
cre/Esr1)5Amc/J from The Jackson Laboratory, Bar Harbor, ME stock number: 4682 
(CAG-Cre) [28].  This Cre line uses the chicken beta actin promoter/enhancer 
coupled with a cytomegalovirus enhancer (CAG) under control of a mutant mouse 
estrogen receptor ligand binding domain. The latter receptor ligand domain is 
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unresponsive to estrogen but sensitive to the synthetic ligand 4-hydroxytamoxifen 
(tamoxifen).  Therefore, the CAG-Cre allele produces robust expression of Cre only 
in the presence of tamoxifen [28]. 
 
4. Genotyping 
Animals were genotyped as appropriate using DNA from either toe or tail 
snips using standard protocols.  Ctgf KO animals were genotyped by PCR with the 
primers: 5’-TCG AGT TCA GAA CCA GAG CT-3’ (common), 5’-TCC GAT TCC TAC 
CAG GAA GT-3’  (endogenous), and 5’-TTA TGG CGC GCC ATC GAT CT-3’ (neo) 
with the conditions (92°C for 30 sec., 58°C for 30 sec, 60°C for 7 min) for 35 cycles.  
Because amplification is passing through the highly repetitive 3’UTR region the 
amplification step is done at a lower temperature to improve Taq fidelity.  The 
endogenous band is 550 bp and the KO band is 320 bp. 
Ctgf Lo alleles were genotyped by PCR with the primers: 5’-CAC TCT GCC 
AGT GGA GTT CA-3’ (common), 5’-TAA TTT CCC TCC CCG GTT AC-3’ 
(endogenous), and 5’-CAC AGC CTG GTG TGT TTC AC-3’ (c-Fos) and the 
conditions: 92°C for 30 sec, 57°C for 45 sec, 65°C for 2.5 min for 35 cycles. The 
endogenous band is 525 bp and the Ctgf KO band is 375 bp.   
Genotyping for Ctgf Hi allele was performed using fluorescent primer probe 
sets in real time PCR with ABI 7500 Fast Real Time PCR 3 system (Life 
Technologies Carlsbad, CA). The Ctgf Lo allele was defined as the presence of the 
bGH-3’UTR and neo and the absence of Cre (where applicable).  The Ctgf Hi allele 
was defined as the presence of both the bGH-3’UTR and Cre as well as a the 
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absence or low neo gene copy number.  Primer sets for bGH-3’UTR: 5’-TGC CAG 
CCA TCT GTT GTT TG-3’ (forward), 5’-ACA GTG GGA GTG GCA TCT T-3’ 
(reverse), and 5’-FTC TCC CCC GTG CCT TCC TTG AQ-3’ (probe), for neo: 5’-
GAC GGC GAG GAT CTC GTC G-3’ (forward), 5’-TAT GTC CTG ATA GCG GTC 
CG-3’ (reverse), and 5-‘FAC CCA TGG CGA TGC CTG CTT GCC GQ-3’ (probe), 
and for Cre: 5-‘GGC AGT AAA AAC TAT CCA GCA-3’ (forward), 5’-GCC GCA TAA 
CCA GTG AAA CA-3’ (reverse), 5’-FAT TGC TGT CAC TTG GTC GTG GCA GCQ-
3’ (probe).  For all probes F is 5’ fluorescein (FAM) and Q is the 3’ quencher 
(TAMRA).  
 
5. Quantitation of Neo gene copy number 
When genotyping by real time PCR, relative gene copy number for the allele 
of interest, in this case the neo gene, is quantitatively measured.  We have used the 
relative neo gene copy number information from RT-PCR genotyping as a proxy for 
determining the efficiency of excision of the Lo (c-fos-3’UTR and neo) portion of the 
Ctgf Lo-Hi allele.  
 
6. Embryo Recovery 
To recover embryos, females were checked for mucosal plugs every morning.  
If a plug was observed the female was separated and watched for pregnancy by 
visual inspection.  At the designated embryonic day point (from E10 – E15 for these 
experiments) mothers were sacrificed and embryos were recovered live.  The 
embryonic sac (amnion) was separated from each embryo and used for genotyping.  
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Each intact embryo was rinsed in PBS then weighed whole (when possible) and 
assessed for phenotype.  At recovery, embryos were phenotypically classified based 
on body weight and gross appearance before genotype was determined.  “Normal” 
embryos were nondysmorphic in appearance and at the expected developmental 
stage for the embryonic age and were within two standard deviations (heavier or 
lighter) of the mean embryo weight for that litter.  “Small” embryos were 
nondysmorphic in appearance and at the expected developmental stage for the 
embryonic age, but were small in size and had a body weight below two standard 
deviations of the litter average (litter averages include all pups that are sufficiently 
intact to be weighed).  “Small atypical” embryos were developmentally delayed, 
macerated, or poorly vascularized and had a body weight below two standard 
deviations of the litter average. Embryos were fixed with 4% paraformaldehyde or 
gluteraldehyde as needed for further studies. 
 
7. Ctgf Gene Expression Profiling 
Mice were euthanized with an overdose of 2,2,2-tribromoethanol and mRNA 
was harvested from tissues for gene expression profiling.  Assays were performed 
by real-time quantitative RT-PCR as previously described [27]. The primer/ probe 
sets used for Ctgf mRNA expression were: 5’-AGT CGC CTC TGC ATG GTC A-3’ 
(forward), 5’-GCG ATT TTA GGT GTC CGG AT-3’ (reverse), and 5’-FCC TGC GAA 
GCT GAC CTG GAG GAA AQ-3’ (probe).  All samples were normalized to β-actin 
using primer set: 5’-AAG AGC TAT AGA CTG CCT GA-3’ (forward), 5’-ACG GAT 
GTC AAC GTC ACA CT-3’ (reverse), and 5’-FCA CTA TTG GCA ACG AGC GGT 
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TCC GQ-3’ (probe).  Additional samples for gene expression were either tail 
samples from 10-12 day old pups or whole embryos harvested from timed matings 
at embryonic day E10-12 (days post-coitum).  For tamoxifen treated animals, three 
weeks after tamoxifen treatment ear tissue biopsies were taken by small punch on 
lightly anesthetized (2,2,2-tribromoethanol) mice at 3-4 months of age. 
 
8. Immunohistochemistry 
 Embryos were recovered and sectioned, as described above.  Sections were 
deparrafinned then stained with Rabbit anti-CTGF primary antiboday at 1:100 or 
1:500 dilution (Genetex Irvine, CA) and an anti-Rabbit Alexa Fluor 594 at 1:200 
dilution (Molecular Probes Eugene, OR).  Sections were counterstained with DAPI to 
visualize nuclei.  To correct for autofluorescence, for each section there was an 
adjacent section stained with secondary antibody only.  Sections were examined on 
a Nikon Eclipse 80i and photographed with Nikon DS-QiMc 12mp digital camera and 
NIS Elements BR 3.0, SP6 (build 539) software. 
 
9. Body mass composition and bone density 
Using Dual Energy X-ray Absorptiometry (DEXA) we measured body mass 
composition and bone density.  Mice were lightly anesthetized with isofluorane then 
scanned, excluding the head, using PIXImus DEXA (Lunar Corporation, Madison, 
WI).  Measurements and calculations were performed as previously described [52].  
For analysis of DEXA data, males and females were pooled into two groups, either 
158 
Ctgf Hi/+ or controls (including sibling controls of the genotypes Ctgf Lo/+;Cre-, Ctgf 
+/+; Cre+, or completely wild type). 
 
10. Tamoxifen Treatment 
The Ctgf Lo/Lo mice were crossed to the tamoxifen inducible CAG-Cre mice 
to produce Ctgf Lo/+ and Ctgf Lo/+; Cre+ mice. At six weeks of age mice were 
treated with tamoxifen at a dose of 3 mg/ kg of body weight for four consecutive 
days [28, 53, 54].  Following treatment the Ctgf Lo/+; Cre+ mice are designated with 
the genotype Ctgf Hi/+.  Mice were monitored for any overt phenotypic changes. 
 
11. PCR Validation of Ctgf Lo-Hi allele 
DNA was isolated from skin biopsy samples of animals that carry a single 
copy of the modified allele and with or without tamoxifen-inducible global Cre 
transgene.  All animals were treated with tamoxifen four months prior to the 
collection of the samples.  The Ctgf-Lo was allele amplified with primer 1 (5’-ACA 
GGA AGA TGT ACG GAG AC-3’, corresponding to the sense strand of Ctgf exon 5) 
and primer 2 (5’-GCT ACA TCT CTG GAA GAG GT-3’, corresponding to the 
antisense strand of cFos 3’UTR) and the Ctgf-Hi allele amplified with primer 1 and 
primer 3 (5’-CAC CTA CTC AGA CAA TGC GA-3’, corresponding to the antisense 
strand of bGH 3’UTR sequence).  PCR products were run on 1.5% agarose gel and 
stained with ethidium bromide to visual bands. 
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12. Western Blot and Protein Quantitation of Plasma 
All plasma samples for western blot and protein quantitation were obtained 
through retro-orbital or tail vein bleed on anesthetized mice.  0.5M EDTA was added 
to whole blood it was spun to obtain plasma.  Plasma was used fresh or frozen at -
20°C until used.  Pre-poured (Nu-Sep iGel) 10% polyacrylamide gels were loaded 
with 1 μL of plasma mixed with loading buffer.  Gels were run, transferred and 
blotted by standard methods.  Membranes were blocked using 10% nonfat milk in 
tris-buffered saline with Tween (TBST). Primary CTGF antibody (US Biological 
Rabbit anti mouse-CTGF) was applied overnight 1:2000 dilution.  Secondary (Cal 
Biochem Goat anti-Rabbit IgG Peroxidase Conjugated) was applied for 3 hours 
1:5000 dilution.  Chemiluminescence (Pierce Biotechnology SuperSignal West Pico 
Chemiluminescent Substrate) was applied per manufacturer instructions.  Band 
density was quantitated with ImageJ software. 
 
13. Microscopy/ Photography 
Adult mice were lightly anesthetized with 2,2,2-tribromoethanol then 
photographed live (Canon Powershot SD600, Canon, NY, USA).  Whole fixed E13.5 
embryos were pictured using a dissecting macroscope (Leica Wild M420 Leica, NY) 
with a QImaging camera (QImaging MicroPublisher MP3, Surrey, BC, Canada).  
Whole unfixed E10.5 embryos were pictured with embryos immersed in buffered 
saline using light microscopy (Olympus America Inc., Melville, New York).  Embryos 
were then fixed and prepared for scanning electron microscopy (EM) as previously 
described [55].  Briefly, embryos were fixed in 2.5% glutaraldehyde in Sorenson’s 
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buffer.  Secondary fixation was performed in 2% osmium tetroxide in Sorenson’s 
buffer [55].  Samples were dehydrated in consecutive ethanol washes then dried.  
Specimens were mounted on aluminum stubs with colloidal silver, sputter coated, 
then viewed and photographed by scanning EM (Zeiss Supra 25 field emission 
scanning electron microscope, Carl Zeiss, Thornwood, NY, USA). 
 
14. Statistics 
Data are presented as mean ± standard error of the mean, and p-values are 
from paired Student t-test performed in Microsoft Excel.  Additional statistics 
including Chi Squares were performed by hand.  Any p-value less than 0.05 was 
considered statistically significant. 
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CHAPTER 6 
CONCLUSIONS 
 
Cardiovascular disease is the number one reason for death in the United 
States and accounts for a large number of unexpected and premature deaths [1].  
Both cardiac hypertrophy and cardiac fibrosis are well recognized phenotypes in the 
pathology of cardiovascular disease, but the molecular causes are not well 
understood and medical interventions remain limited.  Mouse models of 
cardiovascular disease have become a highly effective tool for understanding the 
molecular causes of cardiovascular disease and devising and testing medical 
interventions [2].  Ctgf has been strongly implicated as a regulator of cardiac fibrosis 
[3] and more recently of cardiac hypertrophy [4] so mouse strains with varying levels 
of Ctgf gene expression were generated to test if increased Ctgf gene expression 
enhances cardiac hypertrophy or fibrosis and if reduced expression could lessen 
disease. 
 Mice with a three-fold range in Ctgf gene expression were generated using 
gene duplication and standard gene knockout strategies.  It is important to note that, 
in the absence of a stress, there was no overt phenotype in Ctgf heterozygous 
knockout mice nor Ctgf duplication mice, so three models of cardiac stress were 
used.  Systemic hypertension was induced using either chemical or genetic 
stimulation of the renin-angiotensin system; cardiac overload was induced using 
trans-aortic constriction/ banding; and as a model of normal aging mice were aged to 
one year.  The consequences of each of these models was ascertained using 
echocardiography, gene expression profiling, necropsy, tissue histology, and 
statistical phenotype modeling. 
 Contrary to my expectation, when Ctgf gene expression levels were altered I 
observed a small nearly insignificant impact on fibrosis.  However, altered Ctgf gene 
expression had a measurable impact on levels of cardiac hypertrophy in three of the 
models of cardiac stress.  When Ctgf expression levels were either reduced or 
increased there was an increase or acceleration in cardiac hypertrophy in most of 
the models of hypertrophy tested (Table 6.1).  The cardiac hypertrophy phenotype I 
observed is similar to a report by Yoo et al., who also observed small but not 
statistically significant increase in hypertrophy in the TAC treated transgenic mice 
over-expressing Ctgf.  Unlike my results, however, these authors also observed a 
considerable increase in fibrosis in the Ctgf transgenic [5].  Panek et al., treated 
another transgenic model of increased Ctgf expression with AngII and observed a 
small but not significant increase in hypertrophy and no difference in fibrosis 
compared to treated WT.  Those animals were also aged, and at 4 months their 
hearts were hypertrophic and by 7 months there were signs of dilated 
cardiomyopathy [6].   The differences between these studies and my own may be 
due to the strain of mouse or the levels of gene expression.  Importantly, similar to 
my own work, in both of these studies a stress such as aging or induction of cardiac 
stress is required to induce a hypertrophic phenotype in Ctgf over-expressing 
mutants.  In addition, the presence of hypertrophy did not necessitate the presence 
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of fibrosis, and visa versa, suggesting that the two processes are at least partially 
independent of one another. 
In general, the evidence from the above studies and my own suggests that 
altered Ctgf gene expression is certainly a marker of cardiac hypertrophy and may 
have a greater causative role as well.  Further evidence for a role for CTGF in 
cardiac hypertrophy comes from tissue culture studies which have shown that 
treatment with endothelin-1 or phenylephrine, both potent pro-hypertrophic 
molecules, induces Ctgf expression [7].  In addition, treatment of cardiomyocytes 
with CTGF directly induces cell hypertrophy [4] and Ctgf expression is required for 
the pro-hypertrophic effect of high glucose and free fatty acid on rat cardiomyocytes 
[8].  The role of Ctgf in cardiac hypertrophy is complex and still as yet unclear, but 
certainly warrants further study. 
 
Genotype Experiment Phenotype 1 copy 3 copy 4 copy 
Hypertrophy ↑ ↑↑ N/A Angiotensin II 
Infusion Fibrosis = ↑ N/A 
Hypertrophy N/A = N/A Renin 
Transgene Fibrosis N/A = N/A 
Hypertrophy ↑* ↑# N/A Trans-Aortic 
Constriction Fibrosis = = N/A 
Hypertrophy N/A ↑ ↑↑ 
Aged 
Fibrosis N/A ↑↑ = 
 
Table 6.1. Summary of phenotypes for Ctgf mutant mice.  All phenotypes are relative to treated 
WT animals.  N/A is not applicable for genotypes that were not used in a particular experiment.  * 
TAC treated 1 copy animals were only more hypertrophic than WT at two weeks after treatment 
began.  # TAC treated 3 copy animals were more hypertrophic after two weeks of treatment and less 
hypertrophic or possibly dilated at 4 weeks of treatment. 
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 It has been widely suggested that Ctgf is an important pro-fibrotic factor in a 
large number of fibrotic diseases [3, 9].  It has even been proposed as the key pro-
fibrotic molecule [10].  In addition, knocking down Ctgf has been put forth as an 
excellent target for anti-fibrotic therapy [3].  Therefore, increasing basal Ctgf 
expression in an animal model should produce an obvious increase in fibrosis and 
reducing Ctgf expression should reduce pathological fibrosis.  This is, however, not 
what I observed in the Ctgf duplication and heterozygous KO animals.  For 
enhanced fibrosis to occur there had to be an added element of stress in order to 
cause disease.  Even when fibrotic disease is induced using models of chronic-
hypertension, cardiac pressure overload and normal aging, increased fibrotic 
pathology is only subtle, if any.  In addition, under stress, reduction of Ctgf gene 
expression in the heterozygous knockouts to levels half that of WT does not prevent 
or reduce the levels of fibrosis.  Results from all of the models of cardiac fibrosis 
tested strongly suggested that Ctgf is not the key causative factor of fibrosis that it 
has been proposed to be (Table 6.1). 
Alternatively, because Ctgf gene expression was only moderately increased 
to about 1.5 to 2-fold over WT in the Ctgf duplication mutants, the change was 
insufficient to generate a large increase in fibrosis.  However, recent tissue-specific 
transgenic models of Ctgf over-expression in cardiomyocytes [6], kidney podocytes 
[11], and hepatocytes [12] corroborate our findings.  In all of these models a stress in 
addition to the increased Ctgf expression was required for enhanced fibrosis to 
occur, even with Ctgf gene expression levels increased to 40-fold over wild type, 
only a mild or no increase in fibrosis over WT was observed [6, 11-13].  In two other 
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models, one in lung epithelia [14] and the other in fibroblasts [15], the use of a Ctgf 
transgene resulted in fibrotic pathology.  However, in the lung model fibrosis resulted 
from a developmental defect [14] and in the fibroblast model Ctgf gene expression 
levels were never measured in vivo [15], suggesting that Ctgf has a role in fibrosis 
but still not conclusively showing that increased Ctgf gene expression is causative of 
fibrosis in adult disease.  In all these transgenic mice, the Ctgf gene is not under 
normal regulation.  In light of my own results, using gene targeted mice in which the 
Ctgf gene expression is under normal transcriptional regulation, and of the published 
data, it is most likely that increased Ctgf expression alone is not inherently 
pathological.  My work also suggests that the variations at the level of gene 
expression that may occur in humans as a result of genetic polymorphisms are 
unlikely to be a primary causal player in cardiac fibrosis. 
Ctgf is a cell surface, ECM-bound, and circulating molecule that sensitive to a 
large number of environmental inputs (Fig 6.1).  Increased Ctgf expression is 
associated with both increased expression of ECM components, such as collagen, 
as well as increased expression of molecules that break down ECM (such as MMPs) 
[3, 16], suggesting that the true function of Ctgf is to breakdown, buildup and 
maintain ECM in response to a diversity of environmental cues.  The localization and 
sensitivity of Ctgf make it a strong candidate for being a sensor molecule that 
coordinates response to a myriad of inputs.  In systems biology, these genes are 
referred to as hubs and are at the nexus of complex networks of inputs and outputs.  
As opposed to being a pro-fibrotic molecule as previously proposed, Ctgf may be a 
hub in the molecular regulation of ECM, acting to coordinate the cellular response to 
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a diverse set of sometimes contradictory inputs, ranging from glucose 
concentrations in the blood to cell stretch, in order to balance these inputs and direct 
appropriate gene expression and signaling response. 
 
 
Figure 6.1. Schematic of Ctgf signaling.  A large number of environmental, molecular, and 
chemical cues stimulate Ctgf gene expression.  Once CTGF is translated, it is secreted through the 
Golgi into the intercellular space and into lymph and blood circulation.  It binds directly to multiple 
extracellular matrix proteins and signaling factors as well as signals through a diversity of molecular 
pathways to affect multiple downstream targets. 
 
 
In the case of fibrosis, CTGF is likely to be pro-fibrotic only when it is 
expressed in the presence of other pro-fibrotic molecules.  Once those signaling 
pathways are activated CTGF may amplify and perpetuate signaling.  In the case of 
wound healing extended expression of Ctgf may stimulate recruitment of fibroblasts 
and deposition of excess ECM beyond normal healing leading to scarring, but only 
does so in the presence of other molecular signals such as TGFβ.  As increased 
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Ctgf by itself is not directly pathological, it is likely to be acting in conjunction with 
other molecules, like TGFβ, to amplify their pro-fibrotic function. 
Ctgf is perplexing in that precise control of expression levels is clearly 
important during development as both mouse knockouts and over-expressers die 
prenatally and in utero, respectively.  In contrast, I have repeatedly observed that 
Ctgf levels are very sensitive to environmental cues and wide variations in 
expression were seen within all of the genotypes examined, including WT.  In 
addition, Ctgf is at the hub of a complicated regulatory nexus, is very highly 
conserved in mammals, and is regulating processes required for survival such as 
embryogenesis and wound healing.  It appears to be a contradiction for Ctgf to be 
both tightly regulated and widely varied in expression, as well as for it to be involved 
in homeostasis and in rapid response to environmental cues.  Nevertheless, this 
strange model appears to be how CTGF is functioning, and it may in fact be uniquely 
useful in that Ctgf expression levels are highly responsive to environmental cues, but 
many of the downstream signal cascades rely on the presence of other molecules 
(such as TGFβ or AngII) to be strongly induced.  In this manner, CTGF can be highly 
responsive in a subset of its functions and much less reactive in others depending 
on the balance of other biological factors present.  Thus, CTGF is most likely to be a 
coordinator and amplifier of other signals, which is involved in a large number of 
pathways. 
 Herein, I have tested three different models of cardiac stress using Ctgf 
mutant mice with varying levels of Ctgf gene expression in order to better 
understand the function of CTGF in cardiac hypertrophy and fibrosis.  Increased 
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expression of Ctgf alone is insufficient to induce cardiac fibrosis, and while Ctgf 
expression levels are clearly linked to fibrosis, increased Ctgf gene expression even 
in combination with cardiac stress is not a primary cause of cardiac fibrosis.  
Changes in Ctgf gene expression, both reduced and increased, had a role in 
modulating the severity of cardiac hypertrophy, although the molecular mechanism 
of this function of CTGF is yet to be deciphered.  In addition, efforts to generate 
mouse models with no CTGF or high levels of CTGF have shown that CTGF is 
required for embryogenesis and too little or too much is embryonic lethal.  Further 
study of CTGF should investigate how combining CTGF with other molecular 
partners modifies signaling and phenotypic outcomes as well as determining the role 
of CTGF in phenotypes other than fibrosis. 
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